<allTrials totalCount="813" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">43633950</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of Kabat's technique, connective tissue massage and kinesitherapy</title>
      <scientificTitle>The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of Kabat's technique, connective tissue massage and kinesitherapy - a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Systemic sclerosis is a connective tissue disease characterised by induration of the skin and internal organs, by joint modifications and muscle impairment. Skin fibrosis leads to tissue retraction and atrophy, and consequently to disability and reduction of patients' quality of life. 
 
This trial aims to assess the efficacy of a rehabilitation programme based on the combination of Kabat's technique, connective massage and kinesitherapy specifically conceived for the face of systemic sclerosis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed at baseline, end of treatment (after 9 weeks) and after 9 weeks of follow-up:
1. Improvement of facial skin score (modified Rodnan Skin Score)
2. Mouth opening (distance in centimetres between the tips of upper and lower right incisive teeth)</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline, end of treatment (after 9 weeks) and after 9 weeks of follow-up:
1. Facial systemic sclerosis disability, assessed by the Mouth Handicap In Systemic Sclerosis (MHISS) scale
2. Quality of life, assessed by the 36-item Short Form (SF-36) Health Survey and Health Assessment Questionnaire (HAQ)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43633950</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83b476f5-76bc-4494-aa1f-00016e6ac4ba">
	  <name>Villa Monna Tessa</name>
	  <address/>
	  <city>Florence</city>
	  <state/>
	  <country>Italy</country>
	  <zip>50139</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, no age limits
2. Systemic sclerosis patients fulfilling the American College of Rheumatology (ACR) criteria with facial involvement assessed by a Rodnan skin score greater than or equal to 1</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Does not meet the inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic sclerosis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic sclerosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: 20 patients treated for 9 weeks (twice a week, 1 hour per session) with a combined face rehabilitation programme (Kabat's technique, connective tissue massage, kinesitherapy and home exercise programme)

Control group: 20 patients were assigned only to home exercise programme. 

All patients were assessed at baseline, end of treatment (after 9 weeks) and after 9 weeks of follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18362-0</funderId>
      <contactId>Contact56351_18362</contactId>
      <sponsorId>Sponsor54920</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56351_18362">
    <title>Dr</title>
    <forename>Susanna</forename>
    <surname>Maddali Bongi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Villa Monna Tessa
Viale Pieraccini 18</address>
      <city>Florence</city>
      <country>Italy</country>
      <zip>50139</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54920">
    <organisation>University of Florence (Italy)</organisation>
    <website>http://www.unifi.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Medicine
Viale Morgagni, 85</address>
      <city>Florence</city>
      <country>Italy</country>
      <zip>50134</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8404.8</gridId>
    <rorId>https://ror.org/04jr1s763</rorId>
  </sponsor>
  <funder id="Funder18362-0">
    <name>University of Florence (Italy) - Department of Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">36648909</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in patients with systemic sclerosis</title>
      <scientificTitle>Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in patients with systemic sclerosis: a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Systemic sclerosis is a connective tissue disease characterised by induration of the skin and internal organs, joint modifications and muscle impairment. Deformations of hands lead to a severe loss of range of motion and functionality, affecting quality of life and activities of daily living.  

This trial aims to assess the effectiveness of a rehabilitation programme based on the association of connective massage and Mc Mennell joint manipulation specifically conceived for hands of systemic sclerosis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Fist closure (cm) at baseline, end of treatment (after 9 weeks) and 9 week follow-up.</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline, end of treatment (after 9 weeks) and 9 week follow-up:
1. Hand disability, assessed by the Hand Mobility in Scleroderma (HAMIS) test and the Cochin Hand Functional Disability scale  
2. Quality of life, assessed by 36-item Short Form (SF-36) Health Survey and Health Assessment Questionnaire (HAQ)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at the time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36648909</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="10efe023-43f5-4828-9f76-9b8de1047fbd">
	  <name>Viale Pieraccini 18</name>
	  <address/>
	  <city>Florence</city>
	  <state/>
	  <country>Italy</country>
	  <zip>50139</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, no age limits
2. Caucasian systemic sclerosis patients (diagnosed according the American College of Rheumatology [ACR] criteria) with the typical systemic sclerosis joint involvement (stiffness and loss of joint function due to flexion contractures, caused by progressive sclerotic retraction of skin, subcutaneous tissues and tendon sheaths)</inclusion>
      <ageRange>Other</ageRange>
      <gender>Female</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Does not meet the inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic sclerosis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic sclerosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: 20 systemic sclerosis patients treated for a 9-week period (twice a week, 1 hour per session) with a hand rehabilitation programme based on connective tissue massage and Mc Mennell joint manipulation. Mc Mennell joint manipulation is a technique aiming to recover the "joint play", i.e. the involuntary, subtle range of motion that normal joints display on multiple planes, necessary for normal voluntary joint mobility. It improves articular movement, reduces pain and stretches articular capsulae and ligaments. 

Control group: 20 participants assigned only to a home exercise programme. 

Patients were assessed at baseline, end of treatment (after 9 weeks) and 9 week follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18363-0</funderId>
      <contactId>Contact56352_18363</contactId>
      <sponsorId>Sponsor54921</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56352_18363">
    <title>Dr</title>
    <forename>Susanna</forename>
    <surname>Maddali Bongi </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Viale Pieraccini 18</address>
      <city>Florence </city>
      <country>Italy</country>
      <zip>50139 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54921">
    <organisation>University of Florence (Italy)</organisation>
    <website>http://www.unifi.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Internal Medicine 
Viale Morgagni 85</address>
      <city>Florence </city>
      <country>Italy</country>
      <zip>50134</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8404.8</gridId>
    <rorId>https://ror.org/04jr1s763</rorId>
  </sponsor>
  <funder id="Funder18363-0">
    <name>University of Florence (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">62054712</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of the Rességuier method in the treatment of fibromyalgia: a randomised controlled trial</title>
      <scientificTitle>Rehabilitation of fibromyalgia: efficacy of the Rességuier method - a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Rehabilitation holds an important role in the treatment of fibromyalgia syndrome (FMS). Despite numerous studies, an agreement on a specific rehabilitation line, adaptable to the needs of a heterogeneous group of patients, has not been found yet. The Rességuier method is a rehabilitation technique never experimented in fibromyalgia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Reduction of pain (Numerical Rating Scale [NRS]: 0 - 10)
2. Improvement of disability and quality of life, assessed by the 36-item Short Form (SF-36) Health Survey and Fibromyalgia Impact Questionnaire (FIQ)</primaryOutcome>
      <secondaryOutcome>1. Quality of movement (NRS: 0 - 10)
2. Ability to relax mind and body (NRS: 0 - 10)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at the time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN62054712</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b7f04ec-f3c7-4a8f-96e3-08d5f3f4f5ad">
	  <name>Associazione per lo studio della Sclerosi Sistemica e delle Malattie Fibrosanti (ASSMaF)</name>
	  <address/>
	  <city>Firenze</city>
	  <state/>
	  <country>Italy</country>
	  <zip>50139</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) criteria
2. No age limits</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>Does not meet the inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibromyalgia</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other soft tissue disorders, not elsewhere classified</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>FMS patients were recruited and randomly assigned to the Group A and Group B. The patients of Group A were individually treated with the Rességuier method for 8 weeks, 1 session a week. The patients of Group B were observed for 8 weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18367-0</funderId>
      <contactId>Contact56356_18367</contactId>
      <sponsorId>Sponsor54925</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56356_18367">
    <title>Dr</title>
    <forename>Susanna</forename>
    <surname>Maddali Bongi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Associazione per lo studio della Sclerosi Sistemica e delle Malattie Fibrosanti (ASSMaF)
Viale Pieraccini 18</address>
      <city>Firenze</city>
      <country>Italy</country>
      <zip>50139</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54925">
    <organisation>University of Florence (Italy) </organisation>
    <website>http://www.unifi.it</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Medicine 
Viale GB Morgagni 85</address>
      <city>Florence</city>
      <country>Italy</country>
      <zip>50134</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8404.8</gridId>
    <rorId>https://ror.org/04jr1s763</rorId>
  </sponsor>
  <funder id="Funder18367-0">
    <name>University of Florence (Italy) - Department of Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">20736216</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of physical therapy in patients with shoulder impingement syndrome</title>
      <scientificTitle>Treating patients with shoulder impingement: a single-blind effect study using a scapular stabilisation protocol</scientificTitle>
      <acronym/>
      <studyHypothesis>Is a scapular stabilisation programme more effective than usual care in patients with shoulder impingement syndrome?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be assessed at baseline, after nine therapy sessions and after six months: 
1. Pain: Visual Analogue Scale (VAS), Verbal Rating Scale (VRS), Shoulder Disability Questionnaire (SDQ), Hawkins Impingement Test, Neer Impingement Test, the Empty Can Test 
2. Mobility: inclinometry 
3. Strengh: hand-held dynamometer</primaryOutcome>
      <secondaryOutcome>The following will be assessed at baseline, after nine therapy sessions and after six months: 
1. Scapular Assistance Test
2. Scapular Reposition Test</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Committee of the UZ Brussel University Hospital, Brussels Free University (Vrije Universiteit Brussel), approved on the 15th October 2008 (ref: BUN B14320084388)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20736216</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G842</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised single-blind usual care-controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-11-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b6a15565-a6d7-48bd-a5c3-d6869dff2a78">
	  <name>Vrije Universiteit Brussel</name>
	  <address/>
	  <city>Brussel</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, greater than 18 years of age
2. Primary and secondary impingement</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>46</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46</totalTarget>
      <exclusion>1. Post-surgical
2. Rheumatic arthritis
3. Cervical radicular syndromes
4. Ruptures
5. Less than 18 years of age
6. Congenital
7. Traumatic
8. Instability</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-11-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Shoulder impingement syndrome</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Shoulder lesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Nine sessions (approximatly 30 minutes/session; three sessions/week) of usual care (ultrasound [US], transcutaneous electrical nerve stimulation [TENS], stretching, massage) versus nine sessions of scapular motor control training (exercise therapy for scapular stability muscles). 

Total duartion of interventions: three weeks/patient.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18268-0</funderId>
      <contactId>Contact56256_18268</contactId>
      <sponsorId>Sponsor54825</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56256_18268">
    <title>Prof</title>
    <forename>Jo</forename>
    <surname>Nijs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije Universiteit Brussel 
Pleinlaan 2</address>
      <city>Brussel</city>
      <country>Belgium</country>
      <zip>1050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jo.nijs@vub.ac.be</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54825">
    <organisation>MSD Europe BVBA (Belgium)</organisation>
    <website>http://www.msd-europe.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Neringstraat 7</address>
      <city>Londerzeel</city>
      <country>Belgium</country>
      <zip>1840</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+32 (0)52 311 452</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@msd-europe.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487292.2</gridId>
    <rorId>https://ror.org/01ptrk735</rorId>
  </sponsor>
  <funder id="Funder18268-0">
    <name>MSD Europe BVBA (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">36204907</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of feeding during the first months of life in post-natal health in babies born small for gestational age (SGA)</title>
      <scientificTitle>Influence of early feeding in subsequent cardiovascular risks in infants born small for gestational age: a randomised controlled trial</scientificTitle>
      <acronym>PSO</acronym>
      <studyHypothesis>1. Breastfed small for gestational age (SGA) babies will gain more lean mass and less fat mass over the first 4 months of life
2. SGA babies will have more vsiceral fat at age 24 months as compared to babies born appropriate for gestational age (AGA)
3. SGA babies fed enriched formula will be more insulin resistant, have higher levels of insulin-like growth factor 1 (IGF-1) and altered levels of adipokines, as compared to breastfed SGA babies and SGA babies fed with regular formula</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body composition at age 15 days and at age 4, 12 and 24 months (DXA).</primaryOutcome>
      <secondaryOutcome>1. Insulin
2. IGF-1
3. Adipokines
4. Visceral fat

Measured in cord blood, and in fasting samples at age 4, 12 and 24 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Committee of Hospital Sant Joan de Déu, Esplugues have given approval on the 15th May 2008</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36204907</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-08-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="95ffaf69-a67b-4f3f-bcc5-6665ccf2c85d">
	  <name>Endocrinology Unit</name>
	  <address/>
	  <city>ESplugues</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08950</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Maternally uncomplicated pregnancy (no gestational diabetes, no pre-eclampsia, no use of alcohol, drugs or illicit substances), with delivery at Hospital Sant Joan de Déu in Barcelona
2. Birthweight AGA (between -1 and +1 SD) or SGA (between 1.8 kg and -2 SD) after a term gestation (37 - 42 weeks)
3. Availability of cord serum
4. Ethnically Catalan background</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>140</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90 (SGA), 50 (AGA)</totalTarget>
      <exclusion>1. Dysmorphic features
2. 10-minute Apgar score below 7</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-08-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Small for gestational age (SGA), adipokines, cardiovascular risk factors</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Slow foetal growth and foetal malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Newborns born SGA who will not be breastfed will be randomised to receive a regular or an enriched formula for 4 months. Assessments at birth, 15 days, 4, 12 and 24 months (sampling, dual energy X-ray absorptiometry [DXA] and ultrasound). 

Regular formula: Fat: 28.9 g%; carhohydrates: 55.0 g%; proteins: 11.7 g%
Enriched formula: Fat: 24.7 g%; carbohydrates: 54.9 g%; proteins: 14.5 g%
Feeding is ad libitum and following the recommendations of the primary care paediatricians. This is usually every 3 hours the first month, and every 4 hours thereafter. No additional food is allowed until after month 4.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18343-0</funderId>
      <contactId>Contact56332_18343</contactId>
      <sponsorId>Sponsor54901</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56332_18343">
    <title>Prof</title>
    <forename>Lourdes</forename>
    <surname>Ibanez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Endocrinology Unit
Hospital Sant Joan de Deu</address>
      <city>ESplugues</city>
      <country>Spain</country>
      <zip>08950</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 93 28 04 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">libanez@hsjdbcn.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54901">
    <organisation>Hospital Sant Joan de Deu (Spain) </organisation>
    <website>http://www.hsjdbcn.org/index.jsp</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Passeig de Sant Joan de Deu 2</address>
      <city>Esplugues</city>
      <country>Spain</country>
      <zip>08950</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 93 28 04 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">libanez@hsjdbcn.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411160.3</gridId>
    <rorId>https://ror.org/001jx2139</rorId>
  </sponsor>
  <funder id="Funder18343-0">
    <name>The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain) (ref: PI080443)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">54093934</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of the association of district specific and global rehabilitative techniques tailored for systemic sclerosis (SSc) patients</title>
      <scientificTitle>The rehabilitation of systemic sclerosis: efficacy of the association of district specific and global rehabilitative techniques - a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Systemic sclerosis (SSc) is a systemic disease affecting the microvascular system and the connective tissue, causing important alterations of skin and internal organs and impairing the function of the heart, lung, kidney and peripheral nervous system. In SSc, the most important rehabilitative problems arise from skin induration and joint and muscle involvement often insufficiently responsive to a merely pharmacological approach. In fact, involvement of skin with progressive tissue fibrosis and retraction is a major condition of disability. 

This trial aims to assess the short- and mid-term efficacy of an individualised rehabilitation programme specifically conceived and tailored for SSc and to set the basis of a specific rehabilitative approach to this chronic disease.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in disability and quality of life, assessed by the 36-item Short Form (SF-36) Health Survey and the Health Assessment Questionnaire (HAQ).</primaryOutcome>
      <secondaryOutcome>Hand and face involvement:
1. Hand Mobility in Scleroderma (HAMIS) test
2. Cochin Functional Hand Scale
3. Water Volumetric Test
4. Mouth functionality
5. Hand range of motion</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54093934</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="77637cc0-46f1-4617-8614-6da970bc3c4d">
	  <name>Viale Pieraccini 18</name>
	  <address/>
	  <city>Florence</city>
	  <state/>
	  <country>Italy</country>
	  <zip>50139</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of systemic sclerosis according to the American College of Rheumatology (ACR) criteria 
2. Facial skin score greater than 1 
3. SSc hand involvement 
4. No age limits</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Does not meet the inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic sclerosis (SSc)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic sclerosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>20 SSc patients were enrolled and randomly assigned to Group A or Group B:

Group A (10 patients) was treated for a 9-week period (twice a week, 1 hour per session) with an individualised rehabilitation program whose composition partially differed from patient to patient on the basis of  involved districts and patient's expectations. All patients were treated with hand and face rehabilitation. Hand lymphatic drainage and global methods such as aquatic and land-based global rehabilitation, also comprising respiratory exercises, and Rességuier method were added when  necessary. 

Group B (10 patients) was the observational group, provided with education advices and medical information about SSc.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18366-0</funderId>
      <contactId>Contact56355_18366</contactId>
      <sponsorId>Sponsor54924</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56355_18366">
    <title>Dr</title>
    <forename>Susanna </forename>
    <surname>Maddali Bongi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Viale Pieraccini 18</address>
      <city>Florence</city>
      <country>Italy</country>
      <zip>50139</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54924">
    <organisation>Italian Association for the Study of Systemic Sclerosis and Fibrotic Diseases (ASSMaF) (Italy) </organisation>
    <website>http://www.assmaf.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Viale Pieraccini 18</address>
      <city>Florence</city>
      <country>Italy</country>
      <zip>50139</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487246.b</gridId>
    <rorId>https://ror.org/00feyy410</rorId>
  </sponsor>
  <funder id="Funder18366-0">
    <name>Italian Association for the Study of Systemic Sclerosis and Fibrotic Diseases (ASSMaF) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">26988657</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre comparative clinical trial of the safety and efficacy of a 0.5% timolol-2% dorzolamide-0.2% brimonidine ophthalmic solution in fixed combination (formulated by Laboratorios Sophia S.A. de C.V.) versus Cosopt® in open angle glaucoma or ocular hypertension</title>
      <scientificTitle>Comparative trial of a 0.5% timolol-2% dorzolamide-0.2% brimonidine solution in fixed combination versus Cosopt® in open angle glaucoma or ocular hypertension</scientificTitle>
      <acronym>KOEG</acronym>
      <studyHypothesis>The hypotensive effect of 0.5% timolol-2% dorzolamide-0.2% brimonidine fixed combination is different from that of Cosopt® in patients with diagnosis of primary open-angle glaucoma (POAG) and/or ocular hypertension with or without pseudoexfoliation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intraocular pressure. Duration of follow-up: 3 months (90 days).</primaryOutcome>
      <secondaryOutcome>1. Visual fields. Duration of follow-up: 3 months (90 days).
2. Ocular surface fluorescein staining. Duration of follow-up: 3 months (90 days).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Institute of Ophthalmology, Hospital La Carlota (Intituto de Oftalmologia Hospital La Carlota), gave approval on the 27th November 2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26988657</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>DRTBRII11O6</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II double-blind randomised controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1b5d7cda-fafe-422c-9933-e25203bb026d">
	  <name>Hidalgo No. 861-A</name>
	  <address/>
	  <city>Guadalajara</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>44100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients must have a clinical diagnosis of mild to moderate primary open-angle glaucoma (POAG) with or without pseudoexfoliation and pigmentary dispersion or ocular hypertension
2. Both males and females, aged 18 years or older
3. Patients with intraocular pressure between 21 and 30 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Patients with one blind eye
2. Patients with visual acuity of 20/40 or worse in either of the two eyes without a justifying cause
3. Patients with a history of any concomitant, active-stage ocular disease except the diseases specified in the inclusion criteria 
4. Patients taking any medication, regardless of the route of administration, that decisively interferes with the study results, until 48 hours prior to start of the trial or until a time period in which residual effects could be present
5. Sulfa allergy 
6. Patients with history of hypersensibility or any medical situation that contraindicates or makes risky the use of any of the study articles or their compounds under any route of administration as well as any drug or formulation derived from them or related to them
7. Contact lens users
8. Women of childbearing potential who are not using an adequate contraceptive method, as well as pregnant or breast-feeding women
9. Patients with history of cataract surgery with or without intraocular lens (IOL) implant (pseudoaphakia or aphakia) three months or less prior to Day 1 of the trial
10. Patients enrolled in any medical trial out of the Laboratorios Sophia S.A. de C.V. sponsorship within the last 90 days prior to this trial
11. Legally disqualified or mentally disabled patients who cannot sign the informed consent to participate in this trial
12. Patients who cannot comply with the medical appointments or with all the protocol requirements
13. Patients who disagree to participate in this trial
14. Patients with optic disc excavation greater than or equal to 0.8 
15. Normal-tension glaucoma patients</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary open-angle glaucoma, ocular hypertension</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>According to a random chart, 50 patients will receive over each eye one drop of a topical ophthalmic solution composed of timolol 0.5%, dorzolamide 2% and brimonidine 0.2% in a fixed-combination formula developed by Laboratorios Sophia S.A. de C.V. every 12 hours. The other 50 patients will be administered one drop of Cosopt® over each eye every 12 hours. Both medications will be administered during a period of 90 days. All the study articles will be labeled with a non-consecutive code number that is randomly generated by a computer.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Timolol, dorzolamide, brimonidine, Cosopt®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18248-0</funderId>
      <contactId>Contact56236_18248</contactId>
      <sponsorId>Sponsor54805</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56236_18248">
    <title>Dr</title>
    <forename>Leopoldo</forename>
    <surname>Baiza-Duran</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hidalgo No. 861-A 
Colonia Centro 
Sector Hidalgo</address>
      <city>Guadalajara</city>
      <country>Mexico</country>
      <zip>44100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 (01)33 38264152 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drbvista@sophia.com.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54805">
    <organisation>Laboratorios Sophia S.A de C.V. (Mexico)</organisation>
    <website>http://www.sophia.com.mx</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Hidalgo No. 737 
Colonia Centro 
Sector Hidalgo</address>
      <city>Guadalajara</city>
      <country>Mexico</country>
      <zip>44100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 (01)33 38264251</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drbvista@sophia.com.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487303.b</gridId>
    <rorId>https://ror.org/00zpf2822</rorId>
  </sponsor>
  <funder id="Funder18248-0">
    <name>Laboratorios Sophia S.A. de C.V. (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-23T00:00:00.000Z">74510183</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of pneumatic compression stockings in haemodialysis patients: a randomised crossover trial</title>
      <scientificTitle>The effect of pneumatic compression stockings on haemodynamic parameters in haemodialysis patients: a randomised crossover trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Primary hypothesis: 
To determine the effect of pneumatic compression devices (PCDs), compared to standard of care, on central blood volume in both intradialytic hypotension (IDH) prone and non-IDH prone haemodialysis patients.  

Secondary hypothesis:  
To determine the effect of PCDs on the haemodynamic response during haemodialysis in both IDH-prone and non-IDH prone patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The change in central blood volume with and without PCDs in both IDH-prone patients and non-IDH prone patients. Central blood volume will be determined using ultrasound dilution technique as per standard procedures. Determined within the first 30 minutes of HD and again within the last 15 minutes of the HD session; this is done for each of the study HD sessions (three with treatment, three with control).</primaryOutcome>
      <secondaryOutcome>Determined within the first 30 minutes of HD and again at the last 15 minutes of HD for each of the study sessions:
1. Cardiac output
2. Mean arterial pressure 
3. Bioimpedance derived extracellular fluid (ECF) and intracellular fluid (ICF) values</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The University of Calgary Office of Medical Bioethics approved on 2nd October 2008 (ref: ED-21937)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74510183</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised single centre active-controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a1ec3da4-b5a3-4f97-9186-3592f1cda025">
	  <name>Foothills Medical Centre</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T2N  2T9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic stable HD patients who have been on HD at least three times per week for at least 3 months
2. Both males and females, aged 18 - 95 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>51</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>51</totalTarget>
      <exclusion>1. Dialysing with a central venous catheter
2. Vascular access dysfunction
3. Lower extremity arterial ulcers, severe peripheral arterial disease, lower extremity amputations
4. Active medical issues
5. Unable to provide informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage kidney disease on haemodialysis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Chronic renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For sequence 1, the patient will undergo three HD sessions with PCDs, followed by three HD sessions without PCDs. For sequence 2, the patient will undergo three HD sessions without PCDs, followed by three sessions with PCDs. PCDs will be applied firmly around the calves prior to the initiation of HD with compressions intermittently applied at 40 mmHg throughout HD sessions. Frequencies of the compressions will be three cycles of compressions and decompressions per minute. Each cycle of compression and decompression will last approximately ten seconds. Lower extremities of all patients will be kept horizontal during the dialysis run. 

The total duration of treatment is three consecutive HD sessions at 4 hours each; the follow up period is the same.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18267-0</funderId>
      <contactId>Contact56255_18267</contactId>
      <sponsorId>Sponsor54824</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56255_18267">
    <title>Dr</title>
    <forename>Jennifer</forename>
    <surname>MacRae</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Foothills Medical Centre 
C210, 1403  29th Street NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2N  2T9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 403 944 8168</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jennifer.macrae@calgaryhealthregion.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54824">
    <organisation>University of Calgary (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Jennifer MacRae
Foothills Medical Centre
Calgary Health Region
C210 1403-29th Street NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2N 2T9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 403 944 8168</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jennifer.macrae@calgaryhealthregion.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22072.35</gridId>
    <rorId>https://ror.org/03yjb2x39</rorId>
  </sponsor>
  <funder id="Funder18267-0">
    <name>University of Calgary (Canada) - Faculty of Medicine, Division of Nephrology</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-17T00:00:00.000Z">55731750</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Lymph nodal dissection of the groin in skin malignant melanoma surgery - does the dissection technique have an impact on wound healing: scalpel versus ultrasonic assisted versus electrocauter</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Lymph nodal dissection of the groin for melanoma of the skin is known as a high wound complication procedure. The surgical procedure has been described very similarly for decades. For the tissue dissection there are different well-experienced techniques. These are the traditional scalpel dissection, the ultrasonic assisted and the electrocauter assisted dissection technique. All equipment is CE certified and use is currently up to the surgeons referrals. 

Evidence based decision making should be standard in todays medical treatment. In surgery evidence-based data is very rare. Concerning the described question for the impact of the dissection technique for the groin dissection there is no data available. Wound healing is a major problem in this group of patients. In medical literature a complication rate up to almost 50% (wound infection, healing problems, seroma, lymph fistula, lymphoedema, etc.) is being reported.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Length of hospital stay (days), evaluated at the time of hospital discharge of the patient</primaryOutcome>
      <secondaryOutcome>1. Amount of wound drainage (ml), evaluated at the time of hospital discharge of the patient
2. Time of drainage in situ (days), evaluated at the time of hospital discharge of the patient
3. Cost of treatment (Euro), evaluated after the 3 month follow-up</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval pending from the Ethikkommission der Ärtzekammer Westfalen Lippe as of 28/07/2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55731750</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FKH-PCH-2008-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, double blind, monocentric trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4deed1d5-a20d-42aa-a42b-2c329f21b178">
	  <name>Leitdender Arzt</name>
	  <address/>
	  <city>Münster</city>
	  <state/>
	  <country>Germany</country>
	  <zip>48157</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Indication for a lymph nodal dissection of the groin for a skin malignant melanoma
2. Aged over 18 years, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 (40 patients per group)</totalTarget>
      <exclusion>1. Non-consent
2. Aged under 18 years
3. Mentally disabled</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Wound healing in skin malignoma surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Wound healing</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The surgical procedure is the same for all the patients. There will be three groups for the different tissue dissection techniques:
1. Dissection with the scalpel/scissors
2. Ultrasonic assisted dissection
3. Electrocautery assisted dissection 

The follow-up will be 3 months in all arms.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18002-0</funderId>
      <contactId>Contact55985_18002</contactId>
      <sponsorId>Sponsor54551</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55985_18002">
    <title>Dr</title>
    <forename>Albrecht</forename>
    <surname>Krause-Bergmann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leitdender Arzt
Abteilung für Plastische und Ästhetische Chirurgie
Fachklinik Hornheide
Dorbaumstr. 300</address>
      <city>Münster</city>
      <country>Germany</country>
      <zip>48157</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krause-bergmann@fachklinik-hornheide.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54551">
    <organisation>Ethicon Endo-Surgery (Germany) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Hummelsbütteler Steindamm 71</address>
      <city> Norderstedt</city>
      <country>Gibraltar</country>
      <zip>22851</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419621.9</gridId>
    <rorId>https://ror.org/023edjq13</rorId>
  </sponsor>
  <funder id="Funder18002-0">
    <name>Ethicon Endo-Surgery (Germany) - received funding only; the study was independently performed and initiated by the hospital department</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-11T00:00:00.000Z">91017061</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Low-dose buprenorphine to prevent remifentanil-induced hyperalgesia after major lung resection: a prospective, randomised, controlled, double-blinded study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Remifentanil is now considered one of the favourite agents for fast-track surgery. Despite its advantages, a remifentanil-based general anaesthesia seems to increase post-operative hyperalgesia, mainly during long or painful surgical procedures.

Treating acute post-operative remifentanil-induced hyperalgesia could have several benefits:
1. It could decrease post-operative stress reducing morbidity after surgery, improving patients&#146; outcomes and clinical expense
2. It could decrease analgesic related side effects and improve post-operative pulmonary function
3. It could reduce chronic pain outcomes after surgery

Recent evidences, both experimental and clinical, showed the role of N-methyl D-aspartate (NMDA)-receptor antagonists to prevent remifentanil-induced hyperalgesia. Among all the NMDA-antagonists commercially available, buprenorphine has unique and attractive features.

Hypothesis:
Does a low-dose continuous intra- and post-operative infusion of buprenorphine prevent remifentanil-induced hyperalgesia after open thoracic surgery, reducing post-operative morphine consumption and the extension of the primary hyperalgesic area around the incision site?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Post-operative morphine consumption (PCA).</primaryOutcome>
      <secondaryOutcome>1. Morphine titration at the end of the surgery
2. Visual Analogue Scale (VAS) at rest and during coughing at 24 and 48 hours
3. Hyperalgesic area at 24 and 48 hours (Quantitative Sensory Testing)
4. Length of post-operative hospitalisation
5. Incidence of post-thoracotomy pain after one month from surgery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91017061</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, prospective, randomised, controlled, double-blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4cca7bbf-936c-4a4b-992d-3a748c48b66a">
	  <name>Department of Anaesthesia and Critical Care Medicine</name>
	  <address/>
	  <city>Rome</city>
	  <state/>
	  <country>Italy</country>
	  <zip>00189</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients (American Society of Anaesthesiologists [ASA] grade I - III) undergoing major lung resections
2. Aged greater than 18 years, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Extremely high or low weight (less than 40 kg and greater than 100 kg)
2. Known abuse of opioid drugs
3. Patients unable to manage a patient-controlled analgesia (PCA) device</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-operative remifentanil-induced hyperalgesia</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disturbances of skin sensation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients will receive remifentanil based general anaesthesia (target-controlled infusion [TCI] system), supplemented with oxygen and desflurane. Patients will then be randomised to:
1. Buprenorphine group: intra- and post-operative infusion of 25 µg/h of buprenorphine for 24 hours
2. Morphine group: intra- and post-operative infusion of 834 µg/h of morphine for 24 hours

Follow-up will occur until 30 days after hospital discharge.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Remifentanil-based general anaesthesia, oxygen, desflurane, buprenorphine, morphine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17582-0</funderId>
      <contactId>Contact55544_17582</contactId>
      <sponsorId>Sponsor54128</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55544_17582">
    <title>Prof</title>
    <forename>Roberto</forename>
    <surname>Arcioni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Anaesthesia and Critical Care Medicine
2nd Faculty of Medicine
La Sapienza University of Rome
Sant' Andrea Hospital</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>00189</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">roberto.arcioni@uniroma1.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54128">
    <organisation>La Sapienza University of Rome (Italy) </organisation>
    <website>http://www.uniroma1.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Anaesthesia and Critical Care Medicine
2nd Faculty of Medicine
Sant'Andrea Hosptial
via di Grottarossa 1035</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>0135</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">roberto.arcioni@uniroma1.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7841.a</gridId>
    <rorId>https://ror.org/02be6w209</rorId>
  </sponsor>
  <funder id="Funder17582-0">
    <name>La Sapienza University of Rome (Italy) - 2nd Faculty of Medicine, Sant' Andrea Hospital, Department of Anaesthesia and Critical Care Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-11T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-12-11T00:00:00.000Z">69468314</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Combination of specialist treatment and psychosocial intervention in women after a cardiac event</title>
      <scientificTitle>Combination of specialist treatment and psychosocial intervention in women after a cardiac event: a randomised controlled trial</scientificTitle>
      <acronym>HFH</acronym>
      <studyHypothesis>Combined intervention of specialist treatment and psychosocial rehabilitation specifically tailored for women's needs improves prognosis and psychosocial functioning.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients were followed-up for the following primary outcomes for 6.5 years on average through Swedish health care registers:
1. Mortality
2. Non-fatal myocardial infarction</primaryOutcome>
      <secondaryOutcome>Psychosocial functioning, assessed by the following questionnaires: 
1. Beck Depression Inventory
2. Mastricht Questionnaire measuring vital exhaustion
3. Daily Stress Behaviour Questionnaire
4. Availability of Social Integration
5. Availability of Attachment

All secondary outcomes were assessed at the following four timepoints:
T1: At baseline (6-8 weeks after randomisation)
T2: After 10 weeks i.e. after 10 intervention sessions
T3: After 1 year (end of intervention)
T4: At 1-2 year follow-up measurement</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Karolinska Institute (Karolinska Institutet), approve on 20/07/1995 (ref: 196/94)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69468314</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-08-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4aa9f6b1-8275-411b-b470-85b8108b1698">
	  <name>Norrbacka level 6</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>17176</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women aged &lt;=75 years
2. Those who had either acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Women &gt;75 years of age
2. Those not communicating in the Swedish language
3. Those who participated in other research studies
4. Those who did not belong to the hospital catchment area
5. Those who had serious co-morbidity that would preclude taking part in the 1-year intervention programme, such as malignancy or psychiatric disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-08-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Chronic ischaemic heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants were randomly assigned (randomisation ratio 1:1) to the following two groups: 

Intervention group: A combination of the following two interventions: 
1. Specialist treatment (cardiologist) as opposed to usual care 
2. A 1-year intervention consisting of a psychosocial rehabilitation based on cognitive-behavioural therapy principles tailored to women's needs (20 x 2-hour sessions) 

Control group: Usual care only.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18067552 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a00af362-5cb6-4d48-a9c3-057b7e94958a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18067552"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder18260-0</funderId>
      <contactId>Contact56248_18260</contactId>
      <sponsorId>Sponsor54817</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56248_18260">
    <title>Prof</title>
    <forename>Staffan</forename>
    <surname>Ahnve</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norrbacka level 6
Department of Public Health Sciences
Karolinska University Hospital</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>17176</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 8 737 38 97</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Staffan.Ahnve@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54817">
    <organisation>Public Health Committee/ EXPO-95 (Sweden)</organisation>
    <website>http://www.karolinska.se</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Norrbacka level 8
Karolinska University Hospital</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>17177 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.24381.3c</gridId>
    <rorId>https://ror.org/00m8d6786</rorId>
  </sponsor>
  <funder id="Funder18260-0">
    <name>EXPO-95/ Public Health Committee, Stockholm County Council (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-12-11T00:00:00.000Z">80279999</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Domiciliary application of non-invasive positive pressure ventilation with average volume assured pressure support to subjects with chronic obstructive pulmonary disease (COPD) who remain hypercapnic following the application of non-invasive positive pressure ventilation (NPPV) for an acute exacerbation</title>
      <scientificTitle/>
      <acronym>AVAPS-COPD</acronym>
      <studyHypothesis>Long-term domiciliary non-invasive positive pressure ventilation (NPPV) with average volume assured pressure support (AVAPS) in subjects with chronic obstructive pulmonary disease (COPD) who remain hypercapnic following the application of NPPV for an acute exacerbation will improve daytime partial pressure of carbon dioxide (PCO2) and endothelial dysfunction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Daytime PCO2, measured by arterial blood gases at baseline, 1, 3, 6 months and 1 year
2. Endothelial dysfunction, measured by peripheral arterial tone (PAT) at baseline, 1, 3, 6 months and 1 year</primaryOutcome>
      <secondaryOutcome>1. Lung function, measured by spirometry, according to the joint recommendations of the ERS/ATS. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year 
2. Dyspnoea, measured at rest by the Borg scale. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
3. Fatigue, measured by Fatigue Severity Scale (FSS). The FSS questionnaires contains nine statements that rate the severity of the subject's fatigue symptoms an a scale from 1 to 7. A total score of less than 36 suggests that the subject may not be suffering from fatigue, while a score of greater than or equal to 36 indicates excessive fatigue. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
4. Sleep quality, measured by polysomnography (PSG), including transcutaneous PCO2. At baseline, PSG will be performed in spontaneous breathing in order to characterise the abnormal respiratory events associated with COPD and identify obstructive sleep apnoea (OSA). Sleep and respiratory events will be recorded and scored manually according to standard criteria. REM hypoventilation will be scored when a progressive oxygen desaturation is associated with a sustained reduction in both flow and thoracic components of ventilation. During the same period, a constant or reduced respiratory drive (assessed by a reduction in respiratory effort as demonstrated by pulse transit time) should be observed without characteristic apnoeic or hypopnoeic episodes. At 3 months and 1 year, polysomnography will be done in spontaneous breathing or using non-invasive ventilation depending the arm of the study. Timepoints of assessment: baseline, 3 months and 1 year. 
5. Objective sleepiness as measured by the Osler Test. This test consists of a 40 minutes sleep-resistance challenge conducted in a dark and quiet room. The subject will be asked to remain awake while reacting to a visual stimulus, which appears for 1 second every 3 seconds, by hitting a button. Sleep latency will be defined as the delay between the onset of the test and the moment corresponding to seven consecutive flashes (i.e. 21 seconds) without response. Fluctuations in vigilance and micro-sleep episodes will be quantified as the number of occasions that 3 to 6 consecutive flashes occur without response (i.e. 9 to 18 seconds without response of the patient). Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
6. Exercise capacity. At baseline a practice test will be performed at least one hour before the actual test. The highest 6-minute walk distance will be reported as the patient's 6-minute walk distance at baseline. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
7. Physical activity. This will be objectively measured using the Actiwatch®. The Actiwatch® measures activity with a piezo-electric accelerometer that records intensity, amount and duration of movement in all directions. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
8. Quality of life, measured using the validated French version of the St Georges Respiratory Questionnaire. Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
9. Arterial stiffness, determined by pulse wave velocity (PWV). Timepoints of assessment: baseline, 1, 3, 6 months and 1 year. 
10. Time in hospital over course of follow up period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Protection of Human Subjects, Grenoble University Hospital (CHU de Grenoble) (ref: CPP08-RESP-1), approval pending as of 11/12/2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80279999</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EAME06NIV01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, parallel group pilot study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="66e4e56e-15e8-4c6d-9233-47ac764be7dd">
	  <name>Laboratoire Exploration Fonctionnelle Cardio-Respiratoire (EFCR)</name>
	  <address/>
	  <city>Grenoble</city>
	  <state/>
	  <country>France</country>
	  <zip>38043</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, aged 50 - 80 years
2. Confirmed diagnosis of COPD according to the joint recommendations of the European Respiratory Society/American Thoracic Society (ERS/ATS)
3. Minimum of 48 hours without NPPV after using NPPV or invasive ventilation in hospital during an acute exacerbation of COPD
4. Persistent hypercapnia (partial pressure of carbon dioxide in the arterial blood [PaCO2] greater than or equal to 50 mmHg, but less than 65 mmHg with an arterial pH above 7.32) during room air spontaneous breathing 
5. Able to follow instructions 
6. Able to provide informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Actively smoking 
2. Therapy with systemic steroids 
3. Important concomitant chronic systemic diseases (i.e. chronic heart failure [left ventricular ejection fraction less than 45%], diabetes, infections, neoplasm, forms of sleep disordered breathing, etc)
4. Other chronic respiratory diseases (e.g., significant fibrothorax, bronchiectasis, cystic fibrosis)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Other chronic obstructive pulmonary disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group will receive standard optimal care plus NPPV with AVAPS support, ventilatory support function that dynamically determines the pressure support level, which generates the target or control level of exhaled tidal volume by producing a gradual pressure change based on the preceding several breaths. 

Control group will receive standard optimised care.

Total duration of interventions/follow-up: 1 year</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18123-0</funderId>
      <contactId>Contact56111_18123</contactId>
      <sponsorId>Sponsor54678</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56111_18123">
    <title>Prof</title>
    <forename>J L</forename>
    <surname>Pepin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Laboratoire Exploration Fonctionnelle Cardio-Respiratoire (EFCR)
RDC Haut
CHU Michallon Nord
BP 217
Cedex 09</address>
      <city>Grenoble</city>
      <country>France</country>
      <zip>38043 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">JPepin@chu-grenoble.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54678">
    <organisation>Respironics International, Inc. (France) </organisation>
    <website>http://www.respironics.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>20 Rue-Jacques Daguerre
Rueil-Malmaison</address>
      <city>Paris</city>
      <country>France</country>
      <zip>92500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steven.coughlin@respironics.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425454.6</gridId>
    <rorId>https://ror.org/05jz46060</rorId>
  </sponsor>
  <funder id="Funder18123-0">
    <name>Respironics International, Inc. (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-12-10T00:00:00.000Z">37262487</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and immunogenicity of meningococcus C conjugate vaccine</title>
      <scientificTitle>Safety and immunogenicity of conjugate vaccine for meningococcal C disease: a randomised study</scientificTitle>
      <acronym/>
      <studyHypothesis>Bio-Manguinhos conjugate vaccine against meningococcus C is safe and immunogenic in young healthy adults.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency/intensity of adverse events during 30 days after vaccination.</primaryOutcome>
      <secondaryOutcome>1. Serological conversion, defined as prevaccinal sera non-reactive to meningococcus C, and post-immunisation sera reactive (titre greater than or equal to 8, reciprocal of dilution)
2. Titre of antibodies to meningococcus C after immunisation (intensity of immune response)
3. Measurement of antibodies just before and 30 days after vaccination</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of Evandro Chagas Institute for Clinical Research (Comitê de Ética do Instituto de Pesquisa Clínica Evandro Chagas) gave approval on the 15th February 2008 (ref: CAAE 0068.0.009.000-07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37262487</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ASCLIN/01/2008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7246f5bc-a3a0-44b6-80da-6d83eaa5754d">
	  <name>Av. Brasil 4365</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21040-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy
2. Both sexes
3. Aged between 18 and 50 years
4. Capable of understanding and signing Free and Informed Consent Form
5. Intellectual level which permits filling out records of adverse events at home
6. Capable of understanding risks of the experiment
7. Willing test for human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV)
8. Clinical examination without significant abnormalities
9. Laboratorial tests within normal range, or only with clinically non-significant alterations
10. Pre-vaccinal level of antibodies against tetanus below 5 IU/mL
11. Negative pregnancy test</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Pregnancy or breastfeeding
2. Personal history of meningitis, any kind
3. Previous serious adverse event to any vaccination
4. Severe adverse event to tetanus toxoids
5. Vaccination against tetanus in the last 2 years
6. Anti-allergic vaccines 14 days or less before vaccination
7. Blood products in the last 12 months
8. Any vaccination 30 days or less before vaccination in test
9. Chronic use of any medication, except trivial ones
10. Previous use of cytotoxic or immunosuppressive therapy
11. Asthma which requires hospital care
12. Serious angioedema or anaphylaxis</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Meningococcus C disease</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Meningococcal infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 30 volunteers will receive meningococcus C vaccine conjugate to tetanus toxoid from Bio-Manguinhos, single 0.5 ml dose (10 µg) IM (intramuscularly)
2. 30 volunteers will receive a similar commercial vaccine (reference vaccine), same dose and schedule</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Meningococcus C conjugate vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18325-0</funderId>
      <contactId>Contact56314_18325</contactId>
      <sponsorId>Sponsor54883</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56314_18325">
    <title>Dr</title>
    <forename>Reinaldo</forename>
    <surname>Martins</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. Brasil 4365
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54883">
    <organisation>Bio-Manguinhos/Fiocruz (Brazil) </organisation>
    <website>http://www.bio.fiocruz.br</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Dr Akira Homma
Av. Brasil 4365
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424703.6</gridId>
    <rorId>https://ror.org/05gj5j117</rorId>
  </sponsor>
  <funder id="Funder18325-0">
    <name>Brazilian Ministry of Science and Technology (MCT) (Brazil) - Financing Agency for Studies and Projects (Financiadora de Estudos e Projetos [FINEP])</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-12-10T00:00:00.000Z">18637372</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>EPAS: Epidural versus Picra for Abdominal Surgery</title>
      <scientificTitle>Comparison of epidural catheters versus surgical wound catheters for analgesia after major hepatobiliary and pancreatic surgeries</scientificTitle>
      <acronym>EPAS</acronym>
      <studyHypothesis>We hypothesise that surgical wound catheters with patient controlled anaesthesia are equivalent to epidural catheters with patient controlled anaesthesia with respect to post-operative pain, complications and return to function.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The total amount of analgesic used as determined by the patient controlled anaesthesia pump. This will be assessed via each patient's post-operative anaglesia sheet, which is a common method in our hospital, commonly used by our nursing staff.</primaryOutcome>
      <secondaryOutcome>1. The subjective scores of the post-operative pain, monitored via a Visual Analogue Scale (1 - 10) twice daily (BID)
2. Total time requiring the epidural or wound catheter
3. Total length of hospitalisation
4. Level of ambulation and activity, recorded by nursing staff on analgesic sheets
5. Time for return of full diet, recorded by nursing staff on analgesic sheets 
6. Time for return of full gastrointestinal function, recorded by nursing staff on analgesic sheets</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval pending as of 19/12/2007 from:
1. University of British Columbia 
2. Vancouver Coastal Health</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18637372</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H07-02916</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, prospective controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e80b69ba-e629-4c53-a298-99fb4752b57d">
	  <name>Gordon &amp; Leslie Diamond Health Care Center</name>
	  <address/>
	  <city>Vancouver</city>
	  <state/>
	  <country>Canada</country>
	  <zip>V5Z 1M9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients will be eligible to be enrolled in the study only after each of the following criteria are met:
1. Aged greater than or equal to 18 years, either sex
2. Cheyne abdominal incision used
3. Pre-operative International Normalised Ratio (INR) less than or equal to 1.3
4. Pre-operative platelet count greater than or equal to 100,000/uL
5. No prior epigastric incision
6. Body mass index (BMI) less than 30 kg/m^2
7. No signs of systemic sepsis
8. No allergies to agents or medications
9. Willingness to accept either surgical wound catheter or epidural catheters</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Does not meet the inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major hepatobiliary and pancreatic surgeries</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Hepatobiliary and pancreatic surgeries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Epidural catheters and surgical wound catheters. 

On the day of surgery, the patient will be randomised to either the epidural or wound catheter. The wound catheter will be placed by the attending surgeon at the end of the procedure, while the epidural will be placed by the anaesthesiologist at the beginning of the procedure. Both groups will also be equipped with patient controlled analgesia (PCA). Our Post-operative Pain Service (POPS) will monitor the pain control of these patients and make adjustments regarding the rate of infusion of both these devices. The removal of the devices will be left at the discretion of the attending anaesthesiologist on POPS, which generally is between 2 - 5 days. The duration of follow up and the intervention will be the length of the patient's inpatient stay, which is obviously individualised for each patient.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17372-0</funderId>
      <contactId>Contact55333_17372</contactId>
      <sponsorId>Sponsor53903</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55333_17372">
    <title>Dr</title>
    <forename>Charles</forename>
    <surname>Scudamore</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gordon &amp; Leslie Diamond Health Care Center
5th floor 2775 Laurel Street</address>
      <city>Vancouver</city>
      <country>Canada</country>
      <zip>V5Z 1M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53903">
    <organisation>University of British Columbia (Canada)</organisation>
    <website>http://www.ubc.ca/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Surgery
Faculty of Medicine
3100, 910 West 10th Avenue</address>
      <city>Vancouver</city>
      <country>Canada</country>
      <zip>V5Z 4E3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17091.3e</gridId>
    <rorId>https://ror.org/03rmrcq20</rorId>
  </sponsor>
  <funder id="Funder17372-0">
    <name>Investigator initiated and funded (Canada) - no external funding will be sought</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-10T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2008-12-10T00:00:00.000Z">45882141</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow-up at a minimum of ten years</title>
      <scientificTitle/>
      <acronym>MEA vsTCRE</acronym>
      <studyHypothesis>To compare outcomes and further operations at a minimum of ten years following microwave endometrial ablation (MEA™) or transcervical resection of the endometrium (TCRE).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patient satisfaction and acceptability of treatment, assessed by questionnaires (Timepoints: T1-T5).

Timepoints: 
T0: Within 6 weeks after operation
T1: 4 months after operation
T2: 12 months after operation
T3: Minimum of 2 years after operation
T4: Minimum of 5 years after operation
T5: Minimum of 10 years after operation

Additional data were also obtained via a hospital database.</primaryOutcome>
      <secondaryOutcome>The following were assessed at timepoints T0-T5:
1. Menstrual symptoms (questionnaires) 
2. Changes in health related quality of life, assessed by the SF-36 Health Survey  
3. Additional treatments received (questionnaires)

Timepoints: 
T0: Within 6 weeks after operation
T1: 4 months after operation
T2: 12 months after operation
T3: Minimum of 2 years after operation
T4: Minimum of 5 years after operation
T5: Minimum of 10 years after operation

Additional data were also obtained via a hospital database.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Original study: Grampian Health Board Joint Ethical Committee, approved on 11/12/1995 (Project no.: 2459)
Follow-up study: Grampian Local Research Ethics Committee, approved on 05/02/2007 (ref: 06/S0801/123)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45882141</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06/S0801/123</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-12-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bd965ad0-09b2-4649-b575-3e2641296b65">
	  <name>Ward 42</name>
	  <address/>
	  <city>Aberdeen</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>AB25 2ZN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Premenopausal women, no age limits
2. Heavy menstrual loss 
3. Family was complete (i.e. no desire for further children)
4. No endometrial atypia 
5. Uterine size not greater than ten weeks size</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>263</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>263</totalTarget>
      <exclusion>Unwilling to complete follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-12-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heavy menstrual bleeding</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Excessive, frequent and irregular menstruation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions: 
Microwave endometrial ablation (MEA™) vs transcervical resection of the endometrium (TCRE). 

Start date of RCT: 11/12/1995
End date of RCT: 01/12/1998 (end of follow-up)

Follow-up study: postal questionnaires and operative databank review.

Start date of the follow-up study: 01/03/2007
End date of the follow-up study: 01/10/2008</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/pubmed/10584722 Original trial results
2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12052586 Two-year follow-up results
2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15777447 Five-year follow-up results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="93fb72c8-67d9-4316-aa32-06b6372c2dea" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-11-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/10584722"/>
	<description>Original trial results</description>
	<productionNotes/>
      </output>
      <output id="aee61625-8669-4117-8281-80f6e7c0f034" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12052586"/>
	<description>Two-year follow-up results</description>
	<productionNotes/>
      </output>
      <output id="68380fdc-18c4-4883-a865-a64b14c531a0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15777447"/>
	<description>Five-year follow-up results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder18172-0</funderId>
      <contactId>Contact56160_18172</contactId>
      <sponsorId>Sponsor54728</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56160_18172">
    <title>Dr</title>
    <forename>Kevin</forename>
    <surname>Cooper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ward 42
Aberdeen Royal Infirmary </address>
      <city>Aberdeen</city>
      <country>United Kingdom</country>
      <zip>AB25 2ZN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54728">
    <organisation>NHS Grampian (UK)</organisation>
    <website>http://www.nhsgrampian.org</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Aberdeen Royal Infirmary
Foresterhill</address>
      <city>Aberdeen</city>
      <country>United Kingdom</country>
      <zip>AB25 2ZN  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411800.c</gridId>
    <rorId>https://ror.org/00ma0mg56</rorId>
  </sponsor>
  <funder id="Funder18172-0">
    <name>Aberdeen Royal Infirmary, Gynaecological Endoscopy Research Fund (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-15T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-12-03T00:00:00.000Z">82952463</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Relationship between maternal egg intake and foetal development</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Daily consumption of whole eggs during pregnancy promotes foetal growth and development in children born to low-income women.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Foetal growth, measured at 3 months and 6 months of gestation
2. Newborn ponderal index, measured at birth
3. APGAR score, measured at birth</primaryOutcome>
      <secondaryOutcome>1. Maternal body composition, measured at 3 months of gestation
2. Newborn body composition, measured at birth</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Rutgers Human Subjects Investigational Review Board, approved on 20/05/2008
2. State University of Rio de Janeiro Human Subjects Ethics Board, approved in January 2008</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82952463</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="517042bd-03f5-4906-9a21-7241a195dd78">
	  <name>Rutgers, The State University of New Jersey</name>
	  <address/>
	  <city>New Brunswick</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>08901</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women between the ages of 18 and 40 years
2. Those who are in their 4th or 5th month of singleton pregnancy
3. Free from chronic diseases (heart disease, cancer, diabetes, hypertension, and other disorders that may influence metabolism and growth)
4. Reside in Duque de Caxias in Rio de Janeiro</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>1. Women who are beyond their 6th month of pregnancy
2. Pregnant with more than one foetus
3. Current use of tobacco, alcohol or illegal drugs
4. Younger than 18 or older than 40 years of age</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Maternal nutrition and foetal development</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Maternal care for other known or suspected fetal problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants are allocated to four study arms: 
Group 1: Normal dietary intake who never consume eggs (non-random allocation)
Group 2: Normal diet who are instructed not to consume eggs (random allocation)
Group 3: Normal diet who are instructed to eat at least one egg per day (random allocation). They will be provided with vouchers redeemable at local stores for the purchase of eggs only.
Group 4: Control group (non-random allocation). They will be provided with standard dietary counselling for pregnant women.
 
Total duration of interventions: Three months</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Eggs</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18053-0</funderId>
      <contactId>Contact56040_18053</contactId>
      <sponsorId>Sponsor54605</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56040_18053">
    <title>Dr</title>
    <forename>Daniel</forename>
    <surname>Hoffman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rutgers, The State University of New Jersey
27 Nichol Avenue
Room 228B</address>
      <city>New Brunswick</city>
      <country>United States of America</country>
      <zip>08901</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54605">
    <organisation>Egg Nutrition Center (USA)</organisation>
    <website>http://www.enc-online.org</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>1900 L Street NW Suite 725</address>
      <city>Washington, DC</city>
      <country>United States of America</country>
      <zip>20036</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.468556.c</gridId>
    <rorId>https://ror.org/00289h314</rorId>
  </sponsor>
  <funder id="Funder18053-0">
    <name>Egg Nutrition Center (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-12-02T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-11-28T00:00:00.000Z">17233445</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral supplementation of omega-3 and omega-6 in dry eye syndrome</title>
      <scientificTitle>A three-month, multicentre, double-masked, randomised, controlled, clinical study to investigate the efficacy of Medilar™ in patients suffering from dry eye syndrome</scientificTitle>
      <acronym/>
      <studyHypothesis>Oral supplementation of omega-3 and omega-6 can reduce inflammatory markers in conjunctival cells of patients suffering from dry eye syndrome.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage of conjunctival epithelial cells expressing human leukocyte antigen DR-1 (HLA-DR) inflammatory markers in the worst eye, measured at baseline and month 3.</primaryOutcome>
      <secondaryOutcome>Efficacy (in worst eye): 
1. Global subjective dry eye score (foreign body sensation, dryness, burning, stinging, photophobia)
2. Subjective dry eye score for each symptom
3. Objective dry eye score for each test (fluorescein staining of the cornea, Van Bijsterveld test, tear Break-Up Time [BUT] test, Schirmer-I)
4. Fluorescence intensity of conjunctival cells expressing HLA-DR inflammatory marker
5. Quality of life questionnaire for ocular surface disease

Safety:  
6. Adverse or unexpected events 

All secondary outcomes were assessed at baseline (D0), week 6 and month 3.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Italy: 
1. Ethics Committee of the San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino) gave approval on the 17th February 2006 (ref: 0016378/06)
2. Ethics Committee of the University Polyclinic (Azienda Policlinico Universitario) gave approval on the 12th January 2006 (ref: E 625/05)

France: 
1. Ethics Committee CCPPRB de Bourgogne gave approval on the 29th September 2005 (ref: 2005/20)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17233445</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Study #425</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-masked, two-armed, parallel group, placebo-controlled, multicentre study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-22T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1834d99a-b22c-4468-a36b-2c51c095c936">
	  <name>Hôpital Général</name>
	  <address/>
	  <city>Dijon</city>
	  <state/>
	  <country>France</country>
	  <zip>21034</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Legally adult outpatients, both males and females 
2. Having given their written informed consent 
3. Suffering from dry eye syndrome as defined by the presence of: 
3.1. At least two of the following four objective tests corresponding to the scores below: 
3.1.1. Schirmer-I-values less than 10 mm/5 min 
3.1.2. Break-up-time-values less than 10 sec 
3.1.3. Fluorescein staining of the cornea score greater than or equal to 1 and less than 4 
3.1.5. Van Bijsterveld score greater than or equal to 3 and less than or equal to 6 (Lissamine green) 
3.2. A score of at least 1, for at least two of the five following subjective tests (scored 0 to 3): 
3.2.1. Foreign body sensation 
3.2.2. Dryness 
3.2.3. Burning 
3.2.4. Stinging 
3.2.5. Photophobia 
4. Stable systemic treatment (unchanged for one month or longer)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>140</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>140</totalTarget>
      <exclusion>1. Aged less than 18 years 
2. Severe dry eye (Lissamine green greater than 6 or corneal staining greater than or equal to 4) 
3. Uncontrolled evolutive systemic disease 
4. Patients with an implantable cardioverter defibrillator (ICD) 
5. Uncontrolled inflammatory disease (treated with varying doses of steroids or non-steroidal anti-inflammatory substances) 
6. Change in systemic treatment within the last month 
7. Expected change in treatment of concomitant disease 
8. Patients treated with anticoagulants or predisposed to bleeding or haemorrhage 
9. Drastic change of food and/or food supplements within the last month 
10. Other food supplement with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
11. Patients with a history of recurrent ocular herpes and/or recurrent uveitis 
12. Evidence of acute ocular infection and/or intra-ocular inflammation within one month prior to the onset of this study 
13. Patients who have undergone ocular surgery within the last 6 months 
14. Change in ocular treatment within the last month 
15. Patients currently using any ophthalmic medication including any ocular ointment except artificial tear preparation and eye cleaning solution for treatment of dry eye syndrome 
16. Patients treated with topical ocular, steroidal or non-steroidal anti-inflammatory treatment within the last month 
17. Patients treated with ocular topical cyclosporin within the last month 
18. Occlusion therapy with lacrimal or punctum plugs within the last 3 months 
19. Patients currently wearing contact lenses 
20. Pregnant or lactating women 
21. Women of childbearing potential considering becoming pregnant during the course of the study and those not taking precautions to avoid pregnancy 
22. Patients for whom, in the physician's opinion, any of the protocol procedures may pose a special risk not outweighed by the potential benefits of participating in the study 
23. Patients who are unlikely to comply with the study protocol or who are likely to be moving and lost to follow-up in the study period 
24. Known contraindication, adverse reaction, or hypersensitivity to any constituents of this food supplement 
25. Patients who have participated in any clinical investigation within the last 30 days or are currently participating in a clinical study 
26. Patients who are addicted to alcohol or drugs 
27. Patients with neurotic, psychiatric disorders or suicidal tendencies 
28. Patients who plan to start a diet or to change their diet during the course of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-22T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dry eye syndrome</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Disorders of lacrimal system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Test product - Medilar™: 
Oral supplementation with 855 mg of omega-3 and 15 mg of omega-6, vitamins (C,E, B6, B12) and zinc per day (3 capsules per day) for 3 months.

Comparator: 
Placebo (medium chain triglycerides), 3 capsules per day for 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames>Omega-3, omega-6 (Medilar™)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18227-0</funderId>
      <contactId>Contact56215_18227</contactId>
      <sponsorId>Sponsor54784</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56215_18227">
    <title>Prof</title>
    <forename>Catherine</forename>
    <surname>Creuzot-Garcher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Général
Service d'Ophtalmologie 
3 Rue du Faubourg Raines 
BP 1519 </address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21034</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54784">
    <organisation>Laboratoire Chauvin, Bausch &amp; Lomb Inc. (France)</organisation>
    <website>http://www.bausch.fr</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>416, rue Samuel Morse 
CS 99535 </address>
      <city>Montpellier cedex 2</city>
      <country>France</country>
      <zip>34961</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487287.6</gridId>
    <rorId>https://ror.org/018qejt38</rorId>
  </sponsor>
  <funder id="Funder18227-0">
    <name>Laboratoire Chauvin, Bausch &amp; Lomb Inc. (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-11-27T00:00:00.000Z">80896844</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Vaccination with human minor H antigen (HA-1) peptide after allogeneic stem cell transplantation</title>
      <scientificTitle>Vaccination with human minor H antigen (HA-1) peptide in patients showing minimal residual disease or mixed chimerism after allogeneic stem cell transplantation and donor lymphocyte infusion</scientificTitle>
      <acronym/>
      <studyHypothesis>After allogeneic human leukocyte antigen (HLA)-matched stem cell transplantation (SCT), minor histocompatibility antigens (mHags) are the most likely targets for graft-versus-leukaemia (GvL) associated immune reactivity. Among these mHags, human minor H antigen (HA-1) is expressed by both normal haematopoietic cells and their malignant counterparts. HA-1 specific T-cells have been shown to be capable of eliminating HA-1 positive malignant (precursor) cells in HLA-A2 positive HA-1 positive patients after stem cell transplantation and donor lymphocyte infusion (DLI) administration from a HA-1 negative donor. However, after DLI not all patients develop a HA-1 specific T-cell response and a durable GvL effect in this setting. 

We hypothesise that vaccination with administration of HA-1 peptide vaccine in HLA-A2 and HA-1 positive patients who had undergone HLA-matched allogeneic stem cell transplantation followed by DLI from a HLA-A2 positive, HA-1 negative, donor showing persistent disease or mixed chimerism eight weeks after DLI can induce an immunological response without severe graft-versus-host disease (GVHD).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Toxicity (phase 1), monitored every two weeks until end of study
2. Appearance of HA-1 specific CD8+ lymphocytes, monitored at weeks 6 and 8 and from 10 - 26 weeks after DLI</primaryOutcome>
      <secondaryOutcome>1. Bone marrow chimerism, monitored at weeks 8, 12, 15, 19 and 26
2. Disease activity, monitored at weeks 8, 12, 15, 19 and 26</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Central Committee on Research involving Human Subjects (CCMO) gave approval on the 17th March 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80896844</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LUMC2007-02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single arm open label intervention phase I/II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="96e37044-5372-476b-910b-d63c172ff8d0">
	  <name>Department of Haematology</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 ZA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with acute myeloid leukaemia (AML), myelodysplasia (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) in accelerated phase or blastic transformation before transplantation, chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or aggressive lymphoma, who underwent allo-SCT (both myeloablative and non-myeloablative) followed by DLI for persistent mixed chimerism or smoldering disease
2. Patient and donor HLA-A2 positive, patient HA-1 positive, donor HA-1 negative
3. World Health Organization (WHO) performance status of 0, 1 or 2
4. Female patients of childbearing potential must be neither pregnant nor breastfeeding and must agree to use effective contraception (birth control pills, condoms, approved implant, or intra-uterine device [IUD]) during the course of this trial and for at least three months after the last injection
5. Mixed chimerism or persisting disease 8 weeks after DLI
6. Male and female, aged 18 years and older</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Life expectation of less than 3 months
2. Psychological disturbances
3. Severely limited life expectation due to diseases other than the malignancy
4. Human immunodeficiency virus (HIV) positivity
5. Persistent treatment with high-dose corticosteroids (greater than 20 mg prednisone a day), chemotherapy or other immunosuppressive drugs
6. Rapidly progressive disease
7. GVHD grade 3 or 4
8. HA-1 specific immune response (defined by greater than 0.2% of total CD8+ cells in first six patients and defined by greater than 1.0% of total CD8+ cells in patients 4 - 24 if no toxicity greater than grade II in first three patients). No important increase in percentage HA-1 specific CD8+ cells between 6 and 8 weeks after DLI (defined as a doubling of this percentage resulting in a percentage of greater than 0.2%).</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mixed chimerism after allogeneic stem cell transplantation</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Mixed chimerism</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Week 0: The study starts when DLI is given in an eligible patient
Week 8: Bone marrow investigation for chimerism and/or disease evaluation. GVHD evaluation and measurement of HA-1 specific T cells. If no HA-1 specific response: 
Week 10: First subcutaneous vaccination with HA-1 peptide vaccine and as a control subcutaneous vaccination with Keyhole Limpet Hemocyanin (KLH)
Week 13: Second subcutaneous vaccination with HA-1 peptide vaccine
Week 16: Third subcutaneous vaccination with HA-1 peptide vaccine

Immunological and clinical effects will be evaluated after the first 12 patients treated using the 20mer vaccine. If six or more patients showed an immunological response, the vaccination program using the 20mer vaccine will be continued, aiming for a total number of 24 patients. If less than 6 patients showed an immunologic response, 12 additional patients will be entered and treated using the 20mer + 9mer vaccine If less than 6 patients showed an immunological response to the 20mer + 9mer vaccine, the vaccination strategy using current peptides will be considered inadequate.

Information on vaccines:

20mer vaccine (300 µg peptide): 
The subcutaneous 20mer HA-1 vaccine consists of a single peptide representing the amino-acid sequence 133-152 (LKECVLHDDLLEARRPRAHE) of the HA-1 protein encoded by the gene KIAA0223. The peptide is produced in the Interdivisional GMP-Facility of the LUMC (IGFL), Department of Clinical Pharmacy and Toxicology. Montanide ISA 51 is used as an adjuvant.

KLH: 
Immucothel (Biosyn Arzneimittel GmbH) 1 mg is used to test the capacity for generating an immune response in the patient).

20mer and 9 mer combination vaccine (300 µg 20-mer peptide and 250 µg 9-mer peptide): 
This investigational medical product (IMP) consists of a peptide that comprises LKECVLHDDLLEARRPRAHE, representing the amino-acid sequence 133-152 of the HA-1 protein encoded by the gene KIAA0223, in combination with a peptide that comprises VLHDDLLEA, representing the amino-acid sequence 137-145 of the HA-1 protein encoded by the gene KIAA0223. The peptides are produced in the Interdivisional GMP-Facility of the LUMC (IGFL), Department of Clinical Pharmacy and Toxicology. Montanide ISA 51 is used as an adjuvant.

Total follow-up is 26 weeks after week 0 (so 16 weeks after vaccination).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I/II</phase>
	<drugNames>Human minor H antigen (HA-1) peptide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18250-0</funderId>
      <contactId>Contact56238_18250</contactId>
      <sponsorId>Sponsor54807</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56238_18250">
    <title>Prof</title>
    <forename>JHF</forename>
    <surname>Falkenburg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Haematology 
CR-2 Albinusdreef 2 </address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 526 2271</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">J.H.F.Falkenburg@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54807">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands) </organisation>
    <website>http://www.lumc.nl/english/start_english.html </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2 </address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 526 2267</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.j.m.halkes@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder18250-0">
    <name>Dutch Cancer Society (KWF Kankerbestrijding) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-26T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-11-26T00:00:00.000Z">44627088</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Training and attentional focus in older adults</title>
      <scientificTitle>Training control of bodily orientation as a function of attentional focus in older adults</scientificTitle>
      <acronym/>
      <studyHypothesis>Individuals that receive an external focus (EF) instruction during training of dynamic balance skills will show different development of their balance ability compared to individuals that receive an internal focus (IF) instruction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured in each training session:
1. The weight shift score for medio-lateral movements on the stable BSS platform
2. Performance time on the unstable BSS platform for the dynamic limits of stability (LOS) test and the dynamic stability index derived from this test</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline (pre-training) and after completion of 10 training sessions (post-training):
1. The Expanded Timed Get-up-and-Go (ETGUG) test. Times for the component tasks are measured using a multi-memory stopwatch.
2. The time for 5 consecutive chair rises without the use of hands
3. The Falls Efficacy Scale International (FES-I) questionnaire as a measure of 'concern' about falling</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Ethics Committee of the Canton of Zurich on the 10/10/2006 (ref: EK 19/2006 [ETH])</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44627088</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised single-blind controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d02dc313-a0f9-497d-8a95-52f32cf25ff4">
	  <name>Institute of Human Movement Sciences and Sport</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-8093 Zürich</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, 70 years of age and older
2. Assisted living
3. Ability to see a feedback marker on a computer screen
4. A score of 25 or more in the Mini Mental Status Examination (MMSE)
5. Ability to be able to follow verbal instructions in the German language and the ability to stand upright independently</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. A rapidly progressive or terminal illness
2. Acute illness or unstable chronic illness
3. Those who were undergoing balance training at the time of enrolment or had prior experience with the training task</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postural balance skills in elderly</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Other symptoms and signs involving the nervous and musculoskeletal systems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Balance assessment and training on a Biodex Stability System (BSS) (Biodex Medical Systems Inc., USA) device under two different verbal instruction conditions. 

Participants in both groups were instructed to focus on the visual feedback screen whilst performing their exercises. The screen showed a moving point in the middle of a target and the participants were asked to follow the target through shifting their weight. All participants received an exercise protocol in which the exercises gradually became more complex. 

The IF group participants were, prior to IF trials, instructed with the feedback that the moving point on the feedback screen represented their body centre of gravity. They were instructed to focus on this centre through concentrating on their belly (while looking straight ahead at the video screen) and to volitionally move this point on the screen through exertion of force on this imaginary point. 

The EF group participants were instructed that the moving point on the feedback screen represented an air bubble in a level, (as used in the building industry to determine a level horizontal line), positioned in front of the feet of the participant standing on the plate. Such a level was attached to the platform with an electronic cable, thus suggesting a direct connection between movements of the air bubble in the level and the marker on the screen. The EF participants had to focus on the air bubble (while looking straight ahead at the video screen) and try to consciously move this bubble in the level. 

All participants were expected to perform at least three practice trials per exercise on two week days for five consecutive weeks under the treatment conditions. Before every practice trial, participants were given short reminders to focus on the respective 'moving points'. In a fourth trial, the time needed to perform the exercise under test conditions was measured together with the Dynamic Stability Index of the participants. This procedure was chosen to rule out short-term learning effects. Training duration lasted between 25 and 35 minutes. 

In order to avoid bias, the information that focus of attention of the participants possibly plays an important role in the speed of learning was not disclosed before training commenced. Following the five weeks training programme, complete information on the aim of the study was given to each participant in a debriefing session. The reason for not disclosing this information before the measurements was discussed at the debriefing. Only the results of participants who agreed with this procedure were included in the final data analysis.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18228-0</funderId>
      <contactId>Contact56216_18228</contactId>
      <sponsorId>Sponsor54785</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56216_18228">
    <title>Dr</title>
    <forename>Eling D</forename>
    <surname>de Bruin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Human Movement Sciences and Sport
HIT J 32.3
Wolfgang-Pauli-Str. 27</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>CH-8093 Zürich</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 44 632 40 18</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">debruin@move.biol.ethz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54785">
    <organisation>Swiss Federal Institute of Technology Zürich (ETH Zürich) (Switzerland) </organisation>
    <website>http://www.ibws.ethz.ch</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institute of Human Movement Sciences and Sport
HIT J 32.3
Wolfgang-Pauli-Str. 27</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>CH-8093</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 44 632 40 18</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">debruin@move.biol.ethz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5801.c</gridId>
    <rorId>https://ror.org/05a28rw58</rorId>
  </sponsor>
  <funder id="Funder18228-0">
    <name>Swiss Federal Institute of Technology Zürich (ETH Zürich) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-25T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-11-25T00:00:00.000Z">46725454</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative clinical study of visual results between three types of multifocal lenses</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the patients visual results after bilateral implantation of ReZoom™ multifocal intraocular lens (IOL) (NXG1, Advanced Medical Optics), AcrySof® ReSTOR® IOL (SA60D3, Alcon Laboratories) and Tecnis® multifocal IOL (ZM900, Advanced Medical Optics).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Evaluation of anterior and posterior segments of the eyeball with slit lamp biomicroscope
2. Examination of uncorrected distance visual acuity (UCDVA) and best distance corrected visual acuity (BDCVA)  (logarithm of the minimum angle of resolution [LogMAR] and Snellen's chart)
3. Examination of uncorrected near visual acuity (UNVA) and best distance corrected near visual acuity (BDCNA) (Jaeger reading chart)
4. Axial length
5. Intraocular pressure
6. Measurement of corneal endothelial cell density
7. Contrast sensitivity measurement with CSV-1000 test (Vector Vision)
8. Evaluation of pupil size
9. Measurement of eye aberration with aberrometer WASCA (Carl Zeiss, Inc.)

The primary outcomes were measured 1 day, 1 week, 1, 3 and 6 months after surgery.</primaryOutcome>
      <secondaryOutcome>1. Spectacle dependency
2. Subjective satisfaction with vision using the 14-item Visual Function (VF-14) survey

The secondary outcomes were measured 3 and 6 months after procedure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Standard procedure of cataract removal with implantation of intraocular lenses being in common usage means that no ethics board approval was required.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46725454</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, non-randomised, non-masked study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1830b8e-b73f-4506-a4f0-2ff167019273">
	  <name>University Hospital No. 5 of the Medical University of Silesia</name>
	  <address/>
	  <city>Katowice</city>
	  <state/>
	  <country>Poland</country>
	  <zip>40-952</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 40 - 75 years, either sex
2. Visual acuity equal to or less than 0.7 according to Snellen&#146;s chart
3. Cataract in both eyes classified according to the Lens Opacities Classification System III (LOCS III)
4. Astigmatism less than 1.5 D
5. Mesopic pupil larger than 3.0 mm
6. Lack of other ophthalmological illnesses, such as:
6.1. Post-transplant cornea
6.2. Irregular astigmatism
6.3. Chronic uveoscleritis
6.4. Damage to ciliary/zonular system of lens
6.5. Pseudoexfoliation syndrome
6.6. Glaucoma
6.7. Previous refractive and anti-glaucomatous operations
6.8. Diabetic retinopathy
6.9. Macular degeneration</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Thirty patients</totalTarget>
      <exclusion>1. Age below 45 and more than 75 years
2. Any other diseases besides cataract
3. Unrealistic expectations concerning vision
4. Patients practising professions which required night-time driving</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cataract</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Other cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Phacoemulsification and aspiration of lens mass were carried out with the Infiniti® Vision System (Alcon Laboratories, Inc.) or Sovereign® Compact (Advanced Medical Optics, Inc.) through 2.8 - 3.0 mm in upper temporal quadrant of transparent cornea with no sutures used and consequent artificial lens implantation to native lens capsule with a single-use injector. 

The candidates were provided detailed information concerning the structure and action of each tested multifocal implant and they expressed which type of intraocular lens they would like to have implanted. The doctor also tried to assess the best option for each involved individual based on performing job and lifestyle. Definite reply depended on patient. Follow-up was 6 month in all eyes (from 6 to 13 months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17717-0</funderId>
      <contactId>Contact55691_17717</contactId>
      <sponsorId>Sponsor54263</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55691_17717">
    <title>Prof</title>
    <forename>Stanislawa</forename>
    <surname>Gierek-Ciaciura</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital No. 5 of the Medical University of Silesia
Ceglana 35</address>
      <city>Katowice</city>
      <country>Poland</country>
      <zip>40-952</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54263">
    <organisation>University Hospital No. 5 of the Medical University of Silesia, Katowice (Poland)</organisation>
    <website>http://www.kli-okul.katowice.pl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Ul. Ceglana 35 </address>
      <city>Katowice</city>
      <country>Poland</country>
      <zip>40-952</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411728.9</gridId>
    <rorId>https://ror.org/005k7hp45</rorId>
  </sponsor>
  <funder id="Funder17717-0">
    <name>University Hospital No. 5 of the Medical University of Silesia, Katowice (Samodzielny Publicsny Szpital Kliniczny Nr 5 Śląski Uniwersytet Medyczny w Katowicach) (Poland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-11-21T00:00:00.000Z">64345887</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Abdominal massage for people with constipation: experiences, effects and cost effectiveness</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesis is that abdominal massage for people with constipation could decrease the severity of gastrointestinal symptoms, time to defecate, and laxative use, increase number of bowel movements and quantity of faeces, normalise faeces consistency without increased fluid and fibre intake or increased physical activity. The hypothesis is also that abdominal massage will increase health related quality of life and will be a cost effective intervention.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Severity of gastrointestinal symptom measured with Gastrointestinal Symptom Rating Scale
2. Laxative use
3. Health related quality of life measured with EQ-5D
4. Experience of being constipated and having abdominal massage
5. Cost effectiveness of the intervention
6. Participants' experiences of having abdominal massage. Data was collected by interviews. 
 
The assessments were performed on three occasions: at baseline, Week 4 and 8.</primaryOutcome>
      <secondaryOutcome>1. Time to defecate 
2. Number of bowel movements 
3. Quantity of faeces 
4. Faeces consistency 
5. Fluid and fibre intake 
6. Physical activity 

The secondary outcomes were self reported in protocols Monday to Friday at baseline, Week 4 and 8.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee at the Medical Faculty, Umeå University. Date of approval: 09/02/2005 (ref: Um dnr. 04-132M)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64345887</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="89b6f624-1094-4e28-9fc5-deeb014138aa">
	  <name>Department of Nursing</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-901 87</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults (both males and females) who are constipated, in accordance with Rome II criteria or dependent on laxatives to have sufficient bowel movements
2. Ability to understand and express themselves in Swedish</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Diagnosis of dementia 
2. Psychiatric disease
3. Abdominal hernia
4. Known intestinal cancer
5. Recently undergone surgical operation in the abdomen</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Constipation</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Other functional intestinal disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Age range of the recruited participants: from 36 to 85 years.

The participants in the intervention group had 15 minutes of massage 5 days/week for 8 weeks. The duration of massage and number of assessments were based on experiences from a pilot study and recommendations from experts with experiences with gastroenterological studies. The massage consisted of very gentle strokes with light pressure. The hands and abdomen were massaged (8 and 7 minutes respectively) using a systematic movement pattern to stimulate tactile receptors in the skin. As the effect of the massage was assumed to be different between participants, the use of laxatives was adjusted based on clinical evaluation. 

In the control group, the participants continued with the therapy they were using when they joined the study: bulking agents, osmotic laxative, stimulant laxative, enemas, herbal supplements, or increased fibre intake. Except for a first and a concluding appointment, the contact with the control group during the study consisted of letters with questionnaires.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18057-0</funderId>
      <funderId>Funder18057-1</funderId>
      <funderId>Funder18057-2</funderId>
      <funderId>Funder18057-3</funderId>
      <funderId>Funder18057-4</funderId>
      <contactId>Contact56044_18057</contactId>
      <sponsorId>Sponsor54609</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56044_18057">
    <title>Dr</title>
    <forename>Catrine</forename>
    <surname>Jacobsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nursing
Umeå University</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>SE-901 87</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 9 07 86 9162</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">catrine.jacobsson@nurs.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54609">
    <organisation>Swedish Research Council (Sweden)</organisation>
    <website>http://www.vr.se/2.69f66a93108e85f68d480000.html</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-103 78</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.208387.6</gridId>
    <rorId>https://ror.org/03zttf063</rorId>
  </sponsor>
  <funder id="Funder18057-0">
    <name>Swedish Research Council (Sweden) (Grant ref: K2006-27X-20063-01-3)</name>
    <fundRef>http://dx.doi.org/10.13039/501100004359</fundRef>
  </funder>
  <funder id="Funder18057-1">
    <name>Swedish Association of Health Professionals (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18057-2">
    <name>Ekhaga Foundation (Sweden) (Grant ref: 2006-16)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18057-3">
    <name>County Council of Västerbotten (Sweden) (Grant ref: VLL 1178:3 2006)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18057-4">
    <name>Senior Centre of Västerbotten (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-11-20T00:00:00.000Z">11974092</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase I/II study of vaccination against minor histocompatibility antigens HA1 or HA2 after allogeneic stem cell transplantation for advanced haematological malignancies</title>
      <scientificTitle/>
      <acronym>HA1/HA2</acronym>
      <studyHypothesis>Our aim is to demonstrate the feasibility, safety and efficacy of vaccination with mHag HA1 or HA2 peptides on day +120 after HLA-identical allogeneic haematopoietic stem cell transplantation (HSCT) with mHag disparate donor recipient pairs. We reason that vaccination with recipient mHag will boost the graft-versus-leukaemia effect of HSCT and thus lower the incidence of relapse in patients with high risk haematological malignancies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Toxicity of immunisation</primaryOutcome>
      <secondaryOutcome>Prevention of relapse of leukaemia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. MHH Ethics committee received on 30th May 2007 (ref: 3578)
2. Paul-Ehrlich-Institute received on 12th February 2007 (ref: 1179/01)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11974092</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3578 (MHH) 1179/01 (PEI)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I/II experimental non-randomised, historical control trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="506539aa-a9e0-433e-9413-b66860665807">
	  <name>Hannover Medical School</name>
	  <address/>
	  <city>Hannover</city>
	  <state/>
	  <country>Germany</country>
	  <zip>30625</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Advanced (high risk) leukaemia, after allogeneic haematopoietic stem cell transplantation (HSCT)
2. Disparity in HA1 or HA2 between donor and recipient
3. Informed consent
4. Aged 18 years or older, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>25</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>25</totalTarget>
      <exclusion>1. Acute or chronic graft-versus-host disease (GvHD) after allo-HSCT prior to immunisation
2. No informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haematological malignacies/leukaemic relapse</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukaemia of unspecified cell type</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients will receive immunisation with mHA1 or 2 peptides in HLA-A2 patients with donor-recipient disparities in mHA1 or 2.

Historical controls will be used for evaluation of a benefit for patients with HA1 disparities and advanced haematological malignancies.

Duration of intervention per patient/subject: 18 months after vaccination.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I/II</phase>
	<drugNames>mHag HA1 or HA2 peptides</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18209-0</funderId>
      <contactId>Contact56197_18209</contactId>
      <sponsorId>Sponsor54766</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56197_18209">
    <title>Prof</title>
    <forename>Arnold</forename>
    <surname>Ganser</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hannover Medical School
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
OE6860
Carl-Neuberg-Str. 1</address>
      <city>Hannover</city>
      <country>Germany</country>
      <zip>30625</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54766">
    <organisation>Hannover Medical School (Medizinischen Hochschule Hannover) (Germany)</organisation>
    <website>http://www.mh-hannover.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Carl-Neuberg-Str. 1</address>
      <city>Hannover</city>
      <country>Germany</country>
      <zip>30625</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@mh-hannover.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10423.34</gridId>
    <rorId>https://ror.org/00f2yqf98</rorId>
  </sponsor>
  <funder id="Funder18209-0">
    <name>German Federal Ministry of Education and Research (Bundesministerium Fur Bildung und Forschung [BMBF]) (Germany) - grant via Integriertes Forschungs und Behandlungszentrum MHH (IFB)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-11-20T00:00:00.000Z">60811508</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Enhancement of the physician-patient relationship in inpatient care through a communication and interaction training for assistant and senior physicians in internal medicine</title>
      <scientificTitle>A randomised controlled trial to enhance the physician-patient relationship in inpatient care by a communication training and supervision</scientificTitle>
      <acronym>APKIT</acronym>
      <studyHypothesis>1. Patient satisfaction can be enhanced by systematic communication training for physicians: patient satisfaction within the intervention group is higher after the physicians have completed their training than before the training. Patient satisfaction within the control group will not differ between pre- and post-evaluation.
2. The subjective competence assessment of communication skills of the physicians in the intervention group increases significantly after having completed the communication training
3. The improvement of communication and interaction skills of the intervention group can be shown by performance in a multi-station exercise (MSE)
4. The improvement of communication skills of the intervention group can also be shown in daily physician-patient interaction (through video analysis)
5. The communication training influences patient adherence after discharge: patients seen by physicians of the intervention group show higher adherence levels after the physicians have been trained than before</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patient satisfaction measured by a modified version of the Picker Questionnaire before (t1) and after (t3) the intervention group is trained.

Timepoints: 
t1: two months before the training
t2: intervention (training period, communication and interaction training)
t3: two months after the training</primaryOutcome>
      <secondaryOutcome>Physicians: 
Communication and interaction skills:
1. Measured by self-rating before (t1) and after training (t3)
2. Measured by performance in a multi-station exercise (MSE) directly after training (t2) 
3. Measured by video analysis using the Roter Interaction Process Analysis System (RIAS), before (t1) and after training (t3)

Patients: 
Adherence measured through a 4-item assessment by general practitioners (GP) providing follow-up care using the Visual Analogue Scale (0 = not at all adhered to 10 = totally adhered) (t3).

Timepoints: 
t1: two months before the training
t2: intervention (training period, communication and interaction training)
t3: two months after the training</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The local medical ethics committee (Landesarztekammer Baden-Wurttemberg [Germany] Körperschaft des Offentlichen Rechts Ethik-kommission) granted approval on the 27th August 2008 (ref: 2008-086-f)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60811508</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial (single centred, single blinded)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a06e943c-5217-4488-88b6-1634a4b9c17a">
	  <name>Innere Medizin II</name>
	  <address/>
	  <city>Heidelberg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>69120</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients: 
1. Given consent
2. Receiving in-patient treatment at the Hospital SLK Heilbronn (Germany)
3. Sufficient German language skills
4. Sufficient literacy
5. Aged from 30 - 85 years, either sex  

Physicians: 
1. Given consent
2. Employed by the Hospital SLK Heilbronn (Germany)
3. Currently working shifts in the Department of Internal Medicine
4. Aged from 26 - 50 years, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>742</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Physicians: 42; patients: 700</totalTarget>
      <exclusion>Patients or physicians declined consent.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Physician-patient communication</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Communication in healthcare</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: 
Three-day communication and interaction skills training including role play with standardised patients and supervised ward rounds in between, and a final evaluation with an MSE (multi-station exercise).

Control group: 
Waiting-list control group receiving the same literature as the intervention group. Out of ethical reasons the control group will be given the same intervention after data acquisition is completed.

Joint/Scientific Sponsor Details:
SLK Hospital Heilbronn (Germany)
c/o Dr Urs Riemann
Am Gesundbrunnen 20
74078 Heilbronn
Germany
Website: http://www.slk-kliniken.de/Klinikum-am-Gesundbrunnen.701.0.html

University Hospital Heidelberg (Germany)
c/o Dr Jobst-Hendrik Schultz
MME Bern
Im Neuenheimer Feld 410
69120 Heidelberg
Germany
Website: http://www.klinikum.uni-heidelberg.de/Klinik-fuer-Psychosomatische-und-Allgemeine-Klinische-Medizin.87.0.html

Joint/Scientific Contact Details:
Professor Wolf Langewitz
Universitätsspital Basel
Psychosomatik
Hebelstr.2
CH-4031 Basel
Switzerland</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18236-0</funderId>
      <contactId>Contact56224_18236</contactId>
      <sponsorId>Sponsor54793</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56224_18236">
    <title>Dr</title>
    <forename>Jana</forename>
    <surname>Juenger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Innere Medizin II
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 410</address>
      <city>Heidelberg</city>
      <country>Germany</country>
      <zip>69120</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)6221 563 8872</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jana.juenger@med.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54793">
    <organisation>German Health Insurance Company AOK (Bundesgeschäftsstelle AOK Krankenkasse) (Germany)</organisation>
    <website>http://www.aok-bv.de/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>c/o Dr Schillinger
kortrijkerstr. 1</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53177</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491710.a</gridId>
    <rorId>https://ror.org/004cmqw89</rorId>
  </sponsor>
  <funder id="Funder18236-0">
    <name>German Health Insurance Company AOK (Bundesgeschäftsstelle AOK Krankenkasse) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-11-20T00:00:00.000Z">23974417</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Anal fistula plug versus endorectal advancement flap for the closure of high criptoglandular fistula-in-ano: a randomised study</title>
      <scientificTitle>A randomised study to compare the results of the anal fistula plug (AFP) with the endorectal advancement flap (ERAF) in the treatment of high fistula-in-ano of cryptoglandular origin</scientificTitle>
      <acronym/>
      <studyHypothesis>The use of lyophilised porcine submucosal plugs (Cook Surgisis®, AFPTM) has been proposed as an alternative to conventional surgical techniques for the treatment of anal fistulas. Rates of favourable outcomes are highly variable in the literature (between 13.9% and 87%). Unfortunately, some reports are retrospective studies, others are prospective cohort studies, and only one study has compared the efficacy of this technique with a retrospective review of patients treated with endorectal advancement flap (ERAF). Additionally, these studies include simple and complex anal fistulas, anovaginal fistulas and patients with inflammatory bowel disease. So far, there is not a randomised study comparing the AFP with other surgical procedures suitable for high fistulas. Therefore, the objective of this randomised study was to compare the results of AFP with ERAF in the treatment of high fistula-in-ano of cryptoglandular origin.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Fistula closure rate; recurrence is defined as the presence of an abscess arising in the area, or by obvious evidence of fistulation. Evaluated at 2, 4, 8, 12 weeks after surgery, and at 6, 9 and 12 months.</primaryOutcome>
      <secondaryOutcome>Continence, evaluated pre- and post-operatively (after one year) using the Wexner score.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Comité Ético de Investigación Clínica of the Health Department of the Government of Navarra (Spain) gave approval on the 2nd April 2007 (ref: Pyto. 14_07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23974417</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional randomised single-centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3fba978b-4805-47b4-b519-12f70f6f4561">
	  <name>C/Trinidad Fernandez Arenas</name>
	  <address/>
	  <city>Pamplona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>31002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged above 18 years, either sex
2. High fistula-in-ano of cryptoglandular origin (the fistulas were defined as high when they included the upper two-thirds of the external sphincter complex)
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>186</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>186 patients (93 in each group)</totalTarget>
      <exclusion>1. Secondary tracts
2. Horseshoe fistulas
3. Anovaginal fistulas
4. Rectouretral fistulas
5. Human immunodeficiency virus (HIV)-positive patients
6. Diagnosed from Crohn's disease</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fistula-in-ano of cryptoglandular origin</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Fissure and fistula of anal and rectal regions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients underwent full mechanical bowel preparation and received antibiotic and antithromboembolic prophylaxis. The patients were operated on under general anaesthesia in the lithotomy position. Surgical procedures were performed by two surgeons with accredited degrees in Coloproctology (ESBQ Coloproctology). 

Anal fistula plug (AFP):
The plug was submerged in saline for two minutes; the internal fistula orifice was located by injecting hydrogen peroxide. Curettage of the track was not performed. A probe was inserted in the fistula track. The AFP was placed into the tract until resistance was felt and then fixed in place with a 2-0 polyglactin suture (Vicryl®) which included the internal sphincter. The suture was tied in order to close the internal opening of the fistula over the plug. Care was taken to ensure that the external orifice of the fistula was not completely occluded in order to allow the track to drain. The remaining plug was cut at the level of the external opening. 

Endorectal advancement flap: 
The tract of the fistula was completely excised, including the internal opening. A rectal flap above the internal opening was mobilised, including the mucosa and submucosa, with a 3 to 4 cm broad base. The rectal flap was mobilised sufficiently to cover the internal opening. Exhaustive haemostasis was performed to avoid a haematoma under the flap. Finally, the flap was sutured to the edge of the anal canal, covering the internal opening.

Average duration of treatment: 
Anal Fistula Plug: 30 minutes
Endorectal Advancement Flap: 90 minutes
Total duration of follow-up for all arms of your trial: one year</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18238-0</funderId>
      <contactId>Contact56226_18238</contactId>
      <sponsorId>Sponsor54795</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56226_18238">
    <title>Prof</title>
    <forename>Hector</forename>
    <surname>Ortiz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>C/Trinidad Fernandez Arenas </address>
      <city>Pamplona</city>
      <country>Spain</country>
      <zip>31002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54795">
    <organisation>Hospital Virgen del Camino (Spain) - Public University of Navarra </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>C/ Irunlarrea 4 </address>
      <city>Pamplona</city>
      <country>Spain</country>
      <zip>31008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413524.5</gridId>
    <rorId>https://ror.org/046wwv897</rorId>
  </sponsor>
  <funder id="Funder18238-0">
    <name>Hospital Virgen del Camino (Spain) - Public University of Navarra</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-11-20T00:00:00.000Z">59353477</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment by uninterrupted positive airway pressure by nasal route - Evaluation of REMstar® Auto with C-Flex in clinical practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>REMstar® Auto with C-FLEX is as effective at reducing the apnoea-hypopnoea index (AHI) in sleep apnoea/ hypopnoea patients as continuous positive airway pressure over 30 days when used in the home environment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To determine if the REMstar® Auto in C-Flex mode is as effective as constant positive airway pressure on reducing the AHI of sleep apnoea/ hypopnea patients when used in the home environment. This will be assessed by data obtained during polygraph recording via the Stardust® device at the beginning and end of each period (30 days, 7-day washout then 30 days on alternate arm of study) and between each mode of use. This relates primarily to the following: 
a. AHI index
b. Sa02 night (minimum, maximum and Sa02 95) 

2. Data from the REMstar® device at the beginning and end of each period and between each mode of use. This relates primarily to the following: 
a. Maximum pressure
b. Minimum pressure
c. Average pressure
d. Average number of hours use on nights used
e. AHI index</primaryOutcome>
      <secondaryOutcome>1. To compare the clinical benefits and preference of patients between the REMstar® Auto in C-Flex mode versus conventional fixed pressure. This will be assessed at the beginning and end of each period and between each mode of use. 
2. Quality of life and daytime alertness will be assessed by the Functional Outcome of Sleep Questionnaire (FOSQ) and the Epworth Sleepiness Questionnaire (ESS). Timepoints: Baseline (before first mode of use), after first mode of use is completed and after the second mode of use is completed. 
3. A visual analogue scale will be completed by the participants at the end of each treatment period to assess daytime alertness</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Research Ethics Committee for Protection of Human Subjects, Poitou-Charentes (Comite Consultatif de Protection des Personnes dans la Recherche, Biomedicale de la region Poitou-Charentes), approved on 20/10/ 2005 (ref: 05.09.17)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59353477</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e839049d-bb29-4a1d-a324-65ffcbffc714">
	  <name>Service de Pneumologie</name>
	  <address/>
	  <city>Poitiers</city>
	  <state/>
	  <country>France</country>
	  <zip>86021</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male adults &gt;18 
2. Index of apnoea/ hypopnoeas &gt;30/hour 
3. Able to provide written consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Past experience of treatment with positive airway pressure or non invasive ventilation
2. Participants who require 2 levels of pressure for nocturnal alveolar hypoventilation linked to a co-morbidity (obesity, hypoventilation, chronic obstructive pulmonary disease [COPD]) of sleep aponea/ hypopnoea syndrome
3. Participants that have undergone surgery for the treatment of sleep apnoea/ hypopnoea syndrome, snore or tumour in the last 6 months or after their polysomnography (PSG) diagnosis
4. Tracheostomy
5. Respiratory infection, sinusitis or internal ear infection
6. Dermatitis or other facial lesions preventing the application of a mask
7. Unable to give written informed consent
8. Participants unwilling to volunteer
9. Unstable medication
10. Participants presenting with clinically significant COPD or unstable cardiac insufficiency
11. People benefiting from a reinforced protection will not be included in this study. This refers to subjects protected by law, persons accepted in a health or social establishment, private individuals of freedom by a court or administrative order, ill in urgent situation, and persons hospitalised without consent.
12. Participants should not have participated in a trial in the 3 months preceding or following the study</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact etails below to request a copy of the information sheet</patientInfoSheet>
      <recruitmentStart>2005-10-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sleep apnoea/ hypopnoea syndrome</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Sleep disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants were randomly allocated to the following two arms: 

Arm 1: REMstar® Auto with C-FLEX over 30 days 
Arm 2: Continuous positive airway pressure over 30 days 

The intervention was followed by a 7-day washout period, and then the participants were crossed over to 30 days on alternate arm of study.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase IV</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18155-0</funderId>
      <contactId>Contact56143_18155</contactId>
      <sponsorId>Sponsor54711</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56143_18155">
    <title>Prof</title>
    <forename>J</forename>
    <surname>Meurice</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Service de Pneumologie
Cité Hospitalière La Milétrie
BP 577 </address>
      <city>Poitiers</city>
      <country>France</country>
      <zip>86021</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">meurice@chu-poitiers.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54711">
    <organisation>Respironics International (France)</organisation>
    <website>http://global.respironics.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>20 Rue-Jacques Daguerre 
Rueil-Malmaison</address>
      <city>Paris</city>
      <country>France</country>
      <zip>92500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steven.coughlin@respironics.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425454.6</gridId>
    <rorId>https://ror.org/05jz46060</rorId>
  </sponsor>
  <funder id="Funder18155-0">
    <name>Respironics International (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-31T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-10-31T00:00:00.000Z">30946841</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Selection of lactobacilli in biodefence</title>
      <scientificTitle>Rapid induction of passive immunity against weapon of bioterrorism using transformed GRAS (generally regarded as safe) bacteria</scientificTitle>
      <acronym>Biodefence</acronym>
      <studyHypothesis>To evaluate the safety of consumption of high doses of lactobacilli on selected health indices and to assess the persistence of consumed lactobacilli strains in gastrointestinal tract.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. No adverse effect after consumption according to clinical, blood and intestinal indices. Timepoints of assessment: at recruitment and end of the study (day 20).
2. The best coloniser from the five tested Lactobacillus strains was detected at the end of the study (day 20)</primaryOutcome>
      <secondaryOutcome>Colonisation by L. acidophilus 821-3 confirmed by real time polymerase chain reaction (PCR) in faecal samples at the end of the study (day 20)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Review Committee (ERC) on Human Research at the University of Tartu gave approval on the 24th October 2005 (ref: 142/7)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30946841</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>142/7</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, single-arm, open trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Estonia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="91b6d2f7-ba86-4070-801d-dd63698de186">
	  <name>University of Tartu</name>
	  <address/>
	  <city>Tartu</city>
	  <state/>
	  <country>Estonia</country>
	  <zip>50411</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, aged 20 - 70 years 
2. Wish to participate in the study 
3. Healthy (i.e. no known health problems and no medical conditions that require drug therapy) 
4. Informed consent obtained</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>1. History of any gastrointestinal disease 
2. Use of any antimicrobial drug within last month 
3. Use of any regular concomitant medication, including medical preparations 
4. Pregnancy/breastfeeding 
5. Food allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Passive immunity against weapon of bioterrorism</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fifteen participants (9 women and 6 men) were enrolled in this study. Volunteers received capsules of the freeze-dried putative probiotics (L. gasseri 177, L. acidophilus 821-3, L. gasseri E16B7, L. paracasei 317 and L. fermentum 338-1-1, 10^10 cfu each) orally for 5 days. Blood analyses were taken to exclude the infection and to test putative adverse effect of consumed lactobacilli. The persistence of lactobacilli was detected in faecal samples.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lactobacilli</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18074-0</funderId>
      <funderId>Funder18074-1</funderId>
      <contactId>Contact56062_18074</contactId>
      <sponsorId>Sponsor54628</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56062_18074">
    <title>Prof</title>
    <forename>Marika</forename>
    <surname>Mikelsaar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Tartu 
Ravila 19</address>
      <city>Tartu</city>
      <country>Estonia</country>
      <zip>50411</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54628">
    <organisation>Estonian Science Foundation (Estonia)</organisation>
    <website>http://www.etf.ee/index.php?setlang=eng</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Endla 4</address>
      <city>Tallinn</city>
      <country>Estonia</country>
      <zip>10142</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder18074-0">
    <name>Estonian Science Foundation (Estonia)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001837</fundRef>
  </funder>
  <funder id="Funder18074-1">
    <name>EU Commission (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-31T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-31T00:00:00.000Z">43651633</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial on the impact of collateral damage and disconnections on memory outcome after temporal lobe epilepsy surgery and the relevance of surgically caused memory decline for every day activities and functioning</title>
      <scientificTitle>Subtemporal versus transsylvian approach for selective amygdala-hippocampectomy: a randomised controlled trial on the epileptological and cognitive outcome</scientificTitle>
      <acronym/>
      <studyHypothesis>The aim of the study is to evaluate pre- and post-operative verbal episodic memory, frontal lobe executive functions and reward learning as a function of surgically-caused cortical lesions and dissections of fibre tracts from and to the temporal lobe structures.

As the main surgical variation will be that of a preservation or dissection of the temporal stem, using a subtemporal versus a transsylvian approach, differences due to this variation are expected:
1. Preserving the temporal stem (subtemporal approach) results in a better crosstalk between frontal executive and temporal memory functions. Therefore memory aspects of organisation, differentiation, recognition (source memory) theoretically can be expected to be better preserved after the subtemporal approach as compared to the transsylvian approach.
2. Partial disconnection of the temporal stem (transsylvian approach) is possibly expected to result in a more pronounced effect of reward learning as the importance of the functional connection between temporal and frontal structures for this function has been discussed recently
3. The relevance of cognitive development and seizure control for quality of life and their implication for the patients' every day life are another topic of interest. How much memory decline will be accepted in favor of seizure freeness? With an unfavourable outcome in terms of seizure as well as memory outcome one might assume a negative impact on the patients' memory-dependent activities and their quality of life that might go along with higher rates of depression.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Neuropsychological outcome in memory and non-memory functions as well as in brain activation in three fMRI paradigms will serve as dependent measures. Each patient will undergo comprehensive neuropsychological testing pre-operatively and 12 months post-operatively. The following tests will be applied: 
1. Verbal learning and memory: two parallel versions of a pre- and post-operative Verbal Learning Test (VLMT- Verbaler Lern- und Merkfähigkeitstest). The VLMT (German adaptation of the Rey Auditory Verbal Learning Test) requires five trials of learning and recall of a word list consisting of 15 words, free recall immediately after distraction (learning/recall of a second list in one trial) and a recall after a half-hour delay, which is followed by a recognition trial (list with original words plus distractors). 
2. Figural learning and memory was obtained using the DCS-R, a German, revised version of the DCS, a design list learning test (Diagnostikum für Zerebralschädigung)
3. Language functions: 
3.1. "Confrontation naming", Boston Naming Test
3.2. "Phonematic" and "semantic fluency"
3.3. "Token Test", a subtest of the Aachener Aphasie-Test (a German test battery for aphasia) which is seen to measure verbal comprehension
4. Attention functions:
4.1. "d2-Test", a letter cancellation test
4.2. The c.I.T., a short test to measure cerebral insufficiency (Kurztest für cerebrale Insuffizienz) 
5. Psychomotor speed, mental tracking and cognitive flexibility:
5.1. "Trail Making Test A and B" (TMT-A/B)
5.2. Motoric sequences after Lurija
5.3. Purdue Pegboard 
5.4. Finger Tapping Test
6. Visual and spatial abilities:
6.1. Subtest LPS-7 of the Leistungsprüfsystem (LPS), a German intelligence battery 
6.2. The Mosaic-Test, a subtest of the German version of the Wechsler Adult Intelligence Scale - Revised (HAWIE-R)
6.3. Labyrinth test
7. FMRI investigation: a new fMRI paradigm will be established for reward learning

All respective measures (primary and secondary outcome measures) will be obtained pre-operatively and 12 months post-operatively.</primaryOutcome>
      <secondaryOutcome>These address the question of the patients' quality of life, personality, depression and memory-dependent activities, which will be assessed using the following questionnaires: 
1. A German version of the Beck Depression Inventory (BDI)
2. FPZ (Fragebogen zur Persönlichkeit bei zerebralen Erkrankungen), an unpublished German CNS-disease related personality questionnaire
3. A German adaptation of the QOLIE-10 (Quality of Life Inventory in Epilepsy, 10-Item version), a brief questionnaire to screen for quality of life in epilepsy 
4. "Memory activities in every day life" MADL, a questionnaire on frequencies of memory dependent everyday activities. The MADL, is a new, unpublished rating scale which has been developed as part of a workshop of the International League against Epilepsy in Venice and is intended to fill the gap between neuropsychological memory impairment, subjective opinion and memory in every day life.

All respective measures (primary and secondary outcome measures) will be obtained pre-operatively and 12 months post-operatively.</secondaryOutcome>
      <trialWebsite>http://www.meb.uni-bonn.de/epileptologie/sfb-tr3/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Bonn Medical Centre Ethics Committee approval received on the 30th April 2008 (ref: 032/08)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43651633</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Sonderforschungsbereich (SFB) TR3 subproject A1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, interventional, randomised single-centre study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ed407364-d682-41d3-a140-ea9144cbd42e">
	  <name>Klinik für Neurochirurgie</name>
	  <address/>
	  <city>Bonn</city>
	  <state/>
	  <country>Germany</country>
	  <zip>53105</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Patients suffering from intractable temporal lobe epilepsy 
3. Drug resistance 
4. Presurgical evaluation led to the recommendation of selective amygdalo-hippocampectomy (SAH)
4. Only cases with an magnetic resonance imaging (MRI)-based diagnosis of Ammon's horn sclerosis will be included
5. Adults (greater than 18 years)
6. Patients have to be able to understand the study plan and give written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Previous temporal lobe surgery
2. Inability to undergo neuropsychological testing because of retardation or insufficient German language skills
3. Gravidity
4. Claustrophobia
5. Metallic implants/non-removable piercings
6. Neurological/psychiatric illness</exclusion>
      <patientInfoSheet>General information concerning Epilepsy surgery can be found on the website of our hospital:
http://www.ukb.intern/42256BC8002AF3E7/vwWebPagesByID/3BB88E00CAE320D2C12571D40063EFB9

Patient information concerning our subproject A1:
http://www.ukb.intern/42256BC8002AF3E7/vwWebPagesByID/8BE510569EF540CCC12571D40056E8CD 
and http://www.meb.uni-bonn.de/epileptologie/sfb-tr3/index.html</patientInfoSheet>
      <recruitmentStart>2008-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intractable mesial temporal lobe epilepsy (MTLE)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Epilepsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As part of the pre-surgical evaluation patients and healthy controls will be neuropsychologically tested and investigated with functional as well as structural MRI. Patients were then randomised to either a subtemporal or a transsylvian surgical approach, resulting in a preservation (subtemporal approach) or dissection (transsylvian approach) of the temporal stem. Post-operatively, patients are seen for MRI-scanning, neuropsychological testing and medical consultation 3, 6 and 12 months after surgery.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18160-0</funderId>
      <contactId>Contact56148_18160</contactId>
      <sponsorId>Sponsor54716</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56148_18160">
    <title>Prof</title>
    <forename>Johannes</forename>
    <surname>Schramm</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik für Neurochirurgie
Sigmund-Freud-Str. 25</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54716">
    <organisation>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) </organisation>
    <website>http://www.dfg.de </website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Kennedyallee 40</address>
      <city> Bonn</city>
      <country>Germany</country>
      <zip>53175</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424150.6</gridId>
    <rorId>https://ror.org/018mejw64</rorId>
  </sponsor>
  <funder id="Funder18160-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-30T00:00:00.000Z">15966680</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Use of prednisone for choroidal detachment after trabeculectomy</title>
      <scientificTitle>Use of prednisone for choroidal detachment after trabeculectomy: a double-masked randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>To evaluate the treatment with oral prednisone for choroidal detachment after trabeculectomy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Choroidal detachment resolution. Indirect ophthalmoscopy and ocular ultrasonography (B-mode) were performed weekly to evaluate the choroidal detachment until total reattachment of the choroid. The main outcome measure was the time elapsed between the detection of detachment and total reattachment of the choroid.</primaryOutcome>
      <secondaryOutcome>Intra-ocular pressure, evaluated every 5 days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Ethics Committee of the Federal University of Sao Paulo gave approval on the 27th November 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15966680</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0745/02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-masked randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83c6f45d-4f9d-448c-a717-b7925afb3a20">
	  <name>Federal University of Sao Paulo</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>04023-062</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, older then 18 years old 
2. Primary open or narrow angle glaucoma submitted to trabeculectomy that developed choroidal detachment
3. Choroidal detachment should be diagnosed during the first two weeks after surgery
4. Choroidal detachment should be exudative by ultra-sound</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Other acute ocular disease 
2. Positive Seidel test 
3. Choroidal kissing 
4. Athalamia 
5. Clinical uncontrolled diabetes mellitus or systemic arterial hypertension 
6. Hypersensitivity for any of the drugs components on the trial 
7. Psychiatric disease 
8. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Choroidal detachment after trabeculectomy</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Other disorders of choroid</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral prednisone 1 mg/kg daily for 7 days followed by a progressive reduction of 10 mg every 7 days. Patients in the placebo group received similar capsules containing starch for the same duration as the intervention group. Duration of the treatment ranged from 4 to 7 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18195-0</funderId>
      <contactId>Contact56183_18195</contactId>
      <sponsorId>Sponsor54752</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56183_18195">
    <title>Dr</title>
    <forename>Augusto</forename>
    <surname>Paranhos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Federal University of Sao Paulo
Botucatu, 824</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>04023-062</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">augusto.paranhos@uol.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54752">
    <organisation>Coordination of Improvement of Higher Education (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [CAPES]) (Brazil) </organisation>
    <website>http://www.capes.gov.br</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Ministério da Educação
Anexos I e II - 2º andar 
DF - Caixa Postal 365 </address>
      <city>Brasilia</city>
      <country>Brazil</country>
      <zip>70359-970 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dfreitas@uol.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452295.d</gridId>
    <rorId>https://ror.org/00x0ma614</rorId>
  </sponsor>
  <funder id="Funder18195-0">
    <name>Coordination of Improvement of Higher Education (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [CAPES]) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-31T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-10-30T00:00:00.000Z">99672071</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of rituximab in patients with systemic sclerosis</title>
      <scientificTitle>Efficacy of rituximab in patients with systemic sclerosis: an open label randomised controlled study</scientificTitle>
      <acronym>RTX-Scleroderma</acronym>
      <studyHypothesis>Systemic sclerosis (SSc) is a chronic systemic autoimmune disease characterised by vasculopathy and progressive fibrosis. Rituximab (RTX) is a chimeric monoclonal antibody (mAb) against human CD20 that depletes peripheral B cells. It has been successfully introduced in the treatment of systemic rheumatic diseases and exhibits an acceptable safety profile. The preliminary encouraging results from the use of RTX in animal models of SSc and in humans with chronic graft-versus-host disease (GVHD) has led us to investigate more thoroughly the potential efficacy of RTX in patients with SSc in an open-label, prospective, randomised, controlled study.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Changes in skin histology including collagen deposition and lymphocytic infiltration
2. Changes in pulmonary function as assessed by PFT

Timepoints of assessment for primary and secondary outcomes: baseline and 24 weeks.</primaryOutcome>
      <secondaryOutcome>1. Clinical assessment of skin involvement by the Modified Rodnan Skin Score (MRSS)
2. Changes in HRCT scores
3. Changes in serum levels of soluble markers
4. Changes in overall functional impairment, assessed by the Health Assessment Questionnaire (HAQ)

Timepoints of assessment for primary and secondary outcomes: baseline and 24 weeks.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was aproved by the Ethics Committee of Patras University Hospital in February 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99672071</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PGNP1/8/07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open-label, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8a4ad94b-23ae-4c02-9ae1-8c09359dbd53">
	  <name>25th Martiou</name>
	  <address/>
	  <city>Patras</city>
	  <state/>
	  <country>Greece</country>
	  <zip>26504</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Detection of anti-Scl-70 autoantibodies in their sera
3. Presence of SSc-associated interstitial lung disease (ILD) as indicated by findings in either high-resolution computed tomography (HRCT) of the chest or pulmonary function tests (PFT) or both
4. Absence of any changes in medications and/or dosage of treatment administered during the last 12 months before enrolment</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>Aged less than 18 years</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic sclerosis (SSc)</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Systemic sclerosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants were randomly allocated to the following two arms (ratio 1:1): 
Rituximab arm: four weekly intravenous (IV) pulses of rituximab (375 mg/m^2) x 6 (24 weeks in total) and standard treatment 
Control arm: standard treatment alone 

Patients were fully evaluated at baseline and 24 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Rituximab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18214-0</funderId>
      <contactId>Contact56202_18214</contactId>
      <sponsorId>Sponsor54771</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56202_18214">
    <title>Dr</title>
    <forename>Dimitrios</forename>
    <surname>Daoussis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>25th Martiou
Kato Kastritsi
Rion</address>
      <city>Patras</city>
      <country>Greece</country>
      <zip>26504</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54771">
    <organisation>University Hospital of Patras (Greece)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Rheumatology Departmant
Department of Rheumatology
Rion</address>
      <city>Patras</city>
      <country>Greece</country>
      <zip>26504</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412458.e</gridId>
    <rorId>https://ror.org/03c3d1v10</rorId>
  </sponsor>
  <funder id="Funder18214-0">
    <name>Hellenic Society for Rheumatology (Greece)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-03T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-10-30T00:00:00.000Z">86084115</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does gum chewing enhance return of bowel movement after caesarean section?</title>
      <scientificTitle>Gum chewing and return of bowel motility after elective caesarean section: a randomised controlled single-centre trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Post-operative gum chewing enhances the return of bowel motility after elective caesarean section (CS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>With the time of end of surgery designated as zero hour: 
1. The time interval to first hearing of normal intestinal sounds
2. The time interval to the first passage of flatus
3. The time interval to the first bowel movement
4. The time interval to the discharge from the hospital</primaryOutcome>
      <secondaryOutcome>1. In Group I only: post-operative tolerance of gum chewing
2. In both groups: post-operative complications, including: 
2.1. Febrile morbidity (temperature greater than 38º C on two occasions 6 hours apart)
2.2. Re-operation
2.3. Blood transfusion
2.4. Post-operative ileus. The occurrence of mild ileus symptoms (vomiting or abdominal distension felt by the patient and seen on examination) or post-operative paralytic ileus, defined as a group of manifestations persisting longer than 24 hours or requiring nasogastric tube placement. These manifestations include absent or hypoactive bowel sounds, non-passage of flatus or bowel movement, abdominal distension, more than three episodes of vomiting, with or without generalised crampy abdominal pain. 
2.5. Hospital readmission</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the Ethics and Research Committee of Obstetrics and Gynaecology Department, Faculty of Medicine, Ain Shams University in June 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86084115</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single-centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Egypt</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d5f35125-4dad-44b3-bd89-7a5d1567eb61">
	  <name>Ain Shams University Maternity Hospital</name>
	  <address/>
	  <city>Cairo</city>
	  <state/>
	  <country>Egypt</country>
	  <zip>11566</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant women set for planned elective CS under general anaesthesia
2. No age limits
3. Written and signed informed consent by the patient to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Operation to be done not in the morning session
2. Patients undergoing caesarean hysterectomy or other extensive intra-abdominal surgery as a result of operative complication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Resumption of bowel motility after caesarean section (CS)</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Other complications of labour and delivery, not elsewhere classified</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This trial took place at Ain Shams University Maternity Hospital. The participants will be randomly allocated to the following two groups:
1. Group I (study group): 93 patients will receive one stick of sugarless gum (Samarah Foods, Egypt) for 15 minutes starting two hours after end of CS and every two hours thereafter (during waking time, stopped during overnight sleep) until the passage of flatus or bowel movement
2. Group II (control group): 107 patients will receive traditional post-operative management, with oral intake of clear fluids and soft foods allowed after the passage of flatus and regular diet after bowel movement

For both groups, no subject will be given oral or rectal bowel stimulants after CS. The same post-operative rehabilitation programme for ambulation, excluding gum chewing, will be used for the control group. Auscultation for intestinal sounds will be performed at 4 to 6 hour intervals. The patients will be allowed to sip small amounts of water only 12 hours post-operatively. The oral intake of clear fluids and soft foods will be allowed when normal bowel sounds are detected and flatus has passed with advancement to a regular diet after passage of first bowel motion. 

Eligible criteria for hospital discharge are stable vital signs with no febrile morbidity for at least 24 hours, ability to ambulate and urinate without assistance, passage of a bowel motion, ability to tolerate solid food without emesis and absence of unresolved other post-operative complications. For analgesia, two intramuscular doses of 75 mg diclofenac sodium (Voltaren®, Novartis Pharma, Egypt), a nonsteroidal anti-inflammatory medication, will be routinely given at 2 and 12 hours post-operatively. The need for additional use of narcotics (pethidine, 1 mg/kg) will be recorded. 

The participants are to be followed-up by the study team until discharge from hospital. However, any side-effects, complication and unexpected events presented by the participants during the postpartum period (until 5-6 weeks after delivery) are also to be recorded.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Chewing gum</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18218-0</funderId>
      <contactId>Contact56206_18218</contactId>
      <sponsorId>Sponsor54775</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56206_18218">
    <title>Prof</title>
    <forename>Karim H I</forename>
    <surname>Abd-El-Maeboud </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ain Shams University Maternity Hospital
Abbassia</address>
      <city>Cairo</city>
      <country>Egypt</country>
      <zip>11566</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54775">
    <organisation>Ain Shams University Maternity Hospital (Egypt)</organisation>
    <website>http://med.shams.edu.eg/index.php</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Prof Karim H I Abd-El-Maeboud 
Abbassia </address>
      <city>Cairo</city>
      <country>Egypt</country>
      <zip>11566</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.488444.0</gridId>
    <rorId>https://ror.org/00p59qs14</rorId>
  </sponsor>
  <funder id="Funder18218-0">
    <name>Ain Shams University Maternity Hospital (Egypt)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-10-30T00:00:00.000Z">60768666</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A sequential cohort study to compare tolerability and efficacy in patients receiving Octaplas® or Octaplas® LG</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>After implementation of a novel technology, Octaplas® LG has the same clinical safety and efficacy profile.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To observe the usage of the current product Octaplas® and the product with an additional chromatography step Octaplas® LG under normal clinical conditions to ascertain if there are any differences in patients outcomes with respect to effectiveness and tolerability. 

The effectiveness of Octaplas® and Octaplas® LG will be an objective assessment by the physician based on clinical or laboratory parameters relevant for the indication of whether the use of the product was successful or not. The tolerability will be evaluated on the basis of the number, nature, type and severity of adverse drug reactions (ADR). At the end of the study methods of descriptive statistics will be used to compare the effectiveness and tolerability of Octaplas® and Octaplas® LG.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>As the procedures during this observational study do not interfere with the patient's usual treatment and monitoring of treatment, this study is not regarded as a clinical study as defined by EU Directive 2001/20/EC. Therefore approval by an Independent Ethical Committee and an Institutional Review Board is not required.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60768666</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LAS-201</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-interventional, sequential cohort, observational, open, prospective, multi-centre study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7d35e015-ce82-463f-87eb-a31855aef556">
	  <name>Elisabeth-Selbert-Strasse 11</name>
	  <address/>
	  <city>Langenfeld</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40764</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients of any age who require a transfusion with Octaplas®/Octaplas® LG are eligible for study enrolment.</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Known relative contraindications such as latent or apparent cardial decompensation, hypervolaemia, hyperhydration, lung oedema and selective serum IgA deficiency
2. Known absolute contraindications such as hypersensitive against plasma proteins and antibodies against IgA</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Plasma transfusion in normal clinical practice</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Complications following infusion, transfusion and therapeutic injection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Before the first treatment with Octaplas® or Octaplas® LG, the physician will record the available baseline characteristics such as gender, date of birth, weight, blood group, diagnosis, and indication for use of plasma. Details of any plasma-derived blood or blood products given 24 hours before, during or within 48 hours after the treatment with Octaplas® or Octaplas® LG will also be documented.

Details of all Octaplas® or Octaplas® LG infusions will be recorded (date, times of start and end, batch number(s), number of bags, and transfusion volume). Whether the use of Octaplas® or Octaplas® LG is considered by the physician to be successful (Yes/No question) will be recorded, and the reason for the positive or negative assessment will be documented, together with any additional information that may be relevant. If any laboratory tests are done to assess the therapeutic effect of Octaplas® or Octaplas® LG, including but not limited to the international normalised ratio (INR), these will also be recorded. No investigations must be initiated for the purpose of this non-interventional trial. Details of any adverse drug reactions will also be recorded.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Octaplas®, Octaplas® LG</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18221-0</funderId>
      <contactId>Contact56209_18221</contactId>
      <sponsorId>Sponsor54778</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56209_18221">
    <title>Dr</title>
    <forename>Susanne</forename>
    <surname>Seeger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Elisabeth-Selbert-Strasse 11</address>
      <city>Langenfeld</city>
      <country>Germany</country>
      <zip>40764</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54778">
    <organisation>Octapharma GmbH (Germany) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Elisabeth-Selbert-Strasse 11</address>
      <city>Langenfeld</city>
      <country>Germany</country>
      <zip>40764</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476576.1</gridId>
    <rorId>https://ror.org/002k5fe57</rorId>
  </sponsor>
  <funder id="Funder18221-0">
    <name>Octapharma GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-27T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-10-27T00:00:00.000Z">24003246</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The assessment of the success of implants in the maxillary sinus graft</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This study aimed at analysing the success of maxillary sinus graft using biomaterial (demineralised bovine bone graft) and platelets-rich plasma. Bone neoformation and implant success rate were recorded.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed at 6 months:
1. Implant failure rate
2. Success rate of implants
3. Graft bone formation rate</primaryOutcome>
      <secondaryOutcome>The following were assessed at 6 months:
1. Bone density (subjective), defined during the surgery - D3
2. Sub-antral rating as measured by three-dimensional imaging or radiography - SA1</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>No ethics approval was sought as this trial used only routine procedures, and informed consent was obtained from all participants.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24003246</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1042</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional single-arm trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Other</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="86bc70af-61fe-4459-943d-98ec188263ba">
	  <name>Street benjamin constant 61 s 803</name>
	  <address/>
	  <city>Rio de janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>20241150</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, no age limits 
2. Patients who were admitted to the Centre for Post-Graduate Studies, Dental Center CLIVO, Rio de Janeiro (AORJ, FAISA/ CIODONTO), who needed graft in the maxillary sinus for the insertion of implants and subsequent construction of the prosthesis</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Cases in which, at the time of surgery, membrane was pierced greater than 2 mm, resulting in the abortion procedure.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Grafts for severely reabsorbed edges of the maxillary sinus after tooth extraction</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Other disorders of teeth and supporting structures</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All participants received maxillary sinus graft using biomaterial (demineralised bovine bone graft) and platelets-rich plasma. The implant was evaluated at 6 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18212-0</funderId>
      <contactId>Contact56200_18212</contactId>
      <sponsorId>Sponsor54769</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56200_18212">
    <title>Dr</title>
    <forename>Ana Roseli de </forename>
    <surname>Queiroz Gonçalves</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Street benjamin constant 61 s 803</address>
      <city>Rio de janeiro</city>
      <country>Brazil</country>
      <zip>20241150</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 021 81721981</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">arquegons@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54769">
    <organisation>Dental Center CLIVO (Centro Livre de Odontologia) (Brazil)</organisation>
    <website>http://www.clivo.com.br</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Rio de Janeiro College of Dentistry (AORJ)
RUA Barão do Flamengo
22 S 801</address>
      <city>Rio de Janeiro </city>
      <country>Brazil</country>
      <zip>22220-080 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 021 2225 4113 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cursos@clivo.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder18212-0">
    <name>Dental Center CLIVO (Centro Livre de Odontologia), Rio de Janeiro College of Dentistry (AORJ, FAISA/CIODONTO) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-27T00:00:00.000Z">01405766</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Open multicentre, phase IV study to evaluate efficacy and safety of pegylated interferon alpha-2a (40 KD) plus ribavirin for chronic hepatitis C with normal transaminases in human immunodeficiency virus-infected patients</title>
      <scientificTitle/>
      <acronym>CONTRA</acronym>
      <studyHypothesis>Response of chronic hepatitis C with normal transaminases to the combined treatment of pegylated interferon and ribavirin in human immunodeficiency virus (HIV)-infected patients is not lower than that achieved in patients with elevated levels of transaminases.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Sustained virological response, defined as HCV-RNA less than 50 UI/mL 24 weeks after stopping treatment.</primaryOutcome>
      <secondaryOutcome>1. Percentage of patients with normal ALT levels 24 weeks after stopping treatment
2. Percentage of patients with early virological response, defined as negativity or 2-log decrease at week 12 of treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Reference Research Ethics Board of the IDIBELL, Hospital Universitari de Bellvitge on the 15th May 2006 (EudraCT no.: 2006-001243-55).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01405766</doi>
      <eudraCTNumber>2006-001243-55</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-001243-55</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, multicentre of parallel groups</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6046f361-e147-477d-8f8d-bd7c4c684845">
	  <name>C/Feixa Llarga s/n</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>8907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cases: 
1. HIV-infected patients
2. Older than 18 years
3. With chronic hepatitis C (positive serum hepatitis C virus-ribonucleic acid [HCV-RNA] and hepatitis C virus [HCV] antibody)
4. Persistent normal alanine aminotransferase (ALT)

Controls: 
1. Adult HIV-infected patients
2. With chronic hepatitis C (positive serum HCV-RNA and HCV antibody)
3. Elevated ALT
4. Matched by sex, age, and HCV genotype</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>364</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>364 patients (182 cases and 182 controls)</totalTarget>
      <exclusion>Cases and controls: 
1. Patients with hepatic cirrhosis Child B or C
2. CD4 counts less than 200 cells/mm^3
3. Autoimmune diseases or any contraindication for treatment with interferon or ribavirin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human immunodeficiency virus/hepatitis C virus (HIV-HCV) co-infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Cases and controls will be treated with the combination of pegylated interferon alpha-2a plus ribavirin for 48 weeks. Treatment will be stopped at week 12 if, at least, 2-log decrease or negativity is not achieved at week 12. 

Management of patients during treatment and follow-up will be the same for patients and controls.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase IV</phase>
	<drugNames>Pegylated interferon alpha-2a (40 KD), ribavirin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16549-0</funderId>
      <contactId>Contact54507_16549</contactId>
      <sponsorId>Sponsor53062</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54507_16549">
    <title>Dr</title>
    <forename>Miguel</forename>
    <surname>Santin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>C/Feixa Llarga s/n</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>8907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 93 260 76 25</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msantin@csub.scs.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53062">
    <organisation>Roche Farma S.A. (Spain)</organisation>
    <website>http://www.roche.es/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>C/Eucalipto 33.</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28016</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476717.4</gridId>
    <rorId>https://ror.org/04b8zcj45</rorId>
  </sponsor>
  <funder id="Funder16549-0">
    <name>Roche Farma S.A. (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-27T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-10-27T00:00:00.000Z">49093383</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transcranial doppler sonography with a transorbital approach as a confirmatory test in the diagnosis of brain death</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This study was designed to evaluate whether the routine addition of the transorbital doppler examination of the carotid siphon in patients suspected of brain death improves the efficiency of the transcranial doppler examination protocol.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Blood flow patterns measured by transcranial doppler sonography with a suboccipital, transtemporal and transorbital approach.</primaryOutcome>
      <secondaryOutcome>Efficacy of the transorbital approach in the diagnosis of brain death with transcranial doppler sonography.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Institutional Ethics Committee of the General State Hospital of Athens in 2005 (ref: ICUTCD2005/2).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49093383</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8c8aa5ae-360f-42e2-b399-04165eb7a902">
	  <name>154 Mesogeion Ave</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>11527</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Brain dead patients of the intensive care unit (both males and females, aged greater than 16 years) who were hospitalised from October 2005 to July 2008.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>79</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>79</totalTarget>
      <exclusion>1. Patients with an episode of hypoxia or hypotension during the angiographic or transcranial doppler examinations 
2. Patients with no flow at the initial transcranial doppler examination in any approach</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Brain death</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Other disorders of brain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients underwent cerebral angiography, transcranial doppler examination of the basilar, anterior and middle cerebral arteries bilaterally. In addition, the patients in the intervention group were assessed by transorbital doppler of the carotid siphons bilaterally.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18154-0</funderId>
      <contactId>Contact56142_18154</contactId>
      <sponsorId>Sponsor54710</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56142_18154">
    <title>Prof</title>
    <forename>Andreas</forename>
    <surname>Karabinis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>154 Mesogeion Ave</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 21 0748 0188</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">echolabicu@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54710">
    <organisation>Athens General Hospital "G. Gennimatas" (Greece)</organisation>
    <website>http://www.gna-gennimatas.gr</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>ICU Department 
154 Mesogeion Ave</address>
      <city>Athens </city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theosol@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414012.2</gridId>
    <rorId>https://ror.org/00zq17821</rorId>
  </sponsor>
  <funder id="Funder18154-0">
    <name>Athens General Hospital "G. Gennimatas" (Greece) - Intensive Care Unit (ICU) Department</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-23T00:00:00.000Z">79803808</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of interdisciplinary health programme in the prevention of work-related physical complaints</title>
      <scientificTitle>Prevention of work-related physical complaints: a randomised clinical trial with one year follow-up</scientificTitle>
      <acronym/>
      <studyHypothesis>A client-centred interdisciplinary prevention programme is effective in reducing absenteeism in consequence of work-related physical complaints.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>At baseline, 3 months post-baseline, 6 months post-baseline and 12 months post-baseline:
1. Rate of absenteeism
2. 36-item Short Form Health Survey (SF-36): quality of life</primaryOutcome>
      <secondaryOutcome>At baseline, post-intervention, 3 months post-baseline and 12 months post-baseline:
1. Eurofit (physical fitness test)
2. Baecke (questionnaire physical activity in daily life)
3. Work APGAR test: job satisfaction
4. Utrecht Coping List (UCL): coping</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Board of Free University Brussels, approval submitted 18th August 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79803808</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e098a108-e37e-4a36-a992-8e4047107426">
	  <name>Artesis University College of Antwerp</name>
	  <address/>
	  <city>Merksem</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>B-2170</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Nurses, physical therapists and occupational therapists (18 - 65 years, either sex) working with patients in a general hospital
2. During the latest 12 months: maximum 4 weeks of absenteeism due to work-related physical complaints</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80 participants</totalTarget>
      <exclusion>1. Serious neurological, orthopaedic, cardiovascular or internal diseases
2. Overweight (body mass index [BMI] less than 32 kg/m^2)
3. Drug or alcohol abuse
4. Pregnancy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Work-related physical complaints</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants of a client-centred interdisciplinary primary prevention programme are compared to controls only receving activities of the usual primary prevention policy in the hospital.

The interdisciplinary programme consists of 11 group sessions of one hour and 3 individual 1-hour sessions (spread over 3 months). Throughout the programme, participants are informed and work on topics concerning physical activity, diet, ergonomics and coping.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18134-0</funderId>
      <contactId>Contact56122_18134</contactId>
      <sponsorId>Sponsor54690</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56122_18134">
    <title>Dr</title>
    <forename>Daphne</forename>
    <surname>Kos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Artesis University College of Antwerp
Department of Health Care
Van Aertselaerstraat 31</address>
      <city>Merksem</city>
      <country>Belgium</country>
      <zip>B-2170</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54690">
    <organisation>Artesis University College of Antwerp (Belgium)</organisation>
    <website>http://www.artesis.be</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Van Aertselaerstraat 31</address>
      <city>Merksem</city>
      <country>Belgium</country>
      <zip>B-2170</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.454226.3</gridId>
    <rorId>https://ror.org/0075f1c08</rorId>
  </sponsor>
  <funder id="Funder18134-0">
    <name>Artesis University College of Antwerp (Belgium) - project-based scientific research (ref: G838)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-23T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-10-23T00:00:00.000Z">24855722</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bioequivalence of phenazopyridine HCl in healthy volunteers</title>
      <scientificTitle>Two-treatment, two-period, randomised, single-blind, cross-over bioequivalence of phenazopyridine HCl in 24 healthy volunteers</scientificTitle>
      <acronym/>
      <studyHypothesis>The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic  product. This is necessary to demonstrate bioequivalence to regulatory authorities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the bioequivalence of both formulations of phenazopyridine, as determined by the following (monitored for 24 hours after administration of drug):
1. Measurement of the pharmacokinetic parameters
2. Maximum serum concentration (Cmax)
3. Time to maximum serum concentration (tmax) 
4. Area under the curve (AUC)</primaryOutcome>
      <secondaryOutcome>Side effects of each of the two product regimens, monitored at 4, 10 and 24 hours. Follow up will be carried out after 7 days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>IEC/IRB of the City Medical Committee, Karachi, Pakistan. Date of approval: 02/07/2008 (ref: ERB/HC/002)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24855722</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>URG/STEROP/001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, single-blind, cross-over trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ce5a7afe-bb30-449f-95fb-fa02326e28c2">
	  <name>Office of the Principal</name>
	  <address/>
	  <city>Karachi</city>
	  <state/>
	  <country>Pakistan</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy subjects aged 18 to 55 (male and female)
2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests
3. Informed consent signed by the subject
4. The subject is co-operative and available for the entire study
5. Not pregnant or nursing
6. Normal renal and hepatic function</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, haematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation
2. Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma
3. Evidence of hypertension (blood pressure after 3 minutes sitting &gt;160/95 mmHg)
4. Evidence of chronic or acute infectious diseases
5. History or evidence of malignant tumours
6. Evidence of hyperuricaemia, elevated serum uric acid (&gt;8.0 mg/dl)
7. Hepatic or renal impairment; elevated serum creatinine (&gt;1.4 mg/dl)
8. Planned vaccination during the time course of the study
9. Adherence to a diet (e.g., vegetarian) or life style (including extreme sports) that might interfere with the investigation
10. Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, Hepatitis C virus (HCV) antibody or Hepatitis B (HBs) antigen testing
11. Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)
12. Single use of any medication (including over-the-counter medication) that are not expressively permitted within two weeks prior to start of the study
13. Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)
14. Drug addiction
15. Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 weeks
16. Subjects who are known or suspected:
16.1. not to comply with the study directives
16.2. not to be reliable or trustworthy
16.3. not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed
16.4. to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-08-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Local analgesic for the urinary tract</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>To demonstrate the bioequivalence of a generic product containing phenazopyridine (one tablet x 100 mg) as test product Uropyrine® (Sterop Laboratories, Belgium) with the original formulation of phenazopyridine (one tablet x 100 mg) as reference product Pyridium® (Pfizer, USA). Both drugs will be administered orally in fasting state. All participants will be given each of the two drugs only once, in a cross-over design. The duration of washout period is 7 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Phenazopyridine HCl</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18090-0</funderId>
      <contactId>Contact56078_18090</contactId>
      <sponsorId>Sponsor54644</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56078_18090">
    <title>Prof</title>
    <forename>Waqar H</forename>
    <surname>Kazmi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Office of the Principal
Karachi Medical and Dental College</address>
      <city>Karachi</city>
      <country>Pakistan</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54644">
    <organisation>Phoenix International (UAE) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>PO Box 64613</address>
      <city>Dubai</city>
      <country>United Arab Emirates</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder18090-0">
    <name>Phoenix International (UAE)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-10-21T00:00:00.000Z">92443272</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dengue infection in adults and children in Hanoi: a descriptive clinical and immunological study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that factors other than enhancing antibody level affect viral load and dengue severity. To identify such factors we will focus on patients with symptomatic primary dengue who by definition lack pre-existing dengue antibodies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Proportions of patients with 10 (Immunoglobulin M and Immunoglobulin G ratio [IgM:IgG] greater than or equal to 1.8:1) or 20 (IgM:IgG ratio less than 1.8:1) infections* 
2. Proportions of patients who develop severe dengue (DHF/DSS)  

* as noted in section 4.3 of the protocol; these definitions may change

As it is a descriptive study the data will be analysed once all data have been collected. There are no timepoints for interim analyses.</primaryOutcome>
      <secondaryOutcome>1. The ECG abnormalities of rate, rhythm and ECG intervals (PR, QRS, QT) 
2. Cardiac function (echocardiogram) - ejection fraction (%), cardiac index (L/min/m^2) and rate corrected velocity of circumferential ventricular fibre shortening adjusted for left ventricular wall stress (kilodyne/cm^2) 
3. Lung volumes: forced vital capacity (FVC) in litres, forced expiratory volume in one second (FEV1) in litres/s, and the FEV1/FVC ratio
4. The proportions of patients with pleural effusions and ascites
5. Dengue viral load at baseline and over time
6. NS1 concentration at baseline and over time
7. Cytokine, complement and anti-dengue neutralising antibody concentrations at baseline and over time 
8. Fractional clearances of albumin and other plasma proteins  

As it is a descriptive study the data will be analysed once all data have been collected. There are no timepoints for interim analyses.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. The Oxford Tropical Medicine Research Ethics Committee (OXTREC) (UK) gave approval on the 25th June 2008 (ref: 26/08)
2. Pending as of 25/07/2008 from the NIITD Ethical Committee (Viet Nam)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92443272</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CTU04DXAPR08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational descriptive study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Viet Nam</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3804f57-02cc-4211-9f69-186cb71d2cfe">
	  <name>Oxford University Clinical Research Unit</name>
	  <address/>
	  <city>Hanoi</city>
	  <state/>
	  <country>Viet Nam</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A patient of any age, including pregnant women, with suspected dengue infection using the World Health Organization (WHO) criteria below:
1.1. History of fever and two or more of the following: 
1.1.1. Headache
1.1.2. Retro-orbital pain
1.1.3. Myalgia
1.1.4. Arthralgia
1.1.5. Rash
1.1.6. Haemorrhagic manifestation
1.1.7. Leukopaenia
2. Informed consent signed by the patient or parent/guardian</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Does not comply with the above inclusion criteria.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dengue fever</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Dengue fever [classical dengue]</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Because dengue is seasonal, most of the dengue patients will be recruited over a period of some 6 months, from May to September. During this time, patients will be recruited and then followed up. If some patients have a persistent abnormality that may be dengue related, e.g. evidence of reduced cardiac function, they will be followed up until either their abnormality stabilises or for at least one year. Depending on recruitment, the study may be extended to cover a second dengue season.

Descriptive analyses of the endpoints will consist of proportions for categorical data and means (SD, 95% CIs) and/or median (inter-quartile and full ranges) for continuous data supplemented by graphical displays where relevant. Simple correlations (Pearson's correlation coefficient or Spearman's rho) will be made between continuous data, e.g. cytokine and complement concentrations. Comparative analyses will be between: 
1. Patients who develop severe dengue (DHF/DSS) versus those who do not, and 
2. Patients with 10 and 20 infections

For categorical data, the comparisons will be by chi squared. For continuous data, the student's 't' test for normally distributed data or Mann Whitney U tests for skewed data. 

Other analyses:
1. Full blood count, differential white cell count
2. Clotting studies - prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen and d-dimers. Antithromin III, protein C and S may be done later on stored plasma.
3. Sodium, potassium, urea, creatinine, glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), total creatine kinase (CK), creatine kinase myocardial bands (CKmb) fraction, cardiac troponins, total bilirubin, total protein, albumin
4. Quantitative protein electrophoresis
5. Urine analysis
6. Radiology
7. Electrocardiograms (ECGs)
8. Echocardiograms (ECHO)
9. Spirometry (for lung function)
10. Virology studies</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17994-0</funderId>
      <contactId>Contact55977_17994</contactId>
      <sponsorId>Sponsor54543</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55977_17994">
    <title>Dr</title>
    <forename>Walter Bob</forename>
    <surname>Taylor</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Oxford University Clinical Research Unit
National Institute of Infectious and Tropical Diseases (NIITD) 
78 Giai Phong Street</address>
      <city>Hanoi </city>
      <country>Viet Nam</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54543">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Clinical Trials and Research Governance 
Manor House 
John Radcliffe Hospital 
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 9DZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder17994-0">
    <name>The Wellcome Trust (UK) (grant ref: 077078)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-13T00:00:00.000Z">34868002</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of two dose regimens of Octaplex® in patients with intracranial haemorrhage related to oral anticoagulant therapy</title>
      <scientificTitle>Efficacy and safety of two dose regimens of Octaplex® in patients with intracranial haemorrhage related to oral anticoagulant therapy: a multicentre, prospective, randomised, open-label study</scientificTitle>
      <acronym/>
      <studyHypothesis>To compare the efficacy of two dose regimens of Octaplex® on the international normalised ratio (INR) at 10 ± 5 minutes after the end of injection in patients with intracranial haemorrhage related to oral anticoagulant therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>INR at 10 ± 5 minutes after the end of injection in patients with intracranial haemorrhage related to oral anticoagulant therapy, measured by local laboratories (standard method).</primaryOutcome>
      <secondaryOutcome>Efficacy:
1. Laboratory parameters (coagulation): INR, prothrombin time (PT), thrombin generation assay (TGA), coagulation factors II, VII, IX and X, protein C and protein S at 10 ± 5 minutes, 1, 3, 6 and 24 hours after the end of injection. All these parameters will be analysed by local or central laboratory using standard methods.
2. Medical imaging (CT scan): volume of haematoma at 48 hours after the end of injection (or earlier in case of neurological worsening assessed by National Institutes of Health [NIH] Stroke Scale); the computed tomography images at T0 and T48 hours will be analysed by the central neuroradiology centre with the software OSIRIX
3. Clinical status: Glasgow Coma Scale (score: 3 - 15) and NIH Stroke Scale at 1, 24 and 48 hours, and on days 3 and 30 (or earlier if patient discharged) after the end of injection
4. Global outcome: 
4.1. Survival (is the patient dead? Yes or No)
4.2. Extended Glasgow Outcome Scale (GOS) (score: 1 - 8, 1 = dead, 8 = upper good recovery)
4.3. Modified Rankin Scale (MRS) (score: 0 - 6, 0 = no symtoms at all, 6 = dead)
4.4. Barthel Index (score: 0 - 100, 100 = patient is continent, feeds himself, dresses himself, gets up out of bed and chairs, bathes himself, walks at least a block, and can ascend and descend stairs)
All measured on day 30 (or earlier if patient discharged) after the end of injection.
5. Overall clinical response: this assessment will be done by the investigator using a verbal rating scale:
5.1. None: in spite of sufficient treatment uncontrolled intracranial bleeding growth requiring additional measures
5.2. Moderate: in spite of sufficient treatment uncontrolled intracranial bleeding and haematoma growth; no additional measures required
5.3. Excellent: intracranial bleeding and haematoma growth under control, comparable to a normal patient
Measured 48 hours after the end of injection.

Safety:
6. Study drug actually received
7. Adverse events (AEs) during the whole stay in all patients. AEs will be followed closely by a Data Monitoring Committee (DMC) whose assignment will be to identify possible thromboembolic complications. The DMC will be entitled to issue recommendations to the sponsor and the investigators regarding the continuation or the modification of the study if there is a suspicion of increased risk of thromboembolic complications in the high dose group.
8. Vital signs: continuous monitoring of arterial blood pressure, heart rate, respiratory rate and body temperature during the whole stay in the investigator's ward; recording of values and abnormalities at 10 ± 5 minutes, 1, 6, 24 and 48 hours and on days 3 and 30 (or earlier if patient discharged) after the end of injection
9. Electrocardiogram (ECG): continuous surveillance during the whole stay in the investigator's ward; recording of abnormalities at 10 ± 5 minutes, 1, 3, 6, 24 and 48 hours and on days 3 and 30 (or earlier if patient discharged) after the end of injection
10. Laboratory parameters (coagulation markers): D-dimers, prothrombin fragments F1+2 at 10 ± 5 minutes, 1, 3, 6 and 24 hours after the end of injection
11. Other laboratory parameters: troponins, electrolytes, urea, creatinine, liver function and haematology at 24 hours after the end of injection
12. Digital glucose at 24 hours after the end of injection

Quality of life measurements:
13. Pharmaco-economic patient questionnaire at month 3
14. 36-item short form health survey (SF-36) questionnaire at month 3</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ouest III Ethics Committee (Poitiers, France) on the 7th February 2008 (ref: 08.01.01)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34868002</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LEX-206</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, prospective, multicentre, randomised, open-label, phase III, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eb674f79-921d-4523-bf31-bed16fd62c81">
	  <name>Groupe Hospitalier Pitié Salpêtrière</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>F-75651</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients of 18 years of age or older, either sex
2. Intracranial haemorrhage (intracerebral and acute subdural) confirmed by medical imaging (computed tomography only)
3. Use of oral anticoagulant, only vitamin K antagonist
4. Written informed consent from the patient or a legally acceptable representative if the subject is unable to provide informed consent, or from the investigator and an independent witness from the investigator and the sponsor, if no legally acceptable representative is available at inclusion</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 (2 x 30 patients)</totalTarget>
      <exclusion>1. Deep coma on admission (score 3 to 5 on the Glasgow Coma Scale) because their probability of survival is close to zero
2. Septic shock or severe sepsis in the past fourteen days prior to inclusion
3. Crush injury in the past seven days prior to inclusion
4. Known or suspected disseminated intravascular coagulation 
5. Pulmonary embolism or phlebitis in the last 3 months prior to inclusion
6. Patients receiving vitamin K prior to admission to investigational centre
7. Known allergy to vitamin K or to any of its excipients
8. Hypersensitivity to the active substances of Octaplex® (human coagulation factors II, VII, IX and X) or to any of its excipients (heparin and sodium citrate)
9. Known allergy to heparin or history of heparin-induced thrombocytopenia
10. Participation in another clinical study, currently or during the past three months
11. Pregnant or lactating women
12. Jehovah's witnesses</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intracranial haemorrhage (intracerebral and acute subdural haematoma)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Intracerebral haemorrhage</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Octaplex® intravenous administration at the inclusion, 25 IU/kg or 40 IU/kg according to the randomisation. In addition, administration of 5 mg vitamin K, intravenous infusion for all the patients. 

Possibility of two more administrations upon INR results: 
1. A rescue dose at 10 ± 5 minutes after the first administration if INR not corrected (INR greater than 1.5), intravenous administration within 10 minutes, dose administrated = theoretical dose calculated according to the Summary of Product Characteristics (SmPC) - dose administrated at the inclusion (25 or 40 IU/kg)
2. New dose at 6 hours if INR greater than 2, dose calculated according the SMPc, intravenous administration within 10 minutes

Comparison of two doses of Octaplex®, no placebo or other treatment used. Patients will be followed up during 30 days or less if discharged.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Octaplex®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18102-0</funderId>
      <contactId>Contact56090_18102</contactId>
      <sponsorId>Sponsor54656</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56090_18102">
    <title>Prof</title>
    <forename>Pierre</forename>
    <surname>Coriat</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Groupe Hospitalier Pitié Salpêtrière
Departement d'Anesthésie
Boulevard de l'hôpital 47-83
F-75651 Paris cedex 13</address>
      <city>Paris</city>
      <country>France</country>
      <zip>F-75651</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54656">
    <organisation>Octapharma AG (Switzerland)</organisation>
    <website>http://www.octapharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Seidenstrasse 2 </address>
      <city>Lachen</city>
      <country>Switzerland</country>
      <zip>CH-8853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476576.1</gridId>
    <rorId>https://ror.org/002k5fe57</rorId>
  </sponsor>
  <funder id="Funder18102-0">
    <name>Octapharma AG (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-09T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-10-09T00:00:00.000Z">35444380</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative efficacy of Boswellia serrata extract and 5-Loxin® in the treatment of osteoarthritis of knee: a randomised, double-blind placebo-controlled clinical study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Boswellia serrata extract have been proven to be effective against inflammatory disorders in clinical trials, but no comparative clinical investigation has been carried out to demonstrate the efficacy and underlying mechanistic pathways involved therein. Furthermore, a broad spectrum of studies have evidenced that non-steroidal anti-inflammatory drugs (NSAIDs) induce painful gastrointestinal irritation as well as bleeding. No such adverse effects have been reported for natural Boswellia products.

In recent past, we have developed and proved clinical efficacy of a novel Boswellia serrata extract (5-Loxin®) enriched with 30% acetyl-11-keto-beta boswellic acid (AKBA) (Pending US patent [ref: 2004/0073060A1], Indian patent [ref: 205269], Australian patent [2002242934]). In a published clinical study (http://www.ncbi.nlm.nih.gov/pubmed/18667054; registered with ISRCTN05212803), we have shown that oral administration of 5-Loxin® conferred significant improvement in clinical signs and symptoms of patients with osteoarthristis (OA) of knee. This study also suggests that 5-Loxin® can normalise the elevated Matrix metalloproteinase-3 enzyme in synovial fluid which helps to reduce the cartilage degradation in OA.

However, till date no clinical study has been reported the comparative efficacy of 5-Loxin® and Boswellia serrata extract in OA. Therefore, in the present clinical study we designed to assess comparative efficacy of 5-Loxin® with Boswellia serrata extract (BE) against OA of knee.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain, assessed with VAS 
2. LFI 
3. Western Ontario and McMaster Universities osteoarthritis index (WOMAC)-pain, WOMAC-stiffness and WOMAC-physical ability 

All primary outcomes will be measured at baseline, 7, 30, 60 and 90 days of the study.</primaryOutcome>
      <secondaryOutcome>1. C-Reactive Protein (CRP) 
1. Matrix Metelloproteinase-3 (MMP-3) 

The secondary outcomes will be measured at baseline, 7, 30, 60 and 90 days of the study.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This protocol was approved by the Institutional Review Board of Alluri Sitarama Raju Academy of Medical Sciences (ASRAM) on 16/07/2008 (ref: 08-001 / 5-LO, BE/OA).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35444380</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>08-001/5-Lo, BE/OA</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83e267ec-f742-47b2-bb53-21af69b06efa">
	  <name>Department of Orthopaedics</name>
	  <address/>
	  <city>Eluru</city>
	  <state/>
	  <country>India</country>
	  <zip>534 002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants must understand risks and benefits of the protocol and able to give informed consent 
2. Male and female subjects of 40-80 years of age 
3. Females of child bearing potential must agree to use an approved form of birth control and have a negative pregnancy test result 
4. Unilateral or bilateral OA of the knee for more than 3 months 
5. Visual Analogue Scale (VAS) score during the most painful knee movement between 40-70 mm after 7 day withdrawal of usual medication 
6. Lequesne's Functional Index (LFI) score greater than 7 points after 7 days of withdrawal of usual medication 
7. Ability to walk 
8. Availability for the duration of the entire study period</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>1. History of underlying inflammatory arthropathy or severe rheumatoid arthritis (RA) 
2. Hyperuricemia (greater than 440 umol/L) and/or past history of gout 
3. Recent injury in the area affected by OA of the knee (past 4 months) and expectation of surgery in the next 4 months 
4. Intra-articular corticosteroid injections within the last 3 months 
5. Hypersensitivity to NSAIDs, abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal (GI) haemorrhage, congestive heart failure, hypertension, hyperkalemia 
6. Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders 
7. High alcohol intake (greater than 2 standard drinks per day) 
8. Pregnant, breastfeeding or planning to become pregnant during the study 
9. Use of concomitant prohibited medication other than ibuprofen 
10. Obesity: Body Mass Index (BMI) more than 30</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis of knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Gonarthrosis [arthrosis of knee]</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>75 subjects randomised into 3 groups (n = 25): 
1. 5-Loxin® (oral), 50 mg twice daily (bid) 
2. Boswellia extract (oral), 500 mg bid 
3. Placebo
 
Ibuprofen was used as a rescue medication for all groups. The study duration is 90 days and evaluations are at baseline, 7, 30, 60 and 90 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Boswellia serrata extract (5-Loxin®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18118-0</funderId>
      <contactId>Contact56106_18118</contactId>
      <sponsorId>Sponsor54673</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56106_18118">
    <title>Dr</title>
    <forename>Amar Anand</forename>
    <surname>Vishal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Orthopaedics
ASR Academy of Medical Sciences</address>
      <city>Eluru</city>
      <country>India</country>
      <zip>534 002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54673">
    <organisation>Laila Impex (India)</organisation>
    <website>http://lailaimpex.tradeindia.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>R&amp;D Center
Unit 1 Phase III
Jawahar Autonagar</address>
      <city>Vijayawada</city>
      <country>India</country>
      <zip>520007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 866 254 5244</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lailarescen@sify.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487312.b</gridId>
    <rorId>https://ror.org/05q6g7072</rorId>
  </sponsor>
  <funder id="Funder18118-0">
    <name>Laila Impex (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-09T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-09T00:00:00.000Z">59915743</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improvements in muscle recovery and delayed onset muscle soreness (DOMS) reduction after eccentric exercise with the BounceBack™ product: a randomised, double-blind, two-way crossover, placebo-controlled, pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The current study was designed to induce delayed onset muscle soreness (DOMS) in healthy untrained volunteers, assess the level of DOMS through functional and biochemical methods, and determine if the BounceBack™ product is superior to placebo in accelerating recovery from this condition.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain (Visual Analogue Scale [VAS]) and tenderness, assessed at baseline (pre-exercise), and then at 6, 24, 48 and 72 hours post-exercise.</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline (pre-exercise), and then at 6, 24, 48 and 72 hours post-exercise:
1. Inflammation
2. Muscle damage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by Copernicus Group IRB on 11/02/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59915743</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MANN1001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled, two-way crossover, pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ca65f735-0c92-4cb1-bf66-bc2aa019ba3c">
	  <name>Medicus Research LLC</name>
	  <address/>
	  <city>Northridge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>91325</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age &gt;=18 and &lt;=45 at screening 
2. Body mass index (BMI) &gt;18 kg/m^2 and &lt;=30 kg/m^2 at screening 
3. Recreationally active but non-resistance trained for the preceding 3 months 
4. Agree to dietary modifications for the day prior to each visit 
5. Subject agrees to all study visits 
6. Must agree to use appropriate birth control methods during the active study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Non-compliance during the screening phase of the study
2. Weight loss of &gt;10 pounds in the last 6 months
3. Pregnant or lactating
4. Currently attempting to become pregnant
5. Use of medications or supplements promoting weight gain (steroids, high-protein supplements)
6. Daily use of acid blocking medication. Must agree to withhold acid blocking medication while on study (Includes all prescription and over the counter acid blockers including PPIs, H2RAs, and calcium carbonate [Tums]).
7. Cigarette smoking
8. Abnormal physical examination
9. Subjects unable to understand or follow the study protocol
10. Subjects participating or participated in another clinical trial during the 1 month prior to screening
11. Subjects with active eating disorder including anorexia nervosa, bulimia, restrained eating, and/or obsessive compulsive eating disorders (Subjects will be screened with a standardised eating disorder questionnaire)
12. Subjects with known sensitivities to the ingredients in the product
13. Subjects with untreated significant depression or other psychiatric disease noted during the initial screening. Subjects with stable depression who are receiving medication and/or therapy may be included.
14. Subjects with active coronary artery disease, congestive heart failure, stroke, arrhythmia, or uncontrolled hypertension
15. Any liver, gallbladder or renal disease
16. Subjects with a history of seizure
17. Subjects with any cancer in the last 5 years (except skin cancer)
18. Subjects on anticoagulation therapy
19. Subjects with known alcohol abuse or recreational drug abuse
20. Subjects with chronic malabsorption
21. Subjects with a history of diverticulosis or diverticulitis
22. Subjects with inflammatory bowel disease (ulcerative colitis or Crohn's disease)
23. Subjects with a history of intestinal obstruction or those prone to intestinal obstruction
24. Subjects with short bowel syndrome
25. Subjects with a history of any surgery on their gastro-intestinal system
26. Subjects with a history of perforation of the stomach or intestines
27. Subjects with a history of pancreatitis, pancreatic insufficiency, pancreatic psuedocyst, carcinoma of the pancreas
28. Type I or type II diabetes 
29. Subjects with any other endocrinologic disorders (including Cushing's syndrome and/or hypothyroidism)
30. Subjects with a history of lactic acidosis
31. Subjects with a history of symptomatic hypoglycemia
32. Subjects with brain and/or spinal cord injury
33. Subjects who have had diarrhoea in the month prior to the screening visit</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Delayed onset muscle soreness (DOMS)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The test product is BounceBack™, which contains enzymes, curcumin, vitamin C, avocado, soy extract and resveratrol. 

Dosage: BounceBack™ (oral) 1000 mg/day

Schedule of interventions:
Thirty days of consumption of the test product or placebo, followed by exercise on Day 31 and post-exercise evaluations on Day 32, 33 and 34. After a two-week washout period, the intervention was repeated in a crossover design.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>BounceBack™</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18133-0</funderId>
      <contactId>Contact56121_18133</contactId>
      <sponsorId>Sponsor54689</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56121_18133">
    <title>Dr</title>
    <forename>Jay</forename>
    <surname>Udani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medicus Research LLC 
18250 Roscoe Blvd. 
Suite 240</address>
      <city>Northridge</city>
      <country>United States of America</country>
      <zip>91325</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 818 882 9442</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jay.udani@medicusresearch.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54689">
    <organisation>Mannatech, Inc (USA)</organisation>
    <website>http://www.mannatech.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>600 S. Royal Lane
Suite 200</address>
      <city>Coppell</city>
      <country>United States of America</country>
      <zip>75019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487251.d</gridId>
    <rorId>https://ror.org/031g1ba05</rorId>
  </sponsor>
  <funder id="Funder18133-0">
    <name>Mannatech, Inc (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-10-08T00:00:00.000Z">34755982</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Nitroglycerin for management of retained placenta: a multicentre trial</title>
      <scientificTitle>Medical treatment with nitroglycerin for management of retained placenta: a multicentre trial</scientificTitle>
      <acronym/>
      <studyHypothesis>To study the effect of medical treatment with 1 mg of nitroglycerin administered sublingually on retained placenta, i.e. does placenta detach on the treatment?

Background: 
Retained placenta occurs in 3% of all deliveries. The results from a pilot study indicate that medical treatment with a combination of oxytocin and the utero-relaxing agent nitroglycerin adminstered 1 mg sublingually seems to have an effect. The primary aim of this study is to investigate in a larger multicentre trial if the good results from the pilot study using nitroglycerin for management of retained placenta can be confirmed. Every woman who 30 minutes after vaginal delivery has a retained placenta and can be recruited to the study according to inclusion and exclusion criteria will be asked to participate in the study. The multicentre trial will be performed in the Swedish cities of Gothenburg, Trollhattan, Boras and Norrkoping.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The numbered of detached placentas following sequential treatment with 10 IU oxytocin intravenously and 1 mg nitroglycerin sublingually compared to placebo group.</primaryOutcome>
      <secondaryOutcome>1. To measure blood loss on the treatment compared to placebo group, at 0 minutes, 5 minutes and 15 minutes. The amount of blood loss will be measured before and after detachment and the total blood loss until placental delivery will be measured. 
2. To study possible side effects such as headache, palpitations, hot flushes, at 0 minutes, 5 minutes and 15 minutes
3. To study possible effects on blood pressure and pulse rate, at 0 minutes, 5 minutes and 15 minutes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Regional Ethical Committee of Gothenburg, approved on the 5th May 2008 (ref: 107-08)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34755982</doi>
      <eudraCTNumber>2008-001346-92</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EudraCT number: 2008-001346-92</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre randomised placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="114c220a-1edc-4ffc-ac2e-f4767e28732c">
	  <name>Kvinnokliniken Ostra Hospital</name>
	  <address/>
	  <city>Gothenburg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>41685</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy women with no medication, aged 18 - 45 years 
2. Uncomplicated vaginal delivery 
3. Term pregnancy (greater than 37 weeks) 
4. Retained placenta 45 minutes after delivery 
5. The woman wishes to participate in the study 
6. No excessive vaginal bleeding (less than 500 ml) 
7. Circulatory stability</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Excessive vaginal bleeding 
2. Preterm labour 
3. Daily medication 
4. Placenta accreta/percreta 
5. Known uterine abnormailty</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Retained placenta</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Retained placenta and membranes, without haemorrhage</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>If placenta has not detached 30 minutes after delivery the patient will be given 10 IU oxytocin (Syntocinon®) intravenously. Five minutes later the doctor tries to expel the placenta by gentle traction of the umbilical cord. If the placenta doesn't detach the patient will be asked to participate in the study and will randomly be selected to either active treatment or placebo. 

Of 120 patients included in the study 60 will randomly be selected to be administered two tablets of 0.5 mg glyceryl trinitrate (Nitromex®) sublingually, and 60 patients in the placebo group will be administered two tablets of 5 mg folic acid (Folacin®). The administration will occur approximately 45 minutes after the vaginal delivery and only once. 

If placenta does not detach 5 minutes later the patient will be taken to the operative theatre for manual removal of the placenta in regional or general anaesthesia. The follow up of the outcomes will be performed up to 30 minutes after inclusion to the study, more specifically until the placenta is detached.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oxytocin (Syntocinon®), glyceryl trinitrate (Nitromex®), folic acid (Folacin®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18159-0</funderId>
      <contactId>Contact56147_18159</contactId>
      <sponsorId>Sponsor54715</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56147_18159">
    <title>Dr</title>
    <forename>Maria</forename>
    <surname>Bullarbo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kvinnokliniken Ostra Hospital
Sahlgrenska University Hospital</address>
      <city>Gothenburg</city>
      <country>Sweden</country>
      <zip>41685</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)31 343 40 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">maria.bullarbo@vgregion.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54715">
    <organisation>The Vastra Gotaland Regional Council (Vastra Gotalandsregionen) (Sweden)</organisation>
    <website>http://www.vgregion.se/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Regionens Hus </address>
      <city>Vanersborg</city>
      <country>Sweden</country>
      <zip>462 80 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 521 27 57 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">post@vgregion.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452005.6</gridId>
    <rorId>https://ror.org/00a4x6777</rorId>
  </sponsor>
  <funder id="Funder18159-0">
    <name>The Gothenburg Medical Society (Goteborgs Lakaresallskap) (Sweden) - Regional FoU resources</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-30T00:00:00.000Z">66115464</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment of psoriasis by pulsed dye lasers: short-term and long-term (4 years) results</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Previous studies with pulsed dye lasers showed improvement of chronic plaques of psoriasis and, sometimes, total clearing. This study aims to investigate the efficacy of the pulsed dye laser treatment on psoriasis plaques by comparing the affected areas that have been treated with the laser against the untreated area within an individual.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Clinical score at baseline and 6 weeks after the last and third treatment by pulsed dye laser.</primaryOutcome>
      <secondaryOutcome>Adverse effects, followed-up for at least 2 years.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local ethics committee (CCPPRB Paris Saint-Louis) on 21st April 2001 (ref: 2001/13)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66115464</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-10-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1bf900f9-5228-402f-ab9a-15384655b02e">
	  <name>Centre Laser Trevise</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, minimum age = 18, no upper age limit
2. Psoriasis: chronic and untreated plaques</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>28</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>28</totalTarget>
      <exclusion>1. Pregnant women
2. Minors
3. Patients who had received local treatment during the last month or oral treatment during the last 6 weeks (cyclosporin, retinoids, methotrexate, corticosteroids)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-10-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psoriasis</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Psoriasis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two plaques were investigated in each patient, and for both plaques, 1/4 of the total area was left untreated (control area). The remaining area of both plaques were treated with the pulsed dye laser. 

Randomisation: The plaques were divided in four quadrants and, by draw (throwing a four sided dice), one quadrant was chosen as the control area and the other three were treated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17899-0</funderId>
      <contactId>Contact55882_17899</contactId>
      <sponsorId>Sponsor54446</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55882_17899">
    <title>Dr</title>
    <forename>Jean Michel</forename>
    <surname>Mazer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre Laser Trevise
49 rue de Trevise </address>
      <city>Paris</city>
      <country>France</country>
      <zip>75009 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54446">
    <organisation>Saint Louis Hospital (France)</organisation>
    <website>http://www.chu-stlouis.fr</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Prof L Dubertret
Department of Dermatology</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75010</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413328.f</gridId>
    <rorId>https://ror.org/049am9t04</rorId>
  </sponsor>
  <funder id="Funder17899-0">
    <name>Saint Louis Hospital (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-30T00:00:00.000Z">61158084</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>BIOmarker-driven DEcision Study with Adalimumab (BIODESA)</title>
      <scientificTitle>Individualised therapy of rheumatoid arthritis with anti-tumour necrosis factor (TNF) antibodies (adalimuab) based on neuroendocrine biomarkers, a prospective clinical study</scientificTitle>
      <acronym>BIODESA</acronym>
      <studyHypothesis>Patients with a biomarker value (cortisol/adrenocorticotropic hormone [ACTH]) below 196,000 are responders to adalimumab treatment as demonstrated by a significantly better outcome (Disease Activity Score using 28 joints [DAS28]). The ratio of serum cortisol/serum ACTH can be used as a biomarker.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>DAS28 at 12 weeks.</primaryOutcome>
      <secondaryOutcome>1. Response to hormonal challenge test (corticotropin releasing hormone [CRH], growth hormone releasing hormone [GHRH], thyrotropin releasing hormone [TRH], and luteinizing hormone releasing hormone [LH&#150;RH] before and after anti-TNF therapy)
2. Behaviour of circadian rhythm curves of cortisol, testosterone, and DHEA (before and after anti-TNF therapy)
3. Volume and morphology of the adrenal glands (magnetic resonance imaging [MRI] before and after anti-TNF therapy)
4. Volume of the anterior cingulate cortex (MRI before and after anti-TNF therapy)
5. Expression of 11-beta&#150;hydroxysteroid-dehydrogenase type 2 as investigated in miniarthroscopically removed synovial tissue (before and after anti-TNF therapy)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Application was submitted to the Ethics Committee of the University of Regensburg on 20/07/2008. Approval expected to be granted in October 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61158084</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase III, non-randomised, double-blind (participants and physicians), two-arm, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="90322eb8-af61-4c56-900f-fabdb563f2f2">
	  <name>Franz-Josef-Strauss-Allee 11</name>
	  <address/>
	  <city>Regensburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>93042</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Rheumatoid arthritis (RA) is diagnosed according to the American College of Rheumatology criteria
2. Both males and females, age must be 18 years or older
3. Patients must have given written informed consent
4. The disease duration should be less than 24 months 
5. The DAS28 score must be above 5.0
6. The number of swollen joints must be &gt;=8
7. The number of tender joints must be &gt;=10
8. The erythrocyte sedimentation rate must be &gt;=28 mm/hour</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Other inflammatory arthropathies such as psoriasis arthritis and similar conditions
2. Treatment with disease modifying anti-rheumatic drugs (DMARDs), glucocorticoids, or biologics 
3. Severe or uncontrolled co&#150;morbidities (e.g. infectious, metabolic, hepatic, cardiac, malignant, psychiatric co&#150;morbidities) 
4. A positive screening test result for tuberculosis (purified protein of tuberculin 5 [PPD5] test, chest radiography). Patients at high risk for tuberculosis are excluded or are treated with isoniazid up to 300 mg/day concomitantly. 
5. Patients of child-bearing potential without adequate contraceptive protection 
6. Patients with contraindications for trial drugs</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants will be allocated to two groups according to a biomarker; the biomarker is the ratio of serum levels (in mol/l) of cortisol divided by ACTH (cortisol/ACTH). Both groups are treated with the already approved anti-TNF antibody adalimumab 40 mg subcutaneously (s.c.) every other week for 24 weeks. The patients and the treating physicians do not know the group allocation. 

We expect that patients with a cortisol/ACTH ratio above 196,000 do not profit much from the anti-TNF therapy, whereas those patients with a ratio below 196,000 will profit from adalimumab therapy. According to good clinical care guidelines, we will have a rescue line at week 12. Those patients that do not profit from the therapy are switched to standard DMARD therapy with methotreaxte and prednisolone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Adalimuab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18009-0</funderId>
      <funderId>Funder18009-1</funderId>
      <contactId>Contact55992_18009</contactId>
      <sponsorId>Sponsor54558</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55992_18009">
    <title>Prof</title>
    <forename>Rainer H</forename>
    <surname>Straub</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Franz-Josef-Strauss-Allee 11 
D-93053</address>
      <city>Regensburg</city>
      <country>Germany</country>
      <zip>93042</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rainer.straub@klinik.uni-regensburg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54558">
    <organisation>University Hospital Regensburg (Universitätsklinikum Regensburg) (Germany)</organisation>
    <website>http://www.uniklinikum-regensburg.de</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Internal Medicine
Franz-Josef-Strauss-Allee 11
93053 </address>
      <city>Regensburg</city>
      <country>Germany</country>
      <zip>93042</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rainer.straub@klinik.uni-regensburg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411941.8</gridId>
    <rorId>https://ror.org/01226dv09</rorId>
  </sponsor>
  <funder id="Funder18009-0">
    <name>University Hospital Regensburg (Universitätsklinikum Regensburg) (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18009-1">
    <name>German Research Foundation (Deutsche Forschungsgemeinschaft) (Germany) - Decision pending</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-29T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-29T00:00:00.000Z">21800909</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The management of neuropathic ulcers of the foot in diabetes by shock wave therapy</title>
      <scientificTitle/>
      <acronym>SWDF</acronym>
      <studyHypothesis>The main objective of the present study was to evaluate healing rates of diabetic foot ulcers during a 20-week period in patients treated by extracorporeal shock wave therapy (ESWT) compared with standard therapy consisting of debridement and Silver dressing.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Wound area reductions, measured with the Rhinoceros program
2. Time to complete ulcer healing, measured as the number of days from the start of treatment to the date that a patient achieved complete wound healing. If the healing wasn't within the 20 weeks of the study, the patient was considered as non-healing and the time wasn't registered.
3. Time to complete healing
4. Index of re-epithelisation of the wound area

The outcomes were measured every 10 days.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Comitato Etico Indipendente Locale Azienda Ospedaliera Ospedale Policlinico Consorziale di Bari) on the 24th June 2008 (ref: 838/CE).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21800909</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>838/CE</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a734087f-226c-404c-926d-373b089799ff">
	  <name>via Napoli, 215</name>
	  <address/>
	  <city>Bari</city>
	  <state/>
	  <country>Italy</country>
	  <zip>70124</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A neuropathic foot plantar ulcer below the malleoli for a period of at least 15 to 30 days with an area wider than 1 cm^2
2. 30 - 70 years old, either sex
3. Diameter of the lesion between 0.5 to 5 cm
4. Diabetes mellitus type I; in insulin treatment since at least 5 years ago</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Peripheral vascular disease
2. By-pass
3. Pregnant
4. Coagulation diseases
5. History of neoplasia 
6. Other conditions based on the principal investigator's clinical judgement around the ESWT applications</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neuropathic Diabetic Foot Ulcers</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Insulin-dependent diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Shock waves and Silvercel dressing versus Silvercel dressing alone. Follow-up in all arms and treatments is for 20 weeks with standard dressing every 3 - 4 days.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17937-0</funderId>
      <contactId>Contact55920_17937</contactId>
      <sponsorId>Sponsor54484</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55920_17937">
    <title>Prof</title>
    <forename>Biagio</forename>
    <surname>Moretti</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>via Napoli, 215</address>
      <city>Bari</city>
      <country>Italy</country>
      <zip>70124</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54484">
    <organisation>University of Bari (Italy) </organisation>
    <website>http://www.uniba.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Piazza G. Cesare, 11</address>
      <city>Bari</city>
      <country>Italy</country>
      <zip>70124</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7644.1</gridId>
    <rorId>https://ror.org/027ynra39</rorId>
  </sponsor>
  <funder id="Funder17937-0">
    <name>University of Bari (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-29T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-29T00:00:00.000Z">06221064</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Fluid In Low risk Labour Trial</title>
      <scientificTitle>The effect of conservative versus routine intrapartum fluid management in women with epidural analgesia on breastfed newborn weight loss: a randomised controlled trial</scientificTitle>
      <acronym>The FILL Trial</acronym>
      <studyHypothesis>For low risk women receiving epidural analgesia in labour, what is the effect of a conservative protocol for fluid management versus usual care on breastfed newborns&#146; weight loss in the first 48 hours of life?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Breastfed newborn weight loss in the first 48 hours.</primaryOutcome>
      <secondaryOutcome>Breastfeeding exclusivity, measured prior to discharge from the postpartum unit.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Research Ethics Board of Sunnybrook Health Sciences Centre on the 21st August 2008 (ref: 237-2008)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06221064</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single site randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-10-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dc21acd6-0efd-45f6-aecb-9806368aebce">
	  <name>98 Bessborough Drive</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M4G 3J1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women in early labour, 19 - 40 years of age
2. Experiencing a labour at no identified risk
3. Anticipating a vaginal birth
4. Planning to breastfeed
5. Requesting an epidural</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Planning discharge before 48 hours
2. Unable to read and write English
3. Previous breast surgery
4. Expected to deliver in the next 4 - 5 hours</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-10-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fluid management in labour</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Total duration of treatment is from the time of admission to the labour unit until the time of delivery. Patients will be randomised to one of the following fluid management techniques:

Usual Intrapartum Fluid Management:
Usual intrapartum fluid management includes the initiation of intravenous therapy prior to epidural analgesia administration or when intravenous drugs need to be administered. Fluid preload for epidural analgesia initiation ranges from 500 cc to 1000 cc of Ringers Lactate and intravenous (IV) fluid is administered throughout labour for non-reassuring foetal heart rate tracings and maternal fever. Hourly infusion volumes vary from 125 to 250 ml per hour or greater. Calculations of fluid balance may not be routinely conducted intrapartum but summarised at the time of transfer of the woman to the postpartum floor. Intrapartum assessments do not routinely include hydration assessments or calculation of intrapartum fluid balance.

Conservative Fluid Management:
A conservative intrapartum fluid management protocol will be administered to the experimental group. This protocol assumes that care is individualised to the labouring woman and will be reflective of the events of her labour. Women will receive an epidural analgesia preload of 250 to 500 ml of Ringers Lactate and the intravenous infusion will continue at the hourly rate of 75 to 100 ml per hour. Hydration assessments and fluid balance calculations will be conducted and recorded every four hours. Reaching critical values for fluid infused greater than 2500 ml will require the nurse to review the fluid management plan with the physician responsible for the woman's care, maternal fever will be treated with acetaminophen. Decisions regarding bolus for abnormal foetal heart rate patterns will at the discretion of the caregivers.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18109-0</funderId>
      <funderId>Funder18109-1</funderId>
      <contactId>Contact56097_18109</contactId>
      <sponsorId>Sponsor54663</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56097_18109">
    <title>Ms</title>
    <forename>Jo</forename>
    <surname>Watson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>98 Bessborough Drive</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M4G 3J1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54663">
    <organisation>Sunnybrook Health Sciences Centre (Canada) </organisation>
    <website>http://www.sunnybrook.ca/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>2075 Bayview Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M4N 3M5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413104.3</gridId>
    <rorId>https://ror.org/03wefcv03</rorId>
  </sponsor>
  <funder id="Funder18109-0">
    <name>Society of Obstetricians and Gynaecologists (Canada) - Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Fellowship</name>
    <fundRef/>
  </funder>
  <funder id="Funder18109-1">
    <name>Sunnybrook Health Sciences Centre (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-18T00:00:00.000Z">18342801</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Laryngeal mask vs endotracheal tube for bariatric surgery</title>
      <scientificTitle>Comparison study on ventilation with laryngeal mask and with endotracheal tube for bariatric surgery</scientificTitle>
      <acronym/>
      <studyHypothesis>Ventilation with laryngeal mask results in better recovery profile than ventilation with endotracheal tube in obese patients undergoing bariatric surgery.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time to independent walking after the end of anesthesia</primaryOutcome>
      <secondaryOutcome>1. Ventilatory parameters
2. Postoperative morbidity
3. Patient and surgeon satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the Ethics Committee, Padua Hospital on 25/07/2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18342801</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1615P</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind (patient, evaluating physician) trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-01-08T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="077a84b7-f391-433a-95c1-b7b5ac9d09fc">
	  <name>Istituto di Anestesiologia</name>
	  <address/>
	  <city>Padova</city>
	  <state/>
	  <country>Italy</country>
	  <zip>35121</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age &gt;18 years
2. American Society of Anaesthesiologists (ASA) classification I-III
3. Obese patients (body mass index [BMI] &gt;30) undergoing bariatric surgery
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>124</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>124</totalTarget>
      <exclusion>1. Psychiatric disorders
2. Drug abuse
3. Known or possible pregnancy
4. Previous airway pathology
5. Pulmonary diseases
6. History of gastro-oesophageal reflux</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-01-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-01-08T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ventilation with laryngeal mask vs ventilation with endotracheal tuber</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18085-0</funderId>
      <contactId>Contact56073_18085</contactId>
      <sponsorId>Sponsor54639</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56073_18085">
    <title>Dr</title>
    <forename>Ulderico</forename>
    <surname>Freo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Istituto di Anestesiologia
Dipartimento di Farmacologia e Anestesiologia
Via C. Battisti, 267</address>
      <city>Padova</city>
      <country>Italy</country>
      <zip>35121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)49 821 3094</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ulderico.freo@unipd.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54639">
    <organisation>Department of Pharmacology and Anaesthesiology, Padua University (Italy)</organisation>
    <website>http://www.istar.unipd.it</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof Carlo Ori
Istituto di Anestesiologia
Dipartimento di Farmacologia e di Anestesiologia
Università di Padova</address>
      <city>Padova</city>
      <country>Italy</country>
      <zip>35121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5608.b</gridId>
    <rorId>https://ror.org/00240q980</rorId>
  </sponsor>
  <funder id="Funder18085-0">
    <name>Department of Pharmacology and Anaesthesiology, Padua University (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-18T00:00:00.000Z">74820169</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised double blind controlled trial of nitazoxanide in intestinal polyparasitism in humans: a Brazilian study</title>
      <scientificTitle>A randomised double blind controlled trial of nitazoxanide of the treatment in intestinal polyparasitism in humans</scientificTitle>
      <acronym/>
      <studyHypothesis>Nitazoxanide is a drug with an ample spectrum of activity, a superior or equivalent effectiveness to secnidazole and/or albendazole in the treatment of  majority of intestinal parasitism in humans, and presents with less adverse effects than the previously cited drugs.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Cure (non-infected) defined as an absence of any species of parasite in the examination of excrements
2. Cure absence (infected) defined as maintenance of the pre-existing parasite

These outcomes will be measured in July and September 2008.</primaryOutcome>
      <secondaryOutcome>Prevalence of adverse effects. These outcomes will be measured in July and September 2008.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Committee of Ethics in Research in Human Beings of Propesq/UFJF, dated 15th March 2007 (ref: 063/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74820169</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind controlled trial, single centre</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7796baeb-5763-4a9c-89a1-13be37747575">
	  <name>Rua Padre Vieira, 50/302</name>
	  <address/>
	  <city>Minas Gerais</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>36025070</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants more than one year of age, either sex
2. Positive for one or more species of intestinal parasites 
3. Rural populations in the Zona da Mata of the State of Minas Gerais (Brazil)
4. Taken care of by the Unified National Health System (SUS)</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Intestinal obstruction for intestinal parasitisms
2. Pregnant
3. Patients with liver or renal insufficiency
4. Alterations in biliary treatment
5. Patient is using warfarin, aspirin, phenytoin, carbamazepine or valproic acid</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intestinal polyparasitism</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Unspecified parasitic disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Nitazoxanide = 15 mg/kg/day every 12 hours for children, 500 mg tablet every 12 hours for adults, during three days
2. Secnidazole = 30 mg/kg/day for children and 2 g for adults in one dose
3. Albendazole = 400 mg in one dose (suspension for 400 mg for children, tablets of 400 mg for adults)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nitazoxanide, secnidazole, albendazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17924-0</funderId>
      <funderId>Funder17924-1</funderId>
      <contactId>Contact55907_17924</contactId>
      <sponsorId>Sponsor54471</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55907_17924">
    <title>Mrs</title>
    <forename>Elisabeth</forename>
    <surname>Andrade</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Padre Vieira, 50/302</address>
      <city>Minas Gerais</city>
      <country>Brazil</country>
      <zip>36025070</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 32 3232 2816</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ecampos@terra.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54471">
    <organisation>Federal University of Juiz de Fora (Brazil) </organisation>
    <website>http://lattes.cnpq.br/0143686778100049 </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Elisabeth Campos de Andrade
Rua Padre Vieira 50 /302 </address>
      <city>Minas Gerais</city>
      <country>Brazil</country>
      <zip>36025-070</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411198.4</gridId>
    <rorId>https://ror.org/04yqw9c44</rorId>
  </sponsor>
  <funder id="Funder17924-0">
    <name>Federal University of Juiz de Fora (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17924-1">
    <name>Farmoquimica S/A (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-18T00:00:00.000Z">90844675</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pulsed Ultrasound to Speed-up Healing after Intramedullary nailing of Tibia fractures</title>
      <scientificTitle/>
      <acronym>PUSH-IT</acronym>
      <studyHypothesis>Adjuvant pulsed ultrasound increases the bony union rate after three months from 20% to 40% after intramedullary nailing of tibia fractures compared to no adjuvant treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Bony union three months (+/- 1 week) after randomisation, as assessed on plain radiographs by independent, blinded raters.</primaryOutcome>
      <secondaryOutcome>1. Delayed union and non-union rates
2. Health-related quality of life (36-item Short Form Health Survey [SF-36], EuroQoL instrument [EQ-5D])
3. Functional outcomes (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC])
4. Duration of sick leave
5. Cost-utility
6. Serious adverse events (SAE)

Secondary outcomes will be assessed after 6 weeks, 3, 6, and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Institutional Review Board (IRB) of the Charité University Medical Centre (Germany), dated 4th June 2008 (ref: EA1/079/08)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN90844675</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PUSH-IT V1.3 08/08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pragmatic, randomised controlled multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bc765f73-6962-4f0a-9705-45e2f05820d8">
	  <name>Department of Trauma and Orthopaedic Surgery</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12683</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women
2. Greater than 18 years old
3. With closed or I° open fractures of the tibia that had been treated by reamed or unreamed locking intramedullary nails less than 10 days prior to randomisation. Patients with fractures of the lateral malleolus, fixed by plates, as well as patients with minor concomitant injuries (bruises, sprains) will be offered trial participation.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250 (O'Brien-Fleming adaptive design: RD 20%, alpha 0.025, power 83%, 2 x 106 patients, assumed drop-out rate 15%)</totalTarget>
      <exclusion>1. Multiple injuries/polytrauma
2. Greater than I° open fractures
3. Pregnant or breastfeeding women
4. Pathological fractures</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Closed or I° open fractures of the tibia</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Fracture of lower leg, including ankle</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental: pulsed, low-energetic ultrasound (Exogen, Smith &amp; Nephew), applied daily for three months
Control: standard of care

The total duration of follow-up is one year after randomisation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18110-0</funderId>
      <contactId>Contact56098_18110</contactId>
      <sponsorId>Sponsor54664</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56098_18110">
    <title>Dr</title>
    <forename>Julia</forename>
    <surname>Seifert, MD PhD</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Trauma and Orthopaedic Surgery
Unfallkrankenhaus Berlin</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12683</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">julia.seifert@ukb.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54664">
    <organisation>German Employer's Liability Insurance for the Administrative Professions (Verwaltungs-Berufsgenossenschaft [VBG]) (Germany) </organisation>
    <website>http://www.vbg.de/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Head Office
Department of Rehabilitation
Deelbögenkamp 4</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>22281</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wolfgang.ebeling@vbg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487358.5</gridId>
    <rorId>https://ror.org/02gaw4292</rorId>
  </sponsor>
  <funder id="Funder18110-0">
    <name>German Employer's Liability Insurance for the Administrative Professions (Verwaltungs-Berufsgenossenschaft [VBG]) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-18T00:00:00.000Z">92199001</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of different types of treatments for chronic neck pain</title>
      <scientificTitle>The effect of neck coordination training on sensorimotor function, symptoms and self-rated health and functioning for non-specific neck-shoulder pain</scientificTitle>
      <acronym/>
      <studyHypothesis>Main hypothesis:
Specific neck coordination training has a better short-term and long-term effect than strength training for the neck-shoulders-arms, and massage, on the primary outcomes of the sensorimotor functions (see Primary outcome measures). 

Further hypotheses:
1. Specific neck coordination training has a better long-term effect than massage on the primary and secondary outcomes of the self-rated health, symptoms and functioning, (see Primary and Secondary outcome measures)
2. Specific neck coordination training as well as strength training for the neck-shoulders-arms have a better long-term effect than treatment as usual on the primary and secondary outcomes of the self-rated health, symptoms and functioning (see Primary and Secondary outcome measures)
3. Specific neck coordination training has a better long-term effect than massage, on the secondary outcomes of the sensorimotor functions (see Secondary outcome measures)
4. Specific neck coordination training as well as strength training for the neck-shoulders-arms have a better long-term effect than massage and treatment as usual on fear of movement and re-injury due to movement, assessed by the TAMPA Scale of Kinesiophobia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Sensorimotor functioning (Timepoints of assessment: 1 week before start of treatment; 1 week and 6 month after end of treatment):
1.1. Magnitude of fast and slow component of postural sway, calculated from force platform centre of pressure data 
1.2. Arm movement precision, measured as end-point precision (variability in horizontal, depth and vertical directions) in a goal-directed arm movement task 

2. Self-rated health, symptoms and functioning (Timepoints of assessment: 1 week before start of treatment; 1 week, 6 month, 1 year after end of treatment):
2.1. Nineteen selected questions addressing ability to perform all daily activity involving neck, shoulder, arm and hand from the DASH questionnaire</primaryOutcome>
      <secondaryOutcome>The following will be assessed at 1 week before start of treatment, 1 week and 6 month after end of treatment:

1. Sensorimotor functioning: 
1.1. Jerkiness of cervical rotation, calculations based on the "minimum jerk" hypothesis 

2. Self-rated health, symptoms and functioning: 
2.1. Measurements covering the 4 core chronic pain outcome domains recommended by Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT): 
a. Pain intensity, assessed by a 0 to 10 numeric rating scale (NRS), 0 = no pain, 10 = worst pain imaginable. 
b. Physical functioning, assessed by the function index of the Profile Fitness Mapping questionnaire, (under publication), a neck specific questionnaire measuring self-rated functional limitations. 
c. Emotional functioning, assessed by the Montgomery Åsberg Depression Rating Scale, a questionnaire which has shown high sensitivity to changes in depression. 
d. Participant ratings of overall improvement, assessed by i) the Patient Global Impression of Change scale and ii) the Profile Fitness Mapping questionnaire - total score, neck-specific symptoms and functional limitations (under publication) 
2.2. Fear of movement and re-injury due to movement, assessed by the TAMPA Scale of Kinesiophobia

Other outcome measures (these outcome measures will be used in exploratory analyses): 
1. Sensorimotor functions: 
1.1. Cervikal range of movement. 
1.2. Peak velocity of cervical rotation. 
1.3. Ankle, hip and neck kinematic coordination during quiet stance 
1.4. Arm joint kinematic coordination during goal directed movements 

2. Self-rated health, symptoms and functioning: 
2.1. Pressure pain threshold, assessed with an algometer, for 3 neck-shoulder points: i) the suboccipital insertion of spinal extensor muscles ii) the trapezius muscle iii) the scapular insertion of the levator scapulae muscle. 
2.2. Area of pain distribution, assessed by pain drawings
2.3. Severity of disability assessed by the Neck Disability Index
2.4. Upper extremity disability and symptoms assessed by the DASH questionnaire 
2.5. General health and wellbeing, assessed by the 36-item Short Form Health Survey (SF-36) 
2.6. Psychologic wellbeing, assessed by the Ryff's Psychological Well-Being scales 
2.7. Pain patients' cognitive, behavioural, and affective responses to their condition, assessed by the Multidimensional Pain Inventory</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Regional Ethical Review Board in Uppsala, Sweden. Protocol was approved on 30/08/2007, complementary application approved on 25/06/2008 (ref: 2007/206)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92199001</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Funder refs: 2006-1162; 51-1010/06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, single-blind, single-centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="44bab192-9afc-4497-b998-1d1fccfa00c4">
	  <name>Centre for Musculoskeletal Research</name>
	  <address/>
	  <city>Gävle</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-801 76</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>Participants with neck-shoulder pain: 
1. Women, age 25-65 years
2. Non-specific neck-shoulder pain with a duration of at least 3 months
3. Decreased physical functioning according to the Disability Arm Shoulder Hand (DASH) questionnaire (at least 9 normalised points on 19 selected questions addressing ability to perform all daily activity involving neck, shoulder and arm)

Baseline control group:
1. Women, age 25-65 years
2. Healthy volunteers without neck pain</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>Participants with neck-shoulder pain: 
1. Trauma to the head and neck associated with the onset or with any worsening of the symptoms
2. Conditions of rheumatic-, inflammatory- or neurological disease or fibromyalgia
3. Evidence of back-, neck- or shoulder surgery or fracture
4. Cervical rhizopathia
5. Signs of vestibular dysfunction

Baseline control group: 
1. Trauma to the head, neck or shoulder that has caused considerable problems
2. Conditions of rheumatic-, inflammatory- or neurological disease or fibromyalgia
3. Evidence of back-, neck- or shoulder operation or fracture</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic non-specific neck-shoulder pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain, not elsewhere classified</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>One hundred forty participants with neck-shoulder pain and 40 participants without neck pain will be recruited into this study. The participants without neck pain will be involved in this trial only for the baseline assessments. 

The participants with neck-shoulder pain will be randomly allocated to the following 4 treatment groups: 
1. Neck coordination training ("index treatment"), 30 min treatment twice a week for 11 weeks 
2. Strength training for neck, shoulder, arms ("best available treatment"), 30 min treatment twice a week for 11 weeks 
3. Massage ("sham treatment" with respect to long-term effects), 30 min treatment twice a week for 11 weeks 
4. No intervention (However, the participants are free to receive "standard treatment" from the national health service if they wish) 

The group allocation will be concealed during data processing and analyses.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18081-0</funderId>
      <funderId>Funder18081-1</funderId>
      <funderId>Funder18081-2</funderId>
      <funderId>Funder18081-3</funderId>
      <funderId>Funder18081-4</funderId>
      <funderId>Funder18081-5</funderId>
      <funderId>Funder18081-6</funderId>
      <contactId>Contact56069_18081</contactId>
      <sponsorId>Sponsor54635</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56069_18081">
    <title>Mr</title>
    <forename>Martin</forename>
    <surname>Björklund</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Musculoskeletal Research
University of Gävle</address>
      <city>Gävle</city>
      <country>Sweden</country>
      <zip>SE-801 76 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54635">
    <organisation>Swedish Council for Working Life and Social Research (Sweden)</organisation>
    <website>http://www.fas.se</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Box 2220</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-103 15 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 8 775 40 70</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fas@fas.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.434365.3</gridId>
    <rorId>https://ror.org/02d290r06</rorId>
  </sponsor>
  <funder id="Funder18081-0">
    <name>Internal funding:</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-1">
    <name>Centre for Musculoskeletal Research, University of Gävle (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-2">
    <name>Department of Community Medicine and Rehabilitation, Physiotherapy, University of Umeå (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-3">
    <name>External funding:</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-4">
    <name>The Swedish Council for Working Life and Social Research (Registration number 2006-1162) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-5">
    <name>Forskning &amp; Framtid ("Research &amp; Future") (Registration number 51-1010/06) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18081-6">
    <name>Alfta Research Foundation (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-09-17T00:00:00.000Z">34110682</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of coadministration of ezetimibe with statin therapy versus statin therapy alone on flow mediated vasodilation in patients with coronary artery disease</title>
      <scientificTitle/>
      <acronym>CEZAR</acronym>
      <studyHypothesis>Atorvastatin 80 mg per day is more effective in the improvement of flow-mediated dilation of the right brachial artery than atorvastatin 10 mg plus ezetimibe 10 mg per day despite comparable reduction of plasma low-density lipoprotein (LDL) cholesterol concentration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effect of treatment on the absolute change (in percentage) in flow-mediated dilation (FMD)  at 8 weeks compared to baseline.</primaryOutcome>
      <secondaryOutcome>Effect of treatment, at 8 weeks compared to baseline, on the following: 
1. Absolute change (in percentage) in nitroglycerin-mediated dilation (NMD)
2. Absolute change in LDL cholesterol plasma concentration
3. Absolute change in C-reactive protein plasma concentration
4. Absolute change in uric acid plasma concentration
5. Absolute change in 8-iso-prostaglandin F2 alpha urine concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Ethics Committee of the Medical Association of Hamburg (Ethik-Kommission der Ärztekammer Hamburg), approved on 13/03/2003
2. State Medical Board of Registration in Rhineland-Palatinate (Landesärztekammer Rhineland-Palatinate), approved on 07/11/2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34110682</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase IV, double-blind, two-arm, parallel-group, randomised controlled trial (single-centre)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5dd83e30-9da0-46df-8b43-9fcb0c4b31e1">
	  <name>Johannes Gutenberg-Universität Mainz</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-55131</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, over 18 years old 
2. Angiographic, documented coronary heart disease with:
a. Generalized wall irregularities (stenosis &lt;40%) and/or 
b. Existence of at least one stenosis &gt;50% 
3. Endothelial dysfunction with flow-dependent dilation of the brachial artery of &lt;6%
4. LDL cholesterol &gt;100 mg/dl 
5. Written consent of the patients for participation in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>58</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>58</totalTarget>
      <exclusion>1. Acute coronary syndrome 
2. Stroke or peripheral revascularisation within 12 weeks before study enrolment
3. Known intolerance towards HMG CoA reductase inhibitors or ezetimibe 
4. Clinically significant valvular disease 
5. Hypertrophic obstructive cardiomyopathy 
6. Sustained ventricular arrhythmias 
7. Syncope within four weeks before the study 
8. Severe respiratory disease 
9. Unstable diabetes mellitus requiring frequent adjustments in insulin doses
10. Known hypothyroidism 
11. Known hyperthyroidism 
12. Gastrointestinal disorders (such as Crohn's disease), which could lead to decreased absorption of the study drug
13. Chronic liver disease 
14. History of pancreatitis 
15. History of organ transplantation 
16. Clinically significant heart failure with left ventricular ejection fraction of &lt;30%
17. Symptoms of orthostatic hypotension, or a systolic blood pressure in the supine position of &lt;90 mmHg
18. Systolic blood pressure &gt;180 mmHg and/or diastolic blood pressure &gt;105 mmHg despite antihypertensive therapy
19. Elevated serum creatinine of &gt;2.0 mg/dL or known nephrotic syndrome
20. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.5 times above the upper normal limit
21. Triglyceride level &gt;400 mg/dl
22. Treatment with an HMG CoA reductase inhibitor during the last three months 
23. Treatment with ezetimibe during the last three months 
24. Initiation of treatment with an angiotensin converting enzyme (ACE) inhibitor, AT1-receptor antagonist, or calcium channel blocker within the past four weeks 
25. Treatment with fibrates or colestipol during the last three months 
26. Current treatment with macrolide antibiotics, niacin or antimycotics of azole type 
27. Expected problems with compliance or follow-up visits (no fixed residence, alcohol or drug abuse, history of failure of medical advice, psychiatric diseases, etc.)
28. For women: pregnancy, breast feeding or possible pregnancy (women of childbearing age on an acceptable method of contraception may be included)
29. Simultaneous participation in another study
30. Therapy with another investigational product within a period of 30 days before the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stable coronary artery disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Chronic ischaemic heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Arm 1: Atorvastatin (oral) 80 mg per day for 8 weeks
Arm 2: Atorvastatin (oral) 10 mg + ezetimibe (oral) 10 mg per day for 8 weeks 

Ultrasonic measurements of endothelial function were carried out at the beginning of treatment and at the end of the 8-week pharmacological intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ezetimibe and atorvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18117-0</funderId>
      <funderId>Funder18117-1</funderId>
      <contactId>Contact56105_18117</contactId>
      <sponsorId>Sponsor54672</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56105_18117">
    <title>Dr</title>
    <forename>Ascan</forename>
    <surname>Warnholtz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Johannes Gutenberg-Universität Mainz
Department of Medicine II 
Langenbeckstrasse 1 </address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>D-55131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54672">
    <organisation>Johannes Gutenberg-University Mainz (Germany) </organisation>
    <website>http://www.uni-mainz.de/eng</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. T. Münzel 
Department of Medicine II 
Langenbeckstrasse 1 </address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>D-55101</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5802.f</gridId>
    <rorId>https://ror.org/023b0x485</rorId>
  </sponsor>
  <funder id="Funder18117-0">
    <name>University of Hamburg (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18117-1">
    <name>Johannes Gutenberg-University Mainz (Germany)</name>
    <fundRef>http://dx.doi.org/10.13039/501100004033</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">43452247</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Mechanisms of transiently impaired renal function during liver transplantation</title>
      <scientificTitle>Renal function during the perioperative period of liver transplantation</scientificTitle>
      <acronym/>
      <studyHypothesis>Hyperreninism is the major mediator of transient and acute anuria during the anhepatic phase of liver transplantation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Renal function: plasma renin activity, assessed in all blood samples (see  Interventions).</primaryOutcome>
      <secondaryOutcome>The following were assessed in all blood samples (see Interventions):
1. Cystatin C
2. Natraemia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Geneva University Hospitals (Commission central d'éthique de la recherche sur l'être humain des HUG). Date of approval: 24/01/2004 (ref: CER 03-159)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43452247</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CER 03-159; SHR 369-08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational, prospective, cross-sectional study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b20d8f5f-14f6-41a9-8a18-3334b175b8ba">
	  <name>Hopitaux Universitaires de Geneve</name>
	  <address/>
	  <city>Geneva</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Age 17-70 years
3. Patients scheduled for liver transplantation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Incapacity to comprehend the study protocol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Liver transplantation</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Observational study: Blood sampling for biologic assessment of renal function at the time of inclusion in the waiting list, at the time of anaesthesia induction on the day of liver transplantation, during the anhepatic phase, 24 hours later and finally at 6 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17903-0</funderId>
      <contactId>Contact55886_17903</contactId>
      <sponsorId>Sponsor54450</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55886_17903">
    <title>Dr</title>
    <forename>Eduardo</forename>
    <surname>Schiffer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hopitaux Universitaires de Geneve
24 Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54450">
    <organisation>Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)</organisation>
    <website>http://www.hug-ge.ch</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>24 Micheli du Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.150338.c</gridId>
    <rorId>https://ror.org/01m1pv723</rorId>
  </sponsor>
  <funder id="Funder17903-0">
    <name>Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">42938377</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Role of oral penicillin prophylaxis in preventing serious infections in Sickle Cell Disease in children aged 3 months to 5 years: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>SCD</acronym>
      <studyHypothesis>The null hypothesis is that in India, the rate of severe infection in children aged 3 months to 5 years of sickle cell anaemia receiving penicillin prophylaxis is not different from those who do not receive prophylaxis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Severe infections.</primaryOutcome>
      <secondaryOutcome>1. Mortality
2. Sickle cell crisis
3. Blood transfusion
4. Number of hospitalisation
5. Unwell days
6. Other infections</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Clinical Ethics Committee of Indira Gandhi Government Medical College, Nagpur on the 13th November 2006 (ref: I.G.G.M.C./Pharm/272/2006).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42938377</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>5/20/12/05</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double blind randomised controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2babf386-f868-4229-800c-cfeb8ab984cb">
	  <name>Professor &amp; Head</name>
	  <address/>
	  <city>Maharashtra</city>
	  <state/>
	  <country>India</country>
	  <zip>440018</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 3 months to 5 years, either sex
2. Homozygous sickle cell (HbSS) pattern of haemoglobin (Hb) on cellulose acetate electrophoresis
3. Subjects whose parents consent to participate</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>65</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>65</totalTarget>
      <exclusion>1. Chronic illness other than sickle cell disease (SCD)
2. On long term medication other than vitamins and trace metals
3. Any known allergy to penicillin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sickle cell anaemia</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Sickle-cell disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Oral penicillin 125 mg twice a day for children below three years and 250 mg twice a day for older children up to 5 years
2. Placebo twice a day in the same doses as above as per age groups

Most children above 2 years also received polyvalent pneumococcal vaccine.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Penicillin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17438-0</funderId>
      <contactId>Contact55399_17438</contactId>
      <sponsorId>Sponsor53969</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55399_17438">
    <title>Dr</title>
    <forename>Archana</forename>
    <surname>Patel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Professor &amp; Head 
Department of Paediatrics
Indira Gandhi Government Medical College
Central Avenue Road
Nagpur</address>
      <city>Maharashtra</city>
      <country>India</country>
      <zip>440018</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)712 277 0509</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ceuiggmc@yahoo.co.in</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53969">
    <organisation>Indira Gandhi Government Medical College (India) </organisation>
    <website>http://www.igmcshimla.org/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Dean
Central Avenue Road
Nagpur</address>
      <city>Maharashtra </city>
      <country>India</country>
      <zip>440018</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414607.0</gridId>
    <rorId>https://ror.org/011r34n61</rorId>
  </sponsor>
  <funder id="Funder17438-0">
    <name>Indira Gandhi Government Medical College, Nagpur (India) - institutional funding (ref: 5/20/12/05)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">13032035</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III study to prove the efficacy, safety and tolerability of Silexan® in patients with anxiety disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To prove the efficacy of Silexan® (a lavender oil preparation) in patients suffering from an anxiety disorder not otherwise specified (NOS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Change in HAMA total score, assessed every 2 weeks for 10 weeks
2. Change in PSQI total score, assessed at baseline and Week 2, 6 and 10</primaryOutcome>
      <secondaryOutcome>1. Subscores of HAMA, assessed every 2 weeks for 10 weeks
2. Subscores of PSQI, assessed at baseline and Week 2, 6 and 10
3. Clinical Global Impressions (CGI) scale at baseline, Week 8 and 10
4. Zung's Self-rating Anxiety Scale, assessed every 2 weeks for 10 weeks 
5. Short-Form 36 (SF-36) Health Survey Questionnaire at baseline and Week 10
6. Safety, assessed every 2 weeks for 10 weeks. After this period, adverse events were monitored until they had subsided or had stabilised.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the State Medical Chamber of Baden-Württemberg (Landesärztekammer Baden-Württemberg). Date of approval: 15/06/2004 (ref: 093-04)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13032035</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>750201.01.013</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase III, multi-centre, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cb284220-e483-44a5-a05b-59e57bca616b">
	  <name>Willmra-Schwabe-Strasse 4</name>
	  <address/>
	  <city>Karlsruhe</city>
	  <state/>
	  <country>Germany</country>
	  <zip>76227</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range: 18 - 65, both males and females
2. Primary diagnosis of an anxiety disorder NOS according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV; 300.00)
3. Severity of anxiety for the inclusion: the Hamilton Anxiety Scale (HAM-A) total score &gt;=18, Item 1 "anxious mood" &gt;=2, Item 2 "insomnia" &gt;=2
4. Severity of sleep disorders for the inclusion: Pittsburgh Sleep Quality Index (PSQI) total score &gt;5</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>220</totalTarget>
      <exclusion>1. A decrease of 25% or more of the HAM-A total score during the screening phase
2. Any clinically important psychiatric or neurological diagnoses other than an anxiety disorder NOS within 6 month before the study
3. Risk of suicide 
4. History or evidence of alcohol and/or substance abuse or dependence
5. Current use of other psychotropic drugs
6. Any unstable acute medical disorder
7. Prohibited concomitant treatment: any psychotropic drugs including benzodiazepines, non-benzodiazepines (zopiclone, zolpidem), neuroleptics, tranquiliser, antidepressives, antiepileptics, antihistaminics
8. Long-term prophylactic treatment
9. Central-acting antihypertensive medication
10. Anti-Parkinson's medication
11. Phyto-anxiolytics
12. Muscle relaxants
13. Analgetics of opiate type
14. Anaesthetics
15. Barbiturates
16. Nootropics
17. Non-medical psychiatric treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Anxiety disorder not otherwise specified</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Other anxiety disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Silexan® 80 mg (1 capsule) per day or placebo orally for 10 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Silexan®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18024-0</funderId>
      <contactId>Contact56008_18024</contactId>
      <sponsorId>Sponsor54574</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56008_18024">
    <title>Dr</title>
    <forename>Angelika</forename>
    <surname>Dienel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Willmra-Schwabe-Strasse 4</address>
      <city>Karlsruhe</city>
      <country>Germany</country>
      <zip>76227</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54574">
    <organisation>Dr. Willmar Schwabe GmbH &amp; Co. KG (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Willmar-Schwabe-Strasse 4</address>
      <city>Karlsruhe</city>
      <country>Germany</country>
      <zip>76227</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476242.1</gridId>
    <rorId>https://ror.org/043rrkc78</rorId>
  </sponsor>
  <funder id="Funder18024-0">
    <name>Dr. Willmar Schwabe GmbH &amp; Co. KG (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">06910890</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of a leadership intervention for implementing recommendations for nursing care for people with diabetes and foot ulcers in community nursing practice</title>
      <scientificTitle>The impact of a tailored leadership intervention on the nursing assessments and management of foot ulcers for people with diabetes in community nursing practice</scientificTitle>
      <acronym/>
      <studyHypothesis>H1: Nurses working in centres that receive the intervention will obtain significantly higher scores for practicing in accordance with guideline recommendations than the control group.  
H0: No change in group means will occur following the intervention.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Nursing Assessments of Client Risk Factors Scores (NACRF), a composite score of 8 items based on recommendations from the Diabetes/Foot Ulcer guidelines.  

Timepoints for primary and secondary outcomes: 12 weeks following completion of the intervention, chart audits will be conducted on all patients being treated for diabetic foot ulcers. To understand the leadership and management behaviours that influenced nursing practice, semi structured qualitative interviews will be conducted 12 weeks following intervention strategy with managers, supervisors, resource nurses and staff nurses at control and experimental centres.</primaryOutcome>
      <secondaryOutcome>1. Proportion of people with healed ulcers at 12 weeks (defined as complete wound closure)
2. Healing time, in number of weeks
3. Types of treatments used (e.g., hydrogel dressings, sharp debridement, offloading devices)
4. Referral rates to specialists services
5. Documented patient education
6. Proportion clients assessed for all items in the NACRF scale (all-or-none measure)
7. Nursing participant satisfaction and perceived utility of elements of the intervention

Timepoints for primary and secondary outcomes: 12 weeks following completion of the intervention, chart audits will be conducted on all patients being treated for diabetic foot ulcers. To understand the leadership and management behaviours that influenced nursing practice, semi structured qualitative interviews will be conducted 12 weeks following intervention strategy with managers, supervisors, resource nurses and staff nurses at control and experimental centres.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The University of Ottawa Health Sciences and Science Research Ethics Board on the 9th May 2007 (ref: H-03-07-09)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06910890</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A two phase mixed method design with matched pair cluster randomised controlled trial and qualitative methods</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a480be5a-90f8-4231-8008-f593819da524">
	  <name>1258 Portland Avenue</name>
	  <address/>
	  <city>Ottawa</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1V 6E9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Service delivery centres with minimum number of clients with diabetes being treated for foot ulcers to satisfy sample size calculations 
2. Chart audit: all adult clients (18 years or older) diagnosed with type 1 or type 2 diabetes that have been treated for a first or recurring foot ulcer(s) in the previous 6 months
3. Intervention: managers, supervisors, resource nurses and two staff nurses from each intervention site</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>4 centres/60 clients</totalTarget>
      <exclusion>1. Service delivery centres that did not have the minimum number of clients on service for diabetic foot ulcers to meet sample size calculations (i.e. 15 clients per centre in 6 months)
2. Clients that do not meet inclusion criteria:
2.1. Under 18 years of age
2.2. Do not have type 1 or type 2 diabetes
2.3. Not receiving home care service for a diabetic foot ulcer</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes/foot ulcers/knowledge translation</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Unspecified diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In addition to &#145;usual&#146; implementation strategy, a 12 week strategy will be offered to mangers, supervisors, resource nurses, and two preceptor staff from each centre consisting of:  
1. Mailed package of printed materials: study purpose; summary of recommendations, models of leadership and planned change; literature article; four questions related to assessing barriers to practice change. Review time: approx 15 - 30 minutes.  
2. Interactive workshop (7.5 hours) at SEHC Corporate Office. Content and structure will be tailored to results of phase one, tentatively planned to include:  
2.1. Evidence and theory on leadership and implementing practice change
2.2. Focus group discussions about barriers to implementing change based on recommendations
2.3. Case study discussions
2.4. Role playing exercises
2.5. Games
2.6. Development of implementation plan for each centre tailored to identified barriers.
Workshop will be facilitated by Co-PI (WG); SEHC senior administrator (NL); and administrative/clinical staff from SEHC to be determined.  
3. Post-workshop teleconferences: (2, 6, and 10 weeks after workshop) to provide a forum for questions, discussions and networking amongst participants</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18050-0</funderId>
      <contactId>Contact56037_18050</contactId>
      <sponsorId>Sponsor54602</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56037_18050">
    <title>Ms</title>
    <forename>Wendy</forename>
    <surname>Gifford</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1258 Portland Avenue</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1V 6E9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 260 8334</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wgifford@rogers.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54602">
    <organisation>Canadian Nurses Foundation (Canada) - Nursing Care Partnership Fund</organisation>
    <website>http://www.cnf-fiic.ca/Home/tabid/36/language/en-US/Default.aspx</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>50 Driveway</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K2P 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 237 2159</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jsolis@cna-aiic.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.478616.a</gridId>
    <rorId>https://ror.org/04j4csk75</rorId>
  </sponsor>
  <funder id="Funder18050-0">
    <name>Canadian Nurses Foundation (Canada) - September 2006</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">65140085</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The role of pre- and probiotics in infections in term infants (De role van pre- en probiotica in infecties in a terme geboren kinderen)</title>
      <scientificTitle/>
      <acronym>VIPP a terme</acronym>
      <studyHypothesis>Supplementation of infant formula with a combination of pre- and probiotics may protect infants against infectious complications such as diarrhoea and respiratory infections. We speculate that the combination of pre- and probiotics is a better protective than only one of these substances. Supplementation of the combination of pre- and probiotics may reduce the incidence of infections to the same level as human milk-fed infants.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Frequency, incidence and duration of diarrhoea and respiratory infections, measured during the first 6 months of life and evaluated by the questionnaires
2. Composition of gut flora, evaluated at week 6, 3 months and 6 months of life (during the period infants receive the study feeds)</primaryOutcome>
      <secondaryOutcome>1. Growth (head circumference, length and weight), measured in the out-patient clinic at 3 and 6 months
2. Feeding tolerance (pattern of defaecation, consistence of faeces, crying, vomiting, stomach ache), assessed with standardised questions</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethical Committee of the Isala Clinics according to article 16 WMO and according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) criteria on the 8th February 2007 (ref: 06.1178).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65140085</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06-1178</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double blind placebo-controlled randomised prospective cohort study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6a3bf346-ad76-4f9e-bd7a-5f74ff1ba4c0">
	  <name>Isala Clinics</name>
	  <address/>
	  <city>Zwolle</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8025 AB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy term infants with a post-menstrual age of 37 - 42 weeks, either sex
2. Birth weight between P10 and P90
3. Informed consent of both parents</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>375</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Formula group: n = 225 (75 in every group). Reference group (human milk ) n = 150.</totalTarget>
      <exclusion>1. Neonatal sepsis
2. Severe congenital malformations
3. Birth asphyxia (apgar less than six at 5 minutes, and/or umbilical cord pH less than 7.00 and/or necessity of reanimation)
4. Admission to a paediatric ward
5. No Dutch or English speaking parents
6. Antibiotics to the mother during labour
7. Antibiotics to the infant in the first week of life
8. History of allergy with parents or siblings</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heathy term infants with intercurrent diseases: diarrhoea and respiratory infections</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Other conditions originating in the perinatal period</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment consists of three types of infant formula:    
1. Standard infant formula (frisolac 1) without addition of prebiotics or probiotics
2. Standard infant formula with addition of galacto-oligosaccharides (GOS); 0.8 g/100 ml (Vivinal Domo, The Netherlands. GOS 10 contains: galacto-oligosaccarides 28.5%, lactose 36%, glucose 9.5%, galactose 0.5%, proteins 17.5%, minerals 3.5%, fat 1.5%, moisture 3.0%) 
3. Standard infant formula with addition of a mixture of prebiotics (GOS [the same as B]) and a probiotic mixture consisting of lactobacillus casei CRL 431 2 x 100,000/ml and bifidobacterium lactis BB 2 x 100,000/ml (Bioflora Pharma Nord, The Netherlands)

The total duration of treatment is 6 months, faeces samples will be taken at 6 weeks, 3 and 6 months. Questionnaires regarding frequency of diarrhoea, airway infection, and feeding tolerance will be filled in by the parents every 2 weeks during the study period (6 months). All questionnaires (e.g. regarding infections, faecal composition and feeding tolerance) are standardised. An outpatient visit for growth measurements will be held at 3 and 6 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prebiotics, probiotics</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17787-0</funderId>
      <contactId>Contact55763_17787</contactId>
      <sponsorId>Sponsor54333</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55763_17787">
    <title>Dr</title>
    <forename>Diny</forename>
    <surname>van Zoeren-Grobben</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Isala Clinics
Neonatal Unit
Dr van Heesweg 2</address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8025 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)38 424 7073</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.van.zoeren@isala.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54333">
    <organisation>Royal Friesland Foods B.V. (The Netherlands) </organisation>
    <website>http://www.frieslandfoods.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr R te Biesebeke
Enhanced Nutrition Specialist Unit
P.Stuyvesantweg 1</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8937 AC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.434547.5</gridId>
    <rorId>https://ror.org/025mtxh67</rorId>
  </sponsor>
  <funder id="Funder17787-0">
    <name>Royal Friesland Foods B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">71737811</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of prebiotic or lactoferrin supplementation in formula on the gut flora of preterm infants</title>
      <scientificTitle/>
      <acronym>VIPP prematuur</acronym>
      <studyHypothesis>Supplementation of preterm formula with prebiotics or lactoferrin may improve the gut flora of preterm infants by promoting growth of apathogenic bacteria. These supplements may produce a gut flora resembling the gut flora of human milk-fed preterm infants and thereby improve their resistance against infections.

Furthermore lactoferrin reduces the availability and absorption of free iron and may thus reduce oxidative stress both locally in the gut and systemically.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Composition of gut flora, evaluated at 6 weeks of full enteral feeds (at the end of the study feeding)
2. Incidence of infections, measured at 6 weeks of full enteral feeds
3. Oxidative stress and iron status, measured at 6 weeks of full enteral feeds</primaryOutcome>
      <secondaryOutcome>1. Growth (head circumference, length, weight), measured at 6 weeks of full enteral feeds
2. Feeding tolerance (composition of faeces, crying pattern, discomfort, vomiting), measured at 6 weeks of full enteral feeds
3. Psychomotor development, taken at 1 year of age</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethcis approval received from the Medical Ethical Committee of the Isala Clinics according to article 16 WMO and to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) criteria on the 8th February 2007 (ref: 06.1179).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN71737811</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06-1179</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind placebo-controlled randomised prospective cohort study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4c5e9e94-dd4c-47da-ab59-20c145cd6b6c">
	  <name>Isala Clinics</name>
	  <address/>
	  <city>Zwolle</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8025 AB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Preterm infants: gestational age 26+0 to 35+6 weeks, either sex
2. Admitted to the Neonatal Intensive Care Unit (NICU) or High Care Unit of the hospital</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Preterm formula group: n = 60 (20 in each group). Human milk group: n = 20.</totalTarget>
      <exclusion>1. Birth weight less than 600 g
2. Life-threatening congenital malformations
3. No Dutch or English speaking parents
4. History of allergy in parents or siblings</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gut flora</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Gut flora</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment consists of three types of preterm formula:    
1. Standard preterm formula (frisolac prematuur) without addition of prebiotics
2. Standard preterm formula with addition of galacto-oligosaccharides (GOS); 0.8 g/100 ml (Vivinal Domo, The Netherlands. GOS 10 containing: galacto-oligosaccarides 28.5%, lactose 36%, glucose 9.5%, galactose 0.5%, proteins 17.5%, minerals 3.5%, fat 1.5%, moisture 3.0%) 
3. Standard preterm formula with addition of dairy lactoferrin 1 mg/100 ml (Vivinal Domo, The Netherlands, containing lactoferrin 90 %, protein 97%, moisture 1.5%, minerals 1.5 %)

The therapy wil be started in the first week of life and therapy will be continued until 6 weeks after the start of full enteral feeds. Blood will be drawn at day 1, day 7, day of full enteral feeds and week 6 after establishment of full enteral feeds. Follow up wil be done at the age of 1 year corrected age.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prebiotic, lactoferrin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17790-0</funderId>
      <contactId>Contact55767_17790</contactId>
      <sponsorId>Sponsor54336</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55767_17790">
    <title>Dr</title>
    <forename>Diny</forename>
    <surname>van Zoeren-Grobben</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Isala Clinics
Neonatal Unit
Dr. Van Heesweg 2</address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8025 AB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)38 424 7073</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.van.zoeren@isala.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54336">
    <organisation>Royal Friesland Foods B.V. (The Netherlands) </organisation>
    <website>http://www.frieslandfoods.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr R te Biesebeke
Enhanced Nutrition Specialist Unit
P. Stuyvesantweg 1</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8937 AC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.434547.5</gridId>
    <rorId>https://ror.org/025mtxh67</rorId>
  </sponsor>
  <funder id="Funder17790-0">
    <name>Royal Friesland Foods B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">26530238</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Antiplaque and antigingivitis effect of lippia sidoides</title>
      <scientificTitle>Antiplaque and antigingivitis effect of lippia sidoides: A double-blind clinical study in humans</scientificTitle>
      <acronym/>
      <studyHypothesis>Gingivitis is a chronic inflammation of gingival tissues and is one of the most frequent periodontal diseases, affecting more than 90% of the population, regardless of age, sex or race. Brazilian epidemiologic studies show a high prevalence of gingival inflammation, ranging from 74% to 100%, although the individual percentages of gingival bleeding reported by the media vary from 28% to 35%. The clinical signs of this disease are bleeding upon probing, plaque accumulation and pain.

This randomised controlled trial evaluated the antiplaque and antigingivitis effect of lippia sidoides (LS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The indexes (plaque index, gingival index and bleeding index) were recorded on the mesiobuccal, buccal, distobuccal, mesiolingual, lingual and distolingual surfaces of the experimental teeth and their mean scores were calculated. Then, mean scores for the 4 experimental teeth in each participant were calculated to determine the mean index score for the individual. Intra-examiner agreement for all indexes was calculated by repeating the measurements in 10 participants. Timepoints of assessment: Baseline and at the end of each of the two 21-day experimental phases.</primaryOutcome>
      <secondaryOutcome>Adverse effects, such as abscess, ulcerations and allergic reactions. The patients will be submitted to weekly evaluations for the observation of side effects within a maximum period of 21 days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Research Ethics Committee (Comitê de Ética em Pesquisa, Coética), University of Fortaleza (UNIFOR). Data of approval: 25/07/2005 (ref: 205/2005)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26530238</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0239723a-c19a-4e2a-84c1-02175093c320">
	  <name>Av. Engo. Leal Lima Verde, 2086</name>
	  <address/>
	  <city>Fortaleza</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>60833-520</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All subjects (both males and females, aged 19 to 25 years) had at least 20 natural teeth, 4 of which were posterior teeth in the lower left quadrant (experimental teeth)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>26</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>26</totalTarget>
      <exclusion>1. Medical disorders
2. Under antimicrobial therapy
3. Smokers
4. Pregnant women
5. Individuals presenting a probing depth &gt;3 mm associated with any mandibular teeth 
6. Subjects with retentive factors of dental plaque, such as carious cavity and excess restoration in the test area</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gingivitis</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Gingivitis and periodontal diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Preparation of experimental gel: The essential oil of LS was extracted by steam distillation. Initially, 1 ml of essential oil was diluted in 9 ml of ethylic alcohol (1:9), preparing a 10% mixture. 50 g of carboxymethylcellulose was added to the LS infusion (1,000 ml) and the mixture was kept boiling until its complete dissolution to obtain the 10% gel concentration. A glycerin/ethanol mixture (50 ml: 50 ml) was added and the solution was vigorously stirred for 15 minutes until gel formation. A very small amount of menthol (flavouring) and conserving agent were added. The control gel had the same formulation except for the LS extract. 

Twenty-six healthy volunteers (13 female and 13 male aged 19 to 25 years) were enrolled in this randomised, double-blind, cross-over study. The trial consisted of a pre-experimental phase and 2 experimental phases of 21 days each with a 1-month washout interval between them. To standardise the groups, the participants were submitted to a meticulous evaluation (pre-experimental phase) to score the plaque index (PLI), gingival index (GI) and the bleeding index (BI) of each tooth. All teeth of each subject were polished and flossed by the examiner to eliminate dental plaque remnants. The importance of oral hygiene was strongly reinforced. 

Thirty days after the initial phase, the participants were randomly assigned to 2 groups (experimental phase). On day 0 of both experimental periods, PLI, GI and BI were recorded. A personal "kit" containing a toothshield, a tube with 90 g of control or test gel and a commercial dentifrice with no anti-inflammatory properties (Sorriso®) was given to all participants. During each 21-day experimental period, the participants were instructed to apply the gel onto the experimental teeth and leave for at least one minute, 3 times a day. The participants were asked to refrain from brushing the test quadrant, while the other teeth were normally brushed 3 times a day using a commercial dentifrice. In addition to verbal instructions, the participants were given written recommendations to follow at home. On the last day of each period (21st day), the indexes were recorded and the teeth were polished with pumice.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17960-0</funderId>
      <contactId>Contact55943_17960</contactId>
      <sponsorId>Sponsor54507</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55943_17960">
    <title>Dr</title>
    <forename>Sérgio Luís</forename>
    <surname>da Silva Pereira</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. Engo. Leal Lima Verde, 2086
Bairro Alagadiço Novo</address>
      <city>Fortaleza</city>
      <country>Brazil</country>
      <zip>60833-520</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54507">
    <organisation>University of Fortaleza (Brazil)</organisation>
    <website>http://www.unifor.br</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Washington Soares, 1321</address>
      <city>Fortaleza</city>
      <country>Brazil</country>
      <zip>60811-905</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412275.7</gridId>
    <rorId>https://ror.org/02ynbzc81</rorId>
  </sponsor>
  <funder id="Funder17960-0">
    <name>University of Fortaleza (UNIFOR) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2008-09-12T00:00:00.000Z">27670575</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Controlling Tungiasis in an Impoverished Community</title>
      <scientificTitle>Controlling tungiasis in an impoverished community: an intervention study</scientificTitle>
      <acronym>CTIC</acronym>
      <studyHypothesis>The implementation of various control measures will result in a drop of prevalence and intensity of infestation of tungiasis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of individuals infested with Tunga penetrans (Prevalence of tungiasis), measured 10 times during the 12 months study period in equal intervals. Reduction of prevalence was measured through comparison with the baseline level.</primaryOutcome>
      <secondaryOutcome>Number of embedded sand fleas per infested individual, measured 10 times during the 12 months study period in equal intervals. This intensity of infestation was measured in terms of categories and total number, both compared to baseline levels.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Review Board of the Federal University of Ceará. Date of approval: 25/10/2002 (ref: 195/02)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27670575</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>195/02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-11-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="20fdb791-4000-4f60-82c8-64fcf908a7d2">
	  <name>Institute for Microbiology and Hygiene</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12203</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Inhabitants of all age groups, both males and females, were eligible for the study, provided they had spent at least four days per week in the village during the last three months
2. Informed written consent obtained from study participant and carers</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>831</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>831</totalTarget>
      <exclusion>1. Absence from the study area for more than 4 days per week
2. Unwillingness to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-11-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tungiasis (Tunga penetrans [sand flea] infestation)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Other infestations</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>One village served as the intervention village and the other served as the control village.  

Target number of recruitment: 597 individuals in the intervention village and 234 individuals in the control village (total 831). The actual number of people living in the villages was 630 for the intervention village and 281 for the control village. 

Intervention village: From November 2002 through January 2003, from all infested individuals, embedded sand fleas were extracted every two to three weeks by experienced health care professionals under sterile conditions. The remaining sore was treated with an antibiotic ointment. During the same period all cats and dogs were treated with trichlorphone 97% in oily solution (Neguvon®, Bayer do Brasil, Brazil) or neck collars impregnated with propoxur and flumethrin (Kiltix®, Bayer Bayer do Brasil, Brazil). In February 2003, deltamethrin was used for focal premise treatment. Focal spraying was performed by trained personnel of the Health Secretariat of Cascavel Municipality. The insecticide was sprayed on the ground next to the houses targeting areas in which off-host development of T. penetrans was suspected to occur, such as preferred whereabouts of dogs and cats, and shady places under trees, or inside houses in the case of a sandy floor. Focal premise treatment using insecticides was repeated twice during a period of six weeks.
 
No intervention took place in the control village.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18941513 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a5c8d32e-5a54-4d80-8996-8b550f84356a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18941513"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17980-0</funderId>
      <contactId>Contact55963_17980</contactId>
      <sponsorId>Sponsor54527</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55963_17980">
    <title>Prof</title>
    <forename>Hermann</forename>
    <surname>Feldmeier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Microbiology and Hygiene
Charite - University Medicine Berlin 
Campus Benjamin Franklin
Hindenburgdamm 27</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12203</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54527">
    <organisation>Mandacaru Foundation (Brazil)</organisation>
    <website>http://www.mandacaru-foundation.org</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua José Vilar de Andrade 257</address>
      <city>Fortaleza</city>
      <country>Brazil</country>
      <zip>CE 60833-830</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487456.c</gridId>
    <rorId>https://ror.org/05h876969</rorId>
  </sponsor>
  <funder id="Funder17980-0">
    <name>Mandacaru Foundation (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-05T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-09-05T00:00:00.000Z">99801051</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of growth and body composition in preterm infants in relation to two different protein intakes: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The goal is to evaluate the safety and the effects on neonatal growth and body composition of two distinct strategies (intervention and control) for parenteral nutrition.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety/tolerance:
1. Haemo-gas analysis twice a week for the first 15 days
2. Blood urea nitrogen and serum ammonium on the 1st day of life, on the 4th/5th, on the 7th/8th and 15th day of life
3. Blood amino acid profile on the 1st day of life (before starting NPT) and on the 4th/5th and 15th day of life</primaryOutcome>
      <secondaryOutcome>Efficacy:
1. Body composition (assessed by means of deuterium and air plethismography-Pea Pod) at birth, at 15 days of life and at 36 weeks of post-conceptional age
2. Growth (weight assessed daily, length and head circumference assessed weekly)
3. Anabolism assessed by means of nitrogen balance on 2nd, 5th, and 8th day of life
4. Blood amino acid profile on the 1st day of life (before starting NPT) and on the 4th/5th and 15th day of life</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee FONDAZIONE IRCCS Ospedale Maggiore Policlinico Mangiagalli Regina Elena on the 24th March 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99801051</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9d79a6c-5282-4b4b-ba06-787262f3fb8f">
	  <name>Via Commenda 12</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20122</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Birth weight between 1000 and 1500 g
2. Being male
3. Being adequate for gestational age (birth weight greater than or equal to 10th percentile according to the Babson and Benda's chart updated) 
4. Need for oxygen (O2) less than 40% within the first 72 hours</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Male</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>9 patients per group (18 in total)</totalTarget>
      <exclusion>1. Starting parenteral nutrition (NPT) after the first 24 hours of life
2. Chromosomal abnormalities 
3. Metabolic disease
4. Congenital infections (toxoplasmosis, rubella, cytomegalovirus, herpes simplex and human immunodeficiency virus [HIV] [TORCH])
5. Score of severity of clinical conditions at birth (CRIBB) greater than 4</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Preterm infant nutrition and body composition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Preterm infant nutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>To detect a difference of 3.0 g/kg per day in weight gain between the two treatment groups (a = 0.25; power = 80%, assuming SD = 2.0 g/kg per day), 9 patients are required for each group. 

Preterm infants will be randomised to receive two different schedules of NPT: high or low protein intake for two weeks. The high protein intake consists of at maximum 3.5 g/Kg/d starting from 2.5 g/Kg/d and the low protein intake consists of 2.5 g/Kg/d starting from 1.5 g/Kg/d.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18019-0</funderId>
      <contactId>Contact56003_18019</contactId>
      <sponsorId>Sponsor54569</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56003_18019">
    <title>Prof</title>
    <forename>Paola</forename>
    <surname>Roggero</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Via Commenda 12</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20122</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54569">
    <organisation>Institute of Paediatrics and Neonatology (Italy)</organisation>
    <website>http://www.mangiagalli.it</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>University Medical School of Milan
Via Commenda 12</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>2012</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4708.b</gridId>
    <rorId>https://ror.org/00wjc7c48</rorId>
  </sponsor>
  <funder id="Funder18019-0">
    <name>Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli Regina Elena (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-01T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-01T00:00:00.000Z">53149519</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sustained release particle of 5-fluorouracil combining transcatheter arterial chemoinfusion to treat hepatocellular carcinoma with portal vein tumour thrombus</title>
      <scientificTitle>Sustained release particle of 5-fluorouracil (Sinofuan®) combining transcatheter arterial chemoinfusion to treat hepatocellular carcinoma with portal vein tumour thrombus: a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>The prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumour thrombus (PVTT) is generally poor. A literature review regarding transcatheter arterial chemoinfusion (TAC) was difficult due to differences in techniques, patient selection, and underlying liver function. In fact, this was an exclusion criterion for some treatments. 

Sinofuan® is a newly approved fluorouracil sustained release particle for HCC in China. It can steadily release fluorouracil for hundreds of hours and maintains effective concentration around its implanting site. Because the portal vein tumour thrombus is mainly composed of tumour tissue, it is supposed that the direct implantation of Sinofuan® into the thrombus should result in a better outcome than single TAC therapy. This trial is designed to examine this hypothesis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Patient dies, measured at one month and six months
2. Disappearance of portal vein thrombus, measured at one month</primaryOutcome>
      <secondaryOutcome>1. Closure of portal vein lateral flow, measured at one and two months
2. Decreased size of thrombus less than or equal to 20% of original, measured at one month, two months, four months and six months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the Affiliated 10th People's Hospital, Tongji University (China) on the 5th March 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN53149519</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, non-blinded, randomised, controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4fbfe736-116a-402a-aa3b-191a92f96a24">
	  <name>YanChang Road, 301</name>
	  <address/>
	  <city>Shanghai</city>
	  <state/>
	  <country>China</country>
	  <zip>200072</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Image-proven HCC
2. Irresectable tumour
3. Failure to previous treatment
4. Child-Pugh scale less than or equal to 10
5. Aged 30 - 80 years, either sex
6. Tumour thrombus is proven within portal vein and its section area exceeds 50% of vessel by computed tomography (CT)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Uncontrolled hypertension
2. Unstable angina
3. Arrhythmias requiring treatment
4. Myocardial infarction (MI)
5. Congestive heart failure or cardiomyopathy requiring treatment</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hepatocellular carcinoma/portal vein tumour thrombus</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Hepatocellular carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Intervention: percutaneously implant the sustained release particle of 5-fluorouracil in the tumour thrombus and treat HCC with TAC
2. Control: single treatment of HCC with TAC

For the intervention group, the sustained release particle of 5-fluorouracil will be percutaneously implanted once and only once. Within one week, TAC will be performed to treat HCC. The total duration of treatment will be no more than one week. The duration of follow-up is six months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>5-fluorouracil (Sinofuan®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17645-0</funderId>
      <contactId>Contact55616_17645</contactId>
      <sponsorId>Sponsor54191</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55616_17645">
    <title>Prof</title>
    <forename>Maoquan</forename>
    <surname>Li</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>YanChang Road, 301</address>
      <city>Shanghai</city>
      <country>China</country>
      <zip>200072</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54191">
    <organisation>Affiliated 10th People's Hospital of Tongji University (China) </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>YanChang Road, 301</address>
      <city>Shanghai</city>
      <country>China</country>
      <zip>200072</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412538.9</gridId>
    <rorId>https://ror.org/03vjkf643</rorId>
  </sponsor>
  <funder id="Funder17645-0">
    <name>Affiliated 10th People's Hospital of Tongji University (China)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-09-01T00:00:00.000Z">25330204</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate®</title>
      <scientificTitle/>
      <acronym>WILCOME</acronym>
      <studyHypothesis>Long-term prophylactic treatment of von Willebrand disease (VWD) patients in clinical practice.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess the bleeding frequency in VWD patients prior to and after introduction of regular prophylactic therapy with the VWF-containing concentrate Wilate®. Outcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.</primaryOutcome>
      <secondaryOutcome>1. To describe the joint morbidity prior to and during prophylaxis with Wilate®, using the haemophilia joint health score
2. To monitor absence from school/work prior to and during prophylaxis with Wilate®
3. To evaluate the patient's health-related quality of life prior to and during prophylaxis with Wilate® and the patient's self-reported health status prior to and during prophylaxis with Wilate®, using the validated generic instruments of World Health Organization Quality of Life-BREF (WHOQOL-BREF) (for adults) and the generic children's health-related quality of life (KINDL) (for children), and the disease specific VWD-QoL questionnaire
4. To assess treatment satisfaction and treatment efficacy prior to and during prophylaxis with Wilate®, using a 4-point Verbal Rating Scale (VRS), and the Hemo-SatA treatment questionnaire adapted for VWD (VWD-Sat)
5. To evaluate the tolerability of prophylactic treatment with Wilate®:
5.1. Using a 3-point VRS
5.2. By documenting all possibly related adverse drug reactions by the patients, and 
5.3. By assessing and - if applicable - reporting all adverse drug reactions by the treating physician occurring during the treatment period with Wilate®

Outcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of University Hospital Malmö on the 7th August 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25330204</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WIL-18</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open-labelled, international multi-centre post-marketing surveillance</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
	<country>Germany</country>
	<country>Russian Federation</country>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7bf4b575-c281-4573-b76c-951b1f72e690">
	  <name>Oberlaaerstrasse 235</name>
	  <address/>
	  <city>Vienna</city>
	  <state/>
	  <country>Austria</country>
	  <zip>1100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female patients of any age 
2. Suffering from congenital VWD 
3. In need of replacement therapy with factor concentrate
4. Patients starting with a prophylactic treatment must have documentation of at least three apparently spontaneous bleeding episodes (any bleeding site and treated with factor concentrate) in the 6 months prior to enrolment
5. Patients switching from a prophylactic treatment with another factor concentrate to prophylaxis with Wilate® should have anamnesis of bleeds with respective documentation in the period of 12 months prior to enrolment</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Presence of a bleeding disorder other than VWD
2. History of non-compliance
3. Difficulties in achieving venous access that would prohibit prophylaxis
4. Incapability to follow the requirements of the surveillance, e.g. unable to keep a patient diary</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request patient information material</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>von Willebrand's disease</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Other coagulation defects</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment details: 
The following dosing regimes are only recommendations, based on the Swedish experience with the long-term prophylaxis in VWD:
1. For mucosal, joint bleeds and menorrhagia, the suggested prophylactic dosing is 30 IU Wilate® (corresponding to 30 IU FVIII:C)/kg body weight 2 - 3 times/week
2. For gastrointestinal bleeds, the suggested prophylactic dosing is 40 IU Wilate® (40 IU FVIII:C)/kg body weight 2 - 3 times/week
Wilate® is administered as an intravenuos bolus injection. Dose and dosing schedule are at the full discretion of the treating physician.  
 
Quality of life:
The Quality of Life assessments performed during the surveillance will include: 
1. The patient's self-reported health-related quality of life prior to and during prophylaxis with Wilate using the validated generic instruments WHOQOL-BREF (for adults and/or parents/legal guardians) and KINDL (for children), and
2. A disease-specific VWD-QoL questionnaire (for adults, children and their parents/legal guardians)

Quality of life assessments will be measured prior to the start of the prophylaxis, as well as after 6 and 12 months of treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase IV</phase>
	<drugNames>Wilate®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18075-0</funderId>
      <contactId>Contact56063_18075</contactId>
      <sponsorId>Sponsor54629</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56063_18075">
    <title>Ms</title>
    <forename>Martina</forename>
    <surname>Jansen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Oberlaaerstrasse 235</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>1100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0)1 61032 1208</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">martina.jansen@octapharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54629">
    <organisation>Octapharma AG (Switzerland)</organisation>
    <website>http://www.octapharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Seidenstrasse 2</address>
      <city>Lachen</city>
      <country>Switzerland</country>
      <zip>8853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)55 4512140</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">robert.kuhelj@octapharma.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476576.1</gridId>
    <rorId>https://ror.org/002k5fe57</rorId>
  </sponsor>
  <funder id="Funder18075-0">
    <name>Octapharma AG (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-08-29T00:00:00.000Z">21120199</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of an assessment-based falls prevention programme in elderly people utilising day-care services</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Implementation of an assessment-based multifactorial intervention on fall prevention in disabled elderly will decrease the number of fallers and the number of falls.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Fall rates and number of falls. Duration of follow-up: 1 year.</primaryOutcome>
      <secondaryOutcome>Fall-related fractures. Duration of follow-up: 1 year.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Ethics Committee of the Tokyo Metropolitan Institute of Gerontology. Date of approval: 26/09/2006 (ref: 16)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21120199</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bcfbf64f-2050-4e92-8899-c61ba1c1e17e">
	  <name>Tokyo Metropolitan Institute of Gerontology</name>
	  <address/>
	  <city>Tokyo</city>
	  <state/>
	  <country>Japan</country>
	  <zip>173-0015</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women who are 65 years of age or older who utilised day-care services.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>5000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>5,000</totalTarget>
      <exclusion>Acute health conditions.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls/ high risk population with falls</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Unspecified fall</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Falls prevention programme, consisting of the following:
1. Fall-risk assessment 
2. Falls prevention education for both the participating care service providers and the elderly participants

Control group: Usual care

Total duration of interventions: 3 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18025-0</funderId>
      <contactId>Contact56009_18025</contactId>
      <sponsorId>Sponsor54575</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56009_18025">
    <title>Dr</title>
    <forename>Hiroyuki</forename>
    <surname>Shimada</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Tokyo Metropolitan Institute of Gerontology
35-2 Sakae-cho
Itabashi</address>
      <city>Tokyo</city>
      <country>Japan</country>
      <zip>173-0015</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54575">
    <organisation>Tokyo Metropolitan Institute of Gerontology (Japan)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>35-2 Sakae-cho
Itabashi-ku</address>
      <city>Tokyo</city>
      <country>Japan</country>
      <zip>173-0015</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420122.7</gridId>
    <rorId>https://ror.org/03rd0p893</rorId>
  </sponsor>
  <funder id="Funder18025-0">
    <name>Tsukui Co (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-08-29T00:00:00.000Z">55370829</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pulmonary Vein Isolation using Robotic navigation: a prospective randomised trial with invasive follow-up</title>
      <scientificTitle/>
      <acronym>RoboticPVI</acronym>
      <studyHypothesis>Non-inferiority trial of robotic navigation (RN) guided pulmonary vein isolation compared to manually steered catheter approach.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Recovery of any pulmonary veins (PVs), measured after a follow up of one year is completed.</primaryOutcome>
      <secondaryOutcome>Peri-/post-procedural complications.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Hamburg Ethics Committee on the 5th May 2008 (ref: 2801/2008).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55370829</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RN/2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised non-blinded clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f5514632-87a4-4372-918b-7ce2fab07dd2">
	  <name>Martinistr. 52</name>
	  <address/>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20249</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Documented, symptomatic atrial fibrillation lasting less than 48 hours 
2. No prior history of electrical cardioversion
3. Both genders aged from 18 - 70 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Left Atrial (LA) diameter greater than 60 mm
2. Refuse to give written informed consent
3. Non-elegibility for interventional therapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-01-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Atrial Fibrillation</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Atrial Fibrillation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Catheter ablation with colled tip electrode with conduction block of all 4 vein proven by circumferential mapping catheter.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17464-0</funderId>
      <contactId>Contact55426_17464</contactId>
      <sponsorId>Sponsor54006</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55426_17464">
    <title>Dr</title>
    <forename>Daniel</forename>
    <surname>Steven</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20249</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.steven@uke.uni-hamburg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54006">
    <organisation>University Heart Center Hamburg (Germany)</organisation>
    <website>http://www.uke.uni-hamburg.de/zentren/herz/index.php</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Martinistr. 52</address>
      <city>Hamburg</city>
      <country>Germany</country>
      <zip>20249</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)49 42803 4125</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@uke.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.13648.38</gridId>
    <rorId>https://ror.org/01zgy1s35</rorId>
  </sponsor>
  <funder id="Funder17464-0">
    <name>Investigator initiated and funded (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-08-28T00:00:00.000Z">66931248</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The role and modulation of the adaptive immune response in human limb ischaemia reperfusion injury by ischaemic preconditioning</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>That local ischaemic preconditioning will alter bedside physiological parameters and systemic T cell activation, cytokine production and release in otherwise healthy patients undergoing lower limb surgery under tourniquet control.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Change in perioperative systemic mean arterial pressure and heart rate
2. Alterations in systemic T cell subsets as evaluated by flow cytometry, assessed on the systemic venous blood collected on admission, at 4 and 24 hours post reperfusion (post-operatively)
3. Alterations in systemic cytokine levels (Interleukin-2 [IL2] and interferon, gamma [IFNg]), assessed on the systemic venous blood collected on admission, at 4 and 24 hours post reperfusion (post-operatively)
4. Co-culture production of IL-2, IL-4, IL-10 and IFNg, assessed using the samples taken from patients 4 hours post reperfusion. Controls were taken from healthy volunteers.
5. Co-culture alteration in T cell subsets, assessed using the samples taken from patients 4 hours post reperfusion. Controls were taken from healthy volunteers.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Clinical Research Ethical Committee at University College Hospital Galway. Date of approval: 15/12/2005 (ref: 48/05)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66931248</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, single-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ireland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="94a09e60-089b-485a-8c49-d8158c3b17fa">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Galway</city>
	  <state/>
	  <country>Ireland</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients (both males and females) diagnosed with anterior cruciate ligament rupture by magnetic resonance imaging (MRI) or arthroscopy and undergoing patellar tendon graft reconstruction under tourniquet control.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>25</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>25</totalTarget>
      <exclusion>1. Age under 18 or over 45
2. Having smoked in the preceding 3 months
3. Diagnosis of systemic auto-immune condition (e.g., thyroxicosis, inflammatory bowel/ coeliac disease, rheumatoid arthritis, systemic lupus erythematosus [SLE])
4. Diabetes
5. Concurrent medical condition
6. Pregnancy
7. Medications other than simple analgesics and non-steroidal anti-inflammatory drugs (NSAID)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Reperfusion injury</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Consecutive patients undergoing anterior cruciate ligament repair were randomised to surgery alone or surgery preceded by three 5 minute cycles of local ischaemic preconditioning to the operative limb within 1 hour of surgery. Surgery to include 1 hour of limb ischaemia. An operative tourniquet was placed on the upper thigh and the limb was exsanguinated using a Rhys Davies air sleeve. Tourniquet pressure was set at 100 mmHg above systolic brachial blood pressure. Ischaemia was verified by arterial doppler distal to the tourniquet. Systemic venous blood was collected on admission, at 4 and 24 hours post reperfusion (post-operatively).</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18034-0</funderId>
      <contactId>Contact56020_18034</contactId>
      <sponsorId>Sponsor54585</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56020_18034">
    <title>Prof</title>
    <forename>Michael</forename>
    <surname>Kerin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Clinical Science Institute
Newcastle Road
National University of Ireland Galway</address>
      <city>Galway</city>
      <country>Ireland</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54585">
    <organisation>National University of Ireland Galway (Ireland)</organisation>
    <website>http://www.nuigalway.ie/surgery</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof Michael Kerin 
University College Hospital 
Department of Surgery 
Clinical Science Institute</address>
      <city>Galway</city>
      <country>Ireland</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6142.1</gridId>
    <rorId>https://ror.org/03bea9k73</rorId>
  </sponsor>
  <funder id="Funder18034-0">
    <name>National University of Ireland Galway, Department of Surgery (Ireland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-21T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-08-21T00:00:00.000Z">91680999</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of omega-7 sea buckthorn oil capsule on mucous membranes of post-menopausal women [omega 7-tyrniöljykapseleiden käyttö vaihdevuosioireiden, emättimen ja muiden limakalvojen kuivuuden ja virtsatieoireiden hoidossa]</title>
      <scientificTitle/>
      <acronym>SBMUCOS2008</acronym>
      <studyHypothesis>Increased oxidative stress to the secretion glands and the cells of mucous membranes is part of the mechanism of ageing-related dryness and inflammation in the mucous membranes of female subjects. Sea buckthorn oil supports the health of mucous membranes by supplying the body with lipid nutrients required for maintaining the structure and function and for regeneration of mucous membranes. High content of antioxidants in sea buckthorn oil will increase the antioxidant capacity and reduce lipid peroxidation of plasma. Supplementation with sea buckthorn oil will decrease the plasma C-reactive protein (CRP) level indicating reduced inflammation in the body.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract at baseline, after one and four months of supplementation
2. Vaginal PH at baseline, after one and four months of supplementation
3. Maturation index of vaginal mucosa at baseline, after one and four months of supplementation</primaryOutcome>
      <secondaryOutcome>1. Plasma total anoxidative capacity at baseline, after one and four months of supplementation
2. Plasma isoprostane level at baseline, after one and four months of supplementation
3. Plasma C-reactive protein level at baseline, after one and four months of supplementation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of the Hospital District of Southwest Finland on the 5th August 2008 (ref: 7/2008 § 254).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91680999</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SBRE2008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A randomised, double blind, placebo-controlled, single-centre parallel study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eb295447-cd6e-4bdd-b5eb-ac7c83d92917">
	  <name>Aromtech Ltd</name>
	  <address/>
	  <city>Turku</city>
	  <state/>
	  <country>Finland</country>
	  <zip>20520</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy post-menopausal females aged 55 - 70 years 
2. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract
3. Problem of the genital tract mucosa shall not have clear association with severe diseases</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Severe diseases and/or receiving systematic medications such as hormone replacement therapy, anti-inflammatory and cholesterol lowering drugs
2. Diabetes
3. Hormonal, renal, haematological, or hepatic dysfunction</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-08-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mucosa membrane dryness</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Menopausal and other perimenopausal disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: omega 7 capsules 2 x 2 capsules per day for 4 months
Group two: placebo capsules (medium chain triglycerides), 2 x 2 capsules per day for 4 months</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sea buckthorn oil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18056-0</funderId>
      <funderId>Funder18056-1</funderId>
      <contactId>Contact56043_18056</contactId>
      <sponsorId>Sponsor54608</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56043_18056">
    <title>Dr</title>
    <forename>Baoru</forename>
    <surname>Yang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Aromtech Ltd
Tykistökatu 4 D (DIO)</address>
      <city>Turku</city>
      <country>Finland</country>
      <zip>20520</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54608">
    <organisation>Turku University Central Hospital (Finland)</organisation>
    <website>http://www.tyks.fi</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Risto Erkkola
Department of Gynecology
TYKS, PL 52</address>
      <city>Turku</city>
      <country>Finland</country>
      <zip>20521</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410552.7</gridId>
    <rorId>https://ror.org/05dbzj528</rorId>
  </sponsor>
  <funder id="Funder18056-0">
    <name>Finnish Funding Agency for Technology and Innovation (TEKES) (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18056-1">
    <name>Aromtech Ltd (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-24T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-08-21T00:00:00.000Z">10111467</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of physician-delivered brief counselling intervention for binge drinkers: randomised controlled trial in primary care practice</title>
      <scientificTitle>Efficacy of brief interventions (BI)  for binge drinkers</scientificTitle>
      <acronym>BINGER</acronym>
      <studyHypothesis>To test the effect of brief interventions (BI) in a sample consisting exclusively of binge drinkers. 

Please note that, as of 24/11/2008, the following amemndments were made to this trial record due to errors in inforamtion provided at time of registration: 

1. Start and end dates were amended from 01/11/2008 and 01/11/2008 to 01/03/2003 and 01/03/2006, respectively
2. The target number of recruitment was changed from 2,433 to 752. The former is the number of participants who screened positive (i.e. binge drinking pattern and Alcohol Use Disorders Identification Test [AUDIT] score 15 or lower), whereas the latter is the number of participants who were randomised to the trial arms</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change in alcohol use: number of binge episodes (&gt;5 drinks for men and &gt;4 drinks for women on a single occasion) in the previous month and the percentage of bingers, assessed at baseline, 6 and 12 months.</primaryOutcome>
      <secondaryOutcome>Changes in weekly alcohol consumption and rates of excessive drinking in the previous 7 days (more than 18 drinks per week for men and more than 13 drinks per week for women), assessed at baseline, 6 and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University Hospital "12 de Octubre" (Hospital Universitario 12 de Octubre). Date of approval: 23/04/2008 (ref: 2008-45-2)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10111467</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>binger01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="67ba633a-956b-499d-af5a-76cface8b0d2">
	  <name>Hospital Universitario 12 de Octubre</name>
	  <address/>
	  <city>Madrid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>28047</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All adults patients aged 18 to 65 years of age will be asked to undergo alcohol use disorders screening (Alcohol Use Disorders Identification Test [AUDIT]) (Rubio et al., 1998) by their primary care physicians (PCPh). All patients who screen positive will be contacted and invited to participate in a face-to-face interview to determine their eligibility for the trial. Patients will be eligible for the randomised trial if they report a pattern of binge drinking and score 15 or lower on the AUDIT (scores above 15 were referred to the Drug Abuse Programme for Treatment). Patients eligible for the study will be binge drinkers, defined as men who had drunk 5 or more standard drinks per occasion (12.8 g of alcohol per drink) on 1 or more occasions in the previous month. Women will be included in the study sample if they had drunk 4 or more standard drinks per occasion on 1 or more occasions in the previous month. 

Rubio, G., Bermejo, J., Caballero, C., Santo-Domingo, J. Validación del test de identificación de trastornos por uso de alcohol (AUDIT) en atención primaria (Spanish validation of the Alcohol Use Disorders Identification Test [AUDIT] in primary care). Rev Clin Esp 1998; 198: 11-14.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>752</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>752</totalTarget>
      <exclusion>1. Pregnant women 
2. Plan to move out of the area within the year
3. Do not have a telephone
4. Those who are already participating in an alcohol intervention programme
5. Those who have an Axis I psychiatric disorder (American Psychiatric Association [APA] 2000) other than substance abuse that, in the judgment of the PCPh, prevents them from participating
6. Unable to complete the informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details provided in the Interventions field to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2003-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>High-risk alcohol drinkers</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Mental and behavioural disorders due to use of alcohol</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a randomised controlled trial with a 12-month follow-up period conducted by 74 physicians in 20 primary care centres in Spain. 

The brief intervention by the physician consisted of 2 short counselling sessions 4 weeks apart. Each 10 to 15-minute face-to-face counselling session was offered within the context of routine patient care by a physician using a scripted workbook. The intervention workbook included a review of alcohol-related health effects, a pie chart displaying the frequency of different types of at-risk drinkers, a list of methods for cutting down drinking, a treatment contract, and cognitive behavioural exercises. 

Subjects assigned to the control group received a booklet on general health issues and were followed up at 6 and 12 months. They were instructed to address any health concerns in their usual manner. 

Please use the following contact details to request a patient information sheet: 
Hospital Universitario 12 de Octubre 
Department of Psychiatry 
Avda Cordoba s/n 
Madrid, 28047
Spain 
Tel: +34 91 390 8022</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Applicable</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18018-0</funderId>
      <contactId>Contact56002_18018</contactId>
      <sponsorId>Sponsor54568</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56002_18018">
    <title>Dr</title>
    <forename>Gabriel</forename>
    <surname>Rubio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital Universitario 12 de Octubre 
Department of Psychiatry
Avda Cordoba s/n</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28047</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 63 920 1870</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">garuva@inicia.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54568">
    <organisation>Brain and Mind Foundation (Fundacion Cerebro y Mente) (Spain) </organisation>
    <website>http://www.cermente.com/en</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>General Oraa 67</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28041</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487148.6</gridId>
    <rorId>https://ror.org/025e2dr05</rorId>
  </sponsor>
  <funder id="Funder18018-0">
    <name>Brain and Mind Foundation (Fundacion Cerebro y Mente) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-28T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2008-08-21T00:00:00.000Z">50562632</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of neurosurgical resection strategies in temporal lobe epilepsy</title>
      <scientificTitle>Prospective and randomised multicentre trial investigating the pros and cons of different extent of mesial resection in surgery for mesial temporal lobe epilepsy</scientificTitle>
      <acronym/>
      <studyHypothesis>There is an ongoing debate about the mesial resection extent in the surgical treatment of temporal lobe (TL) epilepsy patients and its relation to seizure freedom and neuropsychological outcome. Surgical resection strategies developed from larger resections removing up to 2/3 of the temporal lobe to more selective and smaller resection types.

The objective of this study is to assess the significance of the extent of resection of mesial structures (hippocampus and parahippocampus) to achieve seizure freedom after surgery for temporal lobe epilepsy. 

The main goals of this project are to test two hypotheses:  
1. Smaller TL resections are associated with less neuropsychological deterioration
2. Post-operative seizure freedom is comparably good in smaller mesial resection</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Seizure freedom at one year after surgery: defined as class I in the Engel Outcome Scale. The Engel Outcome Scale is administered post-operatively and determines the improvement/worsening after surgical intervention as follows:
1. Engel class I: seizure-free
2. Engel class II: almost seizure-free
3. Engel class III: significant seizure reduction
4. Engel class IV: no significant improvement

Patients belonging to Engel class I are termed as seizure free, the remaining patients (Engel II - IV) as non-seizure free patients in the present study.

Secondary analysis:
Seizure freeness in subgroups (based on neuropathological analyses), e.g. patients with mesial temporal sclerosis.</primaryOutcome>
      <secondaryOutcome>Neuropsychological testing:
Each patient underwent comprehensive neuropsychological testing pre-operatively and 12-months post-operatively. For the comprehensive purpose of this study, various neuropsychological parameters are aggregated, resulting in scores for seven major cognitive domains:
1. Verbal learning and memory: two parallel versions of a pre- and post-operative verbal learning test (Verbaler Lern- und Merkfähigkeitstest [VLMT]). The VLMT (German adaptation of the Rey Auditory Verbal Learning Test) requires five trials of learning and recall of a word list consisting of 15 words, free recall immediately after distraction (learning/recall of a second list in one trial) and a recall after a half-hour delay, which is followed by a recognition trial (list with original words plus distractors). 
2. Figural learning and memory was obtained using the DCS-R, a German revised version of the DCS, a design list learning test (Diagnostikum für Zerebralschädigung) 
3. Language functions: 
3.1. Confrontation naming, Boston Naming Test
3.2. Phonematic and semantic fluency
3.3. Token Test, a subtest of the Aachener Aphasie-Test (a german test battery for aphasia) which is seen to measure verbal comprehension 
4. Attention functions:
4.1. D2-Test, a letter cancellation test
4.2. The c.I.T., a short test to measure cerebral insufficiency (Kurztest für cerebrale Insuffizienz) 
5. Psychomotor speed, mental tracking and cognitive flexibility:
5.1. Trail Making Test A and B (TMT-A/B)
5.2. Motoric sequences after Lurija
5.3. Purdue Pegboard
5.4. Finger Tapping Test
6. Visual and spatial abilities:
6.1. Subtest LPS-7 of the Leistungsprüfsystem (LPS), a german intelligence battery 
6.2. The Mosaic-Test, a subtest of the German version of the Wechsler Adult Intelligence Scale-Revised (HAWIE-R)
6.3. Labyrinth test
7. Behaviour and personality features:
7.1. German version of the Beck Depression Inventory (BDI)
7.2. FPZ (Fragebogen zur Persönlichkeit bei zerebralen Erkrankungen), an unpublished German CNS-disease related personality questionnaire
7.3. Quality of Life Inventory in Epilepsy, 10-item version (QOLI-10) 

All neuropsychological results were classified into five categories (0 = noticeably abnormal, 1 = moderately abnormal, 2 = borderline, 3 = without pathological findings, 4 = above average).</secondaryOutcome>
      <trialWebsite>http://www.meb.uni-bonn.de/epileptologie/sfb-tr3/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the University of Bonn Medical Centre on the 2nd February 2001 (ref: 237/00)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN50562632</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, interventional, randomised multicentre study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f3b2a81-69fe-403c-9970-4110b3214de7">
	  <name>Sigmund-Freud-Str. 25</name>
	  <address/>
	  <city>Bonn</city>
	  <state/>
	  <country>Germany</country>
	  <zip>53105</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients suffering from intractable temporal lobe epilepsy 
2. Drug resistance: seizure history lasting more than two years 
3. Pre-surgical evaluation led to the recommendation of either a partial temporal lobe resection combined with amygdalohippocampectomy or a more restricted selected selective amygdalohippocampectomy (SAH)
4. Only cases with mesial involvement were included
5. Patients had to be at least 18 years old (either sex) and able to understand the study plan 
6. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200 to 250</totalTarget>
      <exclusion>1. Previous temporal lobe surgery
2. Inability to do undergo neuropsychological testing because of retardation or foreign language
3. Mesial resection restricted to uncus and amygdala
4. No usable pre-operative magnetic resonance imaging (MRI) for volumetrical analyses
5. Pathology not allowing for randomisation (far dorsal reaching resection necessary)</exclusion>
      <patientInfoSheet>Patient information can be found at:
http://www.ukb.intern/42256BC8002AF3E7/vwWebPagesByID/8BE510569EF540CCC12571D40056E8CD</patientInfoSheet>
      <recruitmentStart>2002-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intractable mesial temporal lobe epilepsy (MTLE)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Epilepsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As part of the presurgical evaluation patients underwent neuropsychological testing and MRI scanning. Healthy volunteers also underwent neuropsychological testing to serve as a control group regarding the cognitive abilities of the patients. 

Patients were randomised to either a short (2.5 cm of hippocampal resection) or a long (3.5 resection length) resection group. The length of resection was to be determined intra-operatively after the opening of the temporal horn by using millimetre paper from the anterior tip of the temporal horn backwards placed on the hippocampal head along its length axis. Furthermore, manual volumetry of structural MRI datasets was used to evaluate the intended resection length.

Post-operatively, patients are seen for MRI-scanning, neuropsychological testing and medical consultation 3, 6 and 12 months after surgery.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/14742620 Cortical damage results ():
2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15230706 Neuropsychological outcome results ():
2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15270763 One year follow-up results ():
2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16014650 Children and aduly comparative study results ():
2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17131114 MRI volumetry results ():
2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17728360 Research ():
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17941848 Memory and non-memory function results ():
2008 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17955042 Comment ():
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18155965 Cognitive rehabilitation results ():
2008 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/18410360 Review ():
2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18425622 Prospective study results ():</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e9c00fa2-5f7d-4437-810c-85479c1dbb63" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/14742620"/>
	<description>Cortical damage results ():</description>
	<productionNotes/>
      </output>
      <output id="291b6abf-2081-455c-a507-c4560e799360" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15230706"/>
	<description>Neuropsychological outcome results ():</description>
	<productionNotes/>
      </output>
      <output id="33e34297-a1f8-496e-85a9-31fbd94b8358" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15270763"/>
	<description>One year follow-up results ():</description>
	<productionNotes/>
      </output>
      <output id="fa9341db-20a8-4012-acc6-636a65c04cc2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16014650"/>
	<description>Children and aduly comparative study results ():</description>
	<productionNotes/>
      </output>
      <output id="5c31c9d4-5d01-4aa4-bf97-2731e3e3c492" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17131114"/>
	<description>MRI volumetry results ():</description>
	<productionNotes/>
      </output>
      <output id="3eec45e8-c691-4403-a4f9-f4a3034e2aa8" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17728360"/>
	<description>Research ():</description>
	<productionNotes/>
      </output>
      <output id="a88dfc2b-efda-44aa-9542-818d7d097d10" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17941848"/>
	<description>Memory and non-memory function results ():</description>
	<productionNotes/>
      </output>
      <output id="be10a298-650a-4227-a153-61896c1c6b2b" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2008-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17955042"/>
	<description>Comment ():</description>
	<productionNotes/>
      </output>
      <output id="0acb023d-8bf8-4028-8925-f0b622b04fa7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18155965"/>
	<description>Cognitive rehabilitation results ():</description>
	<productionNotes/>
      </output>
      <output id="9f8edb4a-ff70-4c04-9ed7-57806b19edfc" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2008-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18410360"/>
	<description>Review ():</description>
	<productionNotes/>
      </output>
      <output id="50785382-5fbb-42ac-b189-216ee36e174e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18425622"/>
	<description>Prospective study results ():</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder18038-0</funderId>
      <contactId>Contact56024_18038</contactId>
      <sponsorId>Sponsor54589</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56024_18038">
    <title>Prof</title>
    <forename>Johannes</forename>
    <surname>Schramm</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sigmund-Freud-Str. 25</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54589">
    <organisation>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) </organisation>
    <website>http://www.dfg.de/</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Kennedyallee 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53175</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424150.6</gridId>
    <rorId>https://ror.org/018mejw64</rorId>
  </sponsor>
  <funder id="Funder18038-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-11-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2008-08-21T00:00:00.000Z">01779485</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Epidemiology and treatment of soil-transmitted helminthiasis, with particular consideration to strongyloidiasis, in Yunnan province, China</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Single-dose albendazole and single-dose tribendimidine (both drugs will be administered orally at 200 mg for children aged 5-14 years, and 400 mg for individuals aged &gt;=15 years) are safe and efficacious against soil-transmitted helminth infections (Ascaris lumbricoides, hookworm and Trichuris trichuria) 
2. Single-dose tribendimidine has an effect on Strongyloides stercoralis and Taenia spp</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Reduction of infection prevalence of intestinal helminths, assessed by examination of stool samples 2-4 weeks after drug administration 
2. Frequency and severity of adverse events were recorded within 24 hours after drug administration</primaryOutcome>
      <secondaryOutcome>Kato-Katz-derived egg count reduction of common soil-transmitted helminths, assessed 2-4 weeks after drug administration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University and the State of Basel (Ethikkommission beider Basel) (EKBB) Date of approval: 12/06/2007 (ref: 149/07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01779485</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7f7bedf1-c901-4119-b00a-8254c5bb28c1">
	  <name>Department of Public Health and Epidemiology</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>4002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age &gt;=5 years
2. Submission of &gt;=1 stool sample for the baseline parasitological survey
3. For females, not pregnant, as verbally assessed by medical personnel on the day of treatment
4. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment
5. Written informed consent by the head of the household on behalf of the whole family</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Approximately 300</totalTarget>
      <exclusion>1. Presence of any abnormal medical condition, as judged by the medical personnel
2. No stool sample submitted for baseline parasitological survey
3. Enrolled in any other clinical investigation during the study
4. For females: pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Helminth infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participants who were diagnosed with helminthiases at the baseline parasitological survey were randomly allocated to the following arms: 

Arm 1: Single-dose albendazole (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged &gt;=15 years
Arm 2: Single-dose tribendimidine (oral), 200 mg for children aged 5-14 years, and 400 mg for individuals aged &gt;=15 years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Albendazole, tribendimidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18923706 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2b7c36bc-0a3b-4bdd-a276-efec05b6bf87" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18923706"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder18062-0</funderId>
      <funderId>Funder18062-1</funderId>
      <funderId>Funder18062-2</funderId>
      <funderId>Funder18062-3</funderId>
      <funderId>Funder18062-4</funderId>
      <funderId>Funder18062-5</funderId>
      <funderId>Funder18062-6</funderId>
      <contactId>Contact56049_18062</contactId>
      <sponsorId>Sponsor54615</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56049_18062">
    <title>Dr</title>
    <forename>Juerg</forename>
    <surname>Utzinger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Public Health and Epidemiology
Swiss Tropical Institute
Socinstrasse 57
PO Box</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>4002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 61 284 8129</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juerg.utzinger@unibas.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54615">
    <organisation>Swiss National Science Foundation (SNSF) (Switzerland)</organisation>
    <website>http://www.snf.ch</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Wildhainweg 3
PO Box 8232</address>
      <city>Bern</city>
      <country>Switzerland</country>
      <zip>3001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 31 308 22 22</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@snf.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425888.b</gridId>
    <rorId>https://ror.org/00yjd3n13</rorId>
  </sponsor>
  <funder id="Funder18062-0">
    <name>Main funder:</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-1">
    <name>Commission for Research Partnership with Developing Countries (KFPE) through the Swiss Agency for Development and Cooperation (SDC) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-2">
    <name>Other funders:</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-3">
    <name>Voluntary Academic Society (Freiwillige Akademische Gesellschaft) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-4">
    <name>Janggen-Pöhn Foundation (Janggen-Pöhn-Stiftung) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-5">
    <name>Chinese Ministry of Science and Technology, through their support to the Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health (China) (grant ref: 2005DKA21104)</name>
    <fundRef/>
  </funder>
  <funder id="Funder18062-6">
    <name>Swiss National Science Foundation (Switzerland) (project numbers PPOOB-102883 and PPOOB-119129)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001711</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-08-19T00:00:00.000Z">66488490</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Diagnostic accuracy of recently proposed criteria for inflammatory back pain (IBP) in suspected ankylosing spondylitis (AS) and early axial spondyloarthritis (axial SpA)</title>
      <scientificTitle/>
      <acronym>DIVERS</acronym>
      <studyHypothesis>Sensitivity of at least 70% and specificity of at least 70% for the previously proposed criteria for inflammatory back pain (IBP).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Sensitivity, specificity and positive likelihood-ratio (LR+) if two out of four parameters of IBP are present.</primaryOutcome>
      <secondaryOutcome>Sensitivity, specificity and positive likelihood-ratio (LR+) if three or four out of four parameters of IBP are present.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Charité - University Medicine Berlin on the 8th July 2008 (ref: EA4/058/08).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66488490</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational diagnostic accuracy study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="edd69452-fa3f-4144-9bd6-4f67fc7c4bc6">
	  <name>Hindenburgdamm 30</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients (aged greater tha 18 years, either sex) with chronic back pain (greater than 3 months) of unknown origin:
1. Referred to the rheumatologist because of suspected AS/axial SpA
2. Seen by primary care physicians/orthopaedists, who agree to subsequently be referred to the rheumatologists</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>550</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>550</totalTarget>
      <exclusion>Patients with a definite diagnosis (cause) related to their back pain.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ankylosing spondylitis (AS), early axial spondyloarthritis (axial SpA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Ankylosing spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental group (no medical intervention): 
The diagnostic accuracy of IBP will be investigated in four private practices and two hospitals by assessing IBP by an independent and blinded observer (rheumatologist in each setting) in patients with undiagnosed chronic back pain who are referred because of suspected SpA. 

IBP will also be assessed by primary care physicians or orthopaedists in patients with chronic back pain of unclear origin, and also self-assessed by the patient prior to referral to the Rheumatology Department at Charité CBF for further work-up. 

The total duration of the trial is two years. There is no follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17961-0</funderId>
      <contactId>Contact55944_17961</contactId>
      <sponsorId>Sponsor54508</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55944_17961">
    <title>Dr</title>
    <forename>Martin</forename>
    <surname>Rudwaleit</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hindenburgdamm 30</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)30 8445 4547</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">martin.rudwaleit@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54508">
    <organisation>Charite - University Medicine Berlin (Charite - Universitatsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr. Krukenkamp
Charitéplatz 1
Virchowweg 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.krukenkamp@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder17961-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-19T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-08-19T00:00:00.000Z">59953554</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sleep in addiction care</title>
      <scientificTitle>Sleep in substance use disordered patients in addiction care</scientificTitle>
      <acronym/>
      <studyHypothesis>Sleep will improve by a cognitive behavioural therapeutic intervention in patients admitted to an addiction care clinic that show problems in initiating and maintaining sleep in the subacute detoxification phase.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Subjective sleep efficiency as measured by a sleep log. The sleep log will be recorded by the participants during the 6-week treatment period.  The sleep log has several outcome measures: time in bed (TIB), total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), wake after sleep onset (WASO) and number of awakenings (AWAK). 
2. Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) at timepoints T0, T1, T2, T3 and T4

Timepoints:
T0 = Day of clinical intake
T1 = 4th week of treatment
T2 = 6th week of treatment, before randomisation
T3 = At the end of sleep training
T4 = 2 months after the sleep training</primaryOutcome>
      <secondaryOutcome>Vigilance during the day as measured by the Sustained Attention to Response Task  (SART) at T1, T2, T3 and T4. SART will be carried out once a week during the period between T2 and T3. 

Tertiary outcome measures:
1. Severity of dependency on drugs/ alcohol measured by the Composite International Diagnostic Interview - Substance Abuse Module (CIDI-SAM) at T0 and T4
2. Addiction measured using the addiction scales of the Addiction Severity Index (ASI) at T0 and T4
3. Presence of any psychiatric disorder assessed by the Mini International Neuropsychiatric Interview (MINI)
4. Presence of sleep disorders assessed by the SLEEP-50 at T0, T1, T2, T3 and T4
5. Symptom assessment by the Symptom Check List (SCL-90) at T0, T1, T2, T3 and T4
6. Quality of life assessed by the EQ-5D at T0, T1, T2, T3 and T4
7. Actigraphy at T1, T2, T3 and T4. The actigraph registers movements of the right arm in right handed subjects for 48 hours or more.  
8. Go/No-Go response-inhibition task (T1)

Timepoints: 
T0 = Day of clinical intake 
T1 = 4th week of treatment 
T2 = 6th week of treatment, before randomisation 
T3 = At the end of sleep training 
T4 = 2 months after the sleep training</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>To be submitted in July 2008 (as of 21/05/2008)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59953554</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3.000.014</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open clinical trial, in two addiction care centres.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="877a1813-ff9b-4261-a457-bb759a3b3a52">
	  <name>Wanssumseweg 12</name>
	  <address/>
	  <city>Oostrum</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>5807 EA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age limit: 65 
2. Patients who are admitted for at least 5 weeks to an addiction clinic 
3. Those who are "clean" i.e. addicted patients that do not use drugs/alcohol anymore
4. Score of 5 or higher in the Pittsburgh Sleep Quality Index (PSQI)</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Patients with sleep problems other than problems of initiating or maintaining sleep
2. Diagnosis of severe depression, attention deficit hyperactivity disorder (ADHD) 
3. Patients who have a primary benzodiazepine addiction</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Insomnia in patients with substance use disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Nonorganic sleep disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study is a randomised controlled trial in a cohort of patients referred to addiction care (2 addiction clinics). The duration of the study for the participating patients is 15 weeks, plus a follow up at 2 months after completion of the intervention. In order to gather a large study population, the research takes 1.5 years. 

Initially, 600 eligible patients will be enrolled in the study and will undergo various baseline assessments (T0; see primary and secondary outcome measures) and start standard treatment for their sleep problems. During the 4th week in treatment (T1), those who still continue with the treatment will be asked to undergo additional assessments (see primary and secondary outcome measures). In the 5th week of treatment, the patients who show problems in initiating or maintaining sleep at T1 are selected for the next stage of the study. The selected patients (90 patients) are randomly assigned to one of the two treatment groups. 

The participants allocated to the intervention group receive sleep training, consisting of sleep hygiene, sleep education and cognitive behavioural therapy. Cognitive behavioural therapy will be given in 6 sessions of 2 hours, as developed by I. Verbeek (1999; http://www.ncbi.nlm.nih.gov/pubmed/10616231). 

The control group receives standard care (and no sleep training). This means a daily programme of cognitive therapy, group meetings, creative therapy, movement therapy, coffee breaks etc., the regular treatment for a normal addiction clinic. 

The total duration of follow-up per individual is 2 months. On completion of this follow-up assessment, the participants in the control group will also receive the interventions if they wish.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17824-0</funderId>
      <contactId>Contact55806_17824</contactId>
      <sponsorId>Sponsor54371</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55806_17824">
    <title>Miss</title>
    <forename>Ellis</forename>
    <surname>Magnee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wanssumseweg 12</address>
      <city>Oostrum</city>
      <country>Netherlands</country>
      <zip>5807 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 478 527815</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">emagnee@ggznml.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54371">
    <organisation>Mental Health Group in North and Middle Limburg (GGZ Noord- en Midden-Limburg) (Netherlands)</organisation>
    <website>http://www.ggznml.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Stationsweg 46</address>
      <city>Venray</city>
      <country>Netherlands</country>
      <zip>5803 AC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491220.c</gridId>
    <rorId>https://ror.org/00b3xjw51</rorId>
  </sponsor>
  <funder id="Funder17824-0">
    <name>Mental Health Group in North and Middle Limburg (GGZ Noord- en Midden-Limburg) (Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-09-09T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-08-14T00:00:00.000Z">47483728</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Investigation of enzymes in gingival crevicular fluid (GCF) and their gene activation profiles during orthodontic treatment</title>
      <scientificTitle>Pulp molecular and gingival crevicular fluid (GCF) enzymological profiles during orthodontic treatment</scientificTitle>
      <acronym/>
      <studyHypothesis>Enzyme activity will be increased and specific genes will be activated during orthodontic tooth movement.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Activity of the enzymes and genes involved during orthodontic treatment will be identified.</primaryOutcome>
      <secondaryOutcome>Potential enzymes and genes for biomarkers will be determined (biomarkers that are involved in tooth movement i.e inflammation, bone formation, bone resorption).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Research Ethics Committee, Faculty of Dentistry, National University of Malaysia (Universiti Kebangsaan Malaysia). Date of approval: 15/06/2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47483728</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational longitudinal study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Other</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Malaysia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="be660a3e-5c32-4c89-b776-549d15580aa1">
	  <name>Orthodontic Department</name>
	  <address/>
	  <city>Kuala Lumpur</city>
	  <state/>
	  <country>Malaysia</country>
	  <zip>50300</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age range 14-30 years
2. Need for orthodontic treatment 
3. Good general and periodontal health 
4. Not pregnant 
5. No use of antiinflammatory drugs, antibiotics or chlorhexidine mouthwash before and during study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Patient had periodontal disease
2. Poor oral hygiene
3. Have many missing teeth prior to study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Enzyme activity and gene profile during tooth movement</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Dentofacial anomalies [including malocclusion]</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Assessment of the orthodontic appliance and evaluation of tooth movement at monthly interval (week 4, 8 and 12). The whole orthodontic treatment will be monitored clinically over 2 years. 
2. Characterisation of GCF before and after the placement of orthodontic appliances. GCF samples taken at week 1, 2, 3, 4, 6, 8, 11 and 12 at the mesial and distal aspect of test (distalised canine) and control teeth (canine teeth that have not been affected by the orthodontic treatment) after premolar teeth have been extracted 
3. Pulp tissues characterisation of extracted teeth at 6 weeks. The test tooth will be the upper first premolar that will be extracted after orthodontic treatment. The control tooth will be a lower first premolar that has not been affected by the orthodontic treatment. 
4. Characterisation of mRNA from pulp tissues (as in method 3 above) and determination of mRNA quality for microarray hybridisation 
5. Microarray analysis of pulp tissues (as in method 3 above) 
6. Bioinformatic analysis of potential genes involved during tooth movement</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18011-0</funderId>
      <contactId>Contact55994_18011</contactId>
      <sponsorId>Sponsor54560</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55994_18011">
    <title>Dr</title>
    <forename>Rohaya</forename>
    <surname>Megat Abdul Wahab</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Orthodontic Department
Faculty of Dentistry
Universiti Kebangsaan Malaysia
Jalan Raja Muda Abdul Aziz</address>
      <city>Kuala Lumpur</city>
      <country>Malaysia</country>
      <zip>50300 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54560">
    <organisation>Ministry of Science, Technology and Innovation (Malaysia) </organisation>
    <website>http://www.mosti.gov.my</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Level 1-7
Block C4 &amp; C5
Complex C
Pusat Pentadbiran Kerajaan Persekutuan
Putrajaya</address>
      <city>Wilayah Persekutuan</city>
      <country>Malaysia</country>
      <zip>62662</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453014.7</gridId>
    <rorId>https://ror.org/012s3r374</rorId>
  </sponsor>
  <funder id="Funder18011-0">
    <name>Ministry of Science, Technology and Innovation (Malaysia)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003545</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-08T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-08-08T00:00:00.000Z">47762748</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of vitamin A and cyclosporin 0.05% eye drops for treatment of dry eye syndrome</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of this study is to compare the efficacy and safety of vitamin A (retinyl palmitate 0.05%) and cyclosporin A ([CsA] 0.05%) eye drops in treating patients with dry eye disease.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Symptom scoring 
2. Tear film BUT 
3. Schirmer test (without anaesthesia) 
4. Corneal fluorescein staining
5. Conjunctival impression cytologic analysis 

All performed before treatment, and at first, second and third months after initiation of treatment.</primaryOutcome>
      <secondaryOutcome>Goblet cell density, assessed before treatment, and at first, second and third months after initiation of treatment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of KangNam St. Mary's Hospital (South Korea) on the 14th December 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47762748</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41f2ea4f-a17c-4d3e-96d0-4c0c667ae3a1">
	  <name>Department of Ophthalmology</name>
	  <address/>
	  <city>Seoul</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>137-040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed informed consent 
2. Male and female patients aged 21 years and over 
3. Diagnosis of dry eye syndrome refractory to conventional management
4. Schirmer test (without anaesthesia) was less than 5 mm/5 minutes in at least one eye
5. Low tear film break-up time (tBUT) (less than 5 seconds)
6. Mild superficial punctate keratitis, defined as a corneal punctate fluorescein staining score of greater than or equal to 1 in either eye (scale 0 [none] to 3 [severe])
7. Symptoms of ocular irritation as assessed by an Ocular Surface Disease Index (OSDI) score of 25 or greater (on a scale of 0 - 59)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150 patients (300 eyes)</totalTarget>
      <exclusion>1. History of any ocular disorder including injury
2. Ocular infection
3. Non-dry eye ocular inflammation
4. Ocular trauma
5.Ocular surgery within the prior 6 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bilateral dry eye syndrome/ophthalmology</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Disorders of lacrimal system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>150 patients (300 eyes) with dry eye were divided into three groups: vitamin A (N = 50), cyclosporin A (N = 50)  and control (N = 50). Patients were treated twice daily with cyclosporin A 0.05%, four times daily with retinyl palmitate (vitamin A) 0.05%, or with no eye drops. Adjunctive treatment with preservative-free artificial tears was undertaken four times a day in all groups.

Total duration of treatment for each patient was three months, and total duration of follow-up was also three months, making a total of 6 months duration.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A (retinyl palmitate), cyclosporin A (CsA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder18026-0</funderId>
      <contactId>Contact56010_18026</contactId>
      <sponsorId>Sponsor54577</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact56010_18026">
    <title>Prof</title>
    <forename>Choun-Ki</forename>
    <surname>Joo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Ophthalmology 
KangNam St. Mary's Hospital
505 Ban-Po Dong, Seocho-Ku</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>137-040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54577">
    <organisation>The Catholic University of Korea (South Korea) </organisation>
    <website>http://www.catholic.ac.kr/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Ophthalmology and Visual Science
College of Medicine
KangNam St. Mary's Hospital
505 Ban-Po Dong, Seocho-Ku</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>137-040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411947.e</gridId>
    <rorId>https://ror.org/01fpnj063</rorId>
  </sponsor>
  <funder id="Funder18026-0">
    <name>The Catholic University of Korea (South Korea)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002648</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-08T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-08-08T00:00:00.000Z">15105737</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Remifentanil versus sufentanil regimen for intensive care unit (ICU) postoperative sedation after coronary artery bypass graft surgery: a prospective, randomised and double-blinded study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The anaesthetic regimen used during and immediately after coronary artery bypass graft (CABG) surgery is important as it could influence the function of major organ systems, minimise the risks of myocardial ischaemia and hence have direct and indirect implications on the early postoperative evolution of patients admitted to the intensive care unit (ICU). Remifentanil hydrochloride is a potent selective µ opioid receptor agonist characterised by a rapid onset and highly predictable offset of action (context-sensitive half-time of 3 to 6 minutes). In contrast to other opioids it does not accumulate, even after prolonged infusion or high administrated doses and its clearance is unaffected by hepatic or renal dysfunctions. Although its pharmacokinetics properties could be advantageous for postoperative balanced anaesthesia, without compromising early patient extubation, its withdrawal requires a specific strategy for postoperative pain management. Thereby, remifentanil is still not regularly used in the ICU and particularly in the postoperative period of cardiac surgery. The aim of this study was to compare remifentanil combined with propofol to conventional sufentanil-based anaesthesia (sufentanil stopped at the end of the surgery), during the postoperative period of an elective cardio-pulmonary bypass graft surgery with extra corporeal circulation. The haemodynamic effects as well as the influence on early postoperative pain relief and the repercussions on the patients' respiratory status were analysed. We also compared the duration of recovery from anaesthesia and the time for eligible and actual tracheal extubation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>We analysed the effects of these two anaesthetic regimens, used in order to maintain the same depth of anaesthesia, during the early postoperative period: 
1. Haemodynamic effects: Standard monitoring was used and included a CCO/SvO2 pulmonary artery catheter (Edwards Lifesciences, USA) 
2. The following haemodynamic parameters were recorded every 30 minutes from H0 to H4 (duration of the sedation), then hourly until H8 and finally every 2 hours for the next 16 hours: 
2.1. Heart rate (HR) 
2.2. Invasive mean arterial pressure (mean AP) 
2.3. Central venous pressure (CVP) 
2.4. Mean pulmonary arterial pressure (mean PAP) 
2.5. Pulmonary capillary wedge pressure (PCWP) 
2.6. Continuous cardiac output (CCO) 
2.7. Cardiac index (CI) 
2.8. Mixed venous oxygen saturation (SvO2) 
3. Biochemical markers of myocardial damage including troponine I and CPK-MB were analysed before surgery, and repeated at H0, H3, H8, H16 and H30 
4. Respiratory effects: Arterial blood gases evaluated respiratory state, every 4 hours from H0 to 24 hours after extubation 
5. Pain management: Pain evaluation was assessed by VAS ranging from 0: no pain to 100: worst imaginable pain. Each evaluation was performed at rest and just after deep inspiration (stress test). Use of VAS score and PCA recording of piritramide requirements evaluated the efficacy of pain control.</primaryOutcome>
      <secondaryOutcome>1. Duration of non-invasive ventilation (VNI)
2. Duration of patient's recovery from anaesthesia 
3. Time to eligible and actual tracheal extubation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Biomedical Research (Commission d&#146;Ethique Biomédicale Hospitalo-Facultaire),  Catholic University of Louvain (Université Catholique de Louvain), Faculty of Medicine. Date of approval: 01/03/2005 (ref: 2005/11FEV/23)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15105737</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, double-blind, single-centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1cd287d8-babc-4223-af9e-0f71222f730e">
	  <name>Cliniques Universitaires Saint-Luc, 10</name>
	  <address/>
	  <city>Bruxelles</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age &gt;18 years
2. Patients scheduled for elective CABG with cardiopulmonary bypass (CBP)
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Simultaneous valve surgery or any other combined surgery
2. Poor preoperative cardiac function (ejection fraction &lt;30%, severe congestive heart failure)
3. Liver or renal disorders
4. Chronic respiratory diseases
5. Alcohol or drugs abuse and neurological or psychiatric conditions that might impair pain evaluation
 
Postoperative exclusion criteria:
6. Situations where the administration of the anaesthetic regimen was maintained after the fourth postoperative hour</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative sedation of an elective coronary artery bypass graft surgery (CABG)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Other and unspecified disorders of circulatory system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After approval by our ethics committee and written consent obtained the day before surgery, forty patients scheduled for elective CABG with CBP were randomised, using a closed-envelope system, to receive either remifentanil (R group, n = 20) or sufentanil (S group, n = 20) as part of a totally intravenous anaesthesia regimen with propofol. 

Chronic preoperative medications were continued until surgery except for platelet inhibitors. All patients received intramuscular morphine chlorydrate (0.1 - 0.15 mg/kg) and scopolamine (0.25 mg) before surgery as premedication. 

Standard monitoring for cardiac surgery was used and included a CCO/SvO2 pulmonary artery catheter (Edwards Lifesciences, USA) and a bispectral (BIS) monitoring (Aspect Medical Systems, USA) to control the depth of anaesthesia. 

A radial artery catheter was placed before induction of anaesthesia. Induction sequence was similar in both groups, with intravenous administration of ketamine (0.5 mg/kg), midazolam (0.05 mg/kg), sufentanil (0.5 mcg/kg) and rocuronium (1.2 mg/kg). Anaesthesia was maintained by Target Controlled Infusion (TCI) of propofol 2% (Asena PK®, Alaris medical systems, USA) adjusted to a plasma concentration of 1 - 2 mcg/ml, in order to maintain the BIS index between 45-60. Intraoperative analgesia was provided in the R group by a TCI (Asena PK®, Alaris medical systems) of remifentanil (50 mcg/ml) adjusted to a target plasma concentration of 4 ng/ml, and in S group, by continuous infusion of sufentanil (50 mcg/ml) started at 0,5 mcg/kg/h. During surgery the adaptation of doses, depending on the haemodynamic responses to surgical stress, was left to the discretion of the anaesthetist in charge of the patient. 

Standard institutional methods were used for normothermic (36°C) CBP and myocardial protection. At the end of surgery, the propofol infusion was maintained in both groups. The TCI of remifentanil was maintained at a target concentration of 4 ng/ml in the R group while the sufentanil was stopped in the S group. In order to blind the ICU team to the group assignment, the anaesthetist in charge of the patient prepared 40 ml syringes labelled "substance X" containing either remifentanil (50 mcg/ml) for R group or normal saline solution for S group. He also prepared another 20 ml syringe labelled "substance Y" for the postoperative relay of analgesia containing piritramide (0.20 mg/kg) for patients in R group, and normal saline for S group. These syringes accompanied the patient to the ICU. 
The time of the patient's arrival to the ICU was defined as H0. From H0 to H4, all patients were maintained intubated and sedated by continuous administration of propofol 2% and TCI of "substance X" (remifentanil or NaCl 0.9% according to the allocated group). In both groups, the target concentration of substance X was set to 4 ng/ml, whereas propofol infusion was adapted to maintain the bispectral index between 60 and 70. During this period, patients were mechanically ventilated in a pressure-controlled mode (Servo-i Maquett Critical Care, Sweden) with a rate of 10 inflations/min and tidal volume of 8 ml/kg. Arbitrarily, the positive-end expiratory pressure (PEEP) was set at 5 cmH2O and the inspired fraction of oxygen (FiO2) was adjusted to maintain pulse oxygen saturation (SpO2) above 95%. Minute-volume was adjusted to maintain an arterial pH between 7.35 and 7.45 and arterial carbon dioxide tension (PaCO2) between 35 and 45 mmHg. 

The weaning of anaesthesia was as follow: at H3, analgesic treatment including paracetamol (1 g), tramadol (100 mg) and "substance Y" (20 ml piritramide in R group or saline solution in S group) was slowly administered. 

At H4, if all the criteria for weaning were present (temperature &gt;36.5 °C, no sign of haemodynamic impairment, chest tube output &lt;50 ml/h, adequate respiratory exchanges with arterial oxygen tension (PaO2) &gt;=80 mmHg with FiO2 &lt;40%, PaCO2 &lt;=45 mmHg with pH &gt;7.35, urine output &gt;0.5 ml/kg/h), both propofol and "substance X" were stopped. 

Pressure support ventilation was started immediately at patient's awakening. When all the weaning criteria were fulfilled (patient responding adequately to verbal commands, no major organ dysfunction), a T-piece trial was performed during a few minutes. During this period, pain evaluation was assessed by Visual Analogue Scale (VAS) ranging from 0: no pain to 100: worst imaginable pain. Pain relief was achieved with repeated intravenous administrations of piritramide (1 mg/1 mg), until VAS became less than 30 for all patients. Then, if the SpO2 could be maintained above 95% and if the respiratory rate was between 12 and 20/min, patients were extubated. 

From extubation to the discharge from the ICU, every patient received nasal oxygen guided by SpO2 and arterial blood gas measurements. Hypoxemia and/or respiratory acidosis was treated with non-invasive ventilation (VNI) and if necessary with invasive ventilation. 

After extubation, all patients received a continuous intravenous infusion of tramadol (400 mg) during 24 hours, associated with regular administration of paracetamol (1 g every 6 hours). Patient controlled analgesia (PCA) with piritramide provided additional analgesia during 72 hours (concentration of 2 mg/ml, bolus of 1mg, minimal interval of 5 minutes and maximum cumulative dose of 25 mg/4 h). 

During the sedation period, hypotension (mean AP &lt;65 mmHg) and/or inadequate cardiac output for tissue perfusion (CI &lt;2.5 l/min/m2, SvO2 &lt;65%, arterial lactates &gt;1.5 mM/l, urine output &lt;0.5 ml/kg/h) required a decrease in propofol if the BIS level was lower than 60 and fluid loading was administered if filling was inadequate (CVP &lt;12 mmHg and PCWP &lt;15 mmHg). If these measures were insufficient, atrial pacing was initiated at a rate of 90 to 100/min if the intrinsic rate was lower. Continuous intravenous administration of noradrenaline or dobutamine was initiated if hypotension persisted and if CI was respectively higher or lower than 2.5 l/min/m^2. 

Hypertension (mean AP &gt;80 mmHg) required an increase of propofol doses if the BIS level was higher than 70 and if necessary, was treated by afterload reduction with intravenous nicardipine chlorhydrate.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Remifentanil, sufentanil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17904-0</funderId>
      <contactId>Contact55887_17904</contactId>
      <sponsorId>Sponsor54451</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55887_17904">
    <title>Dr</title>
    <forename>Robin</forename>
    <surname>Lovat</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cliniques Universitaires Saint-Luc, 10</address>
      <city>Bruxelles</city>
      <country>Belgium</country>
      <zip>1200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54451">
    <organisation>Saint Luc University Clinic (Cliniques Universitaires Saint Luc) (Belgium)</organisation>
    <website>http://www.saintluc.be</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Avenue Hippocrate 10</address>
      <city>Bruxelles</city>
      <country>Belgium</country>
      <zip>1200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.48769.34</gridId>
    <rorId>https://ror.org/03s4khd80</rorId>
  </sponsor>
  <funder id="Funder17904-0">
    <name>Saint Luc University Clinic (Cliniques Universitaires Saint Luc) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-08-05T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2008-08-01T00:00:00.000Z">64791295</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase III, single-blind trial to assess efficacy and tolerability of genital mucosa after use of product INC056</title>
      <scientificTitle>A phase III, single-blind, single-centre trial to assess efficacy and tolerability of genital mucosa after use of product INC056 in post-menopausal women</scientificTitle>
      <acronym/>
      <studyHypothesis>This study is to confirm the safety, tolerability and efficacy of INC056 in post-menopausal female volunteers.

Hypothesis:
This treatment is expected to lower the vaginal pH in post-menopausal women and thus, to relieve local irritability and dryness of vagina.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Evaluate vaginal acidification after product use (lowering of vaginal pH) at all visits (baseline and days 14, 30, 37 and 52).</primaryOutcome>
      <secondaryOutcome>The following will be assessed at all visits (baseline and days 14, 30, 37 and 52):
1. Assessment of all adverse events reported 
2. Assessment of vaginal dryness and/or sexual discomfort 
3. Occurrence of recurrent vaginal infections in volunteers
4. Investigator's Global Assessment 
5. Volunteer's Global Assessment
6. Assessment measured by acceptability questionnaire 
7. Interruption of use due allergic reactions or irritability</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical approval received from the Ethics Committee of Irmandade de Misericórdia de Campinas - Hospital Irmãos Penteado (Brazil) on the 10th December 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64791295</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>INC056-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A phase III, single-centre, non-randomised, non-controlled, single-blind study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="38a9cdae-07c5-4720-bac7-6706dfc1098c">
	  <name>Rua Vicente Porto, 660.</name>
	  <address/>
	  <city>Campinas</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>13085-080</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy female volunteers aged between 40 and 65 years
2. Post-menopausal women
3. Vaginal pH of 5.0 or higher 
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>65</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>65 volunteers</totalTarget>
      <exclusion>1. Pregnancy or lactation
2. Skin disease at site of administration 
3. Diabetes mellitus
4. Immunological insufficiency 
5. Use of systemic corticoid, antibiotics or steroids
6. Use of immunosuppressive drugs
7. Skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis
8. Antifungal therapy within the last month at screening
9. History of infection at the site of drug administration
10. History of allergies to components of product
11. Other diseases or medications that could interfere with the research result or endanger the volunteer</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Local irritability and dryness of vagina</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Pain and other conditions associated with female genital organs and menstrual cycle</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pre-trial visit:
Prior to interventions, written informed consent will be gained. Screening assessment, vaginal pH testing, gynaecological exam and interview will be performed. The dose is one disposable applicator full of INC056 product (approximately 4 grams), applied intravaginally at bedtime.

Volunteers will be instructed to administrate the product as following:
1. Once every 3 days during 30 days
2. A 7 days washout period
3. Once daily for next 14 days

Visits will be performed on days 15, 30, 37 and 53.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>INC056</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17986-0</funderId>
      <contactId>Contact55969_17986</contactId>
      <sponsorId>Sponsor54534</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55969_17986">
    <title>Dr</title>
    <forename>André Luiz</forename>
    <surname>Vergnanini</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Vicente Porto, 660. 
Barão Geraldo</address>
      <city>Campinas</city>
      <country>Brazil</country>
      <zip>13085-080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54534">
    <organisation>Incrementha PD&amp;I (Brazil) </organisation>
    <website>http://www.incrementha.com.br</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Av. Professor Lineu Prestes, 2242
Prédio do Cietec - Sala 11
Cidade Universitária</address>
      <city>São Paulo</city>
      <country>Brazil</country>
      <zip>05508-000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 11 3039 8429</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fernando.francisco@incrementha.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17986-0">
    <name>Incrementha PD&amp;I (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-31T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-31T00:00:00.000Z">90497703</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Short-term administration of prulifoxacin: a preventive strategy to reduce Bacillus Calmette-Guerin (BCG)-induced toxicity in patients with superficial bladder cancer</title>
      <scientificTitle>Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus Calmette-Guerin (BCG) instillations: a prospective, randomised, open-label, controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Prulifoxacin decrease Bacillus Calmette-Guerin (BCG)-induced moderate to severe adverse events by 30%</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Adverse events classified by the investigator according to a classification grid considering duration and intensity.  Total duration of follow-up: 3 months.</primaryOutcome>
      <secondaryOutcome>Efficacy of BCG therapy in terms of 3-month cystoscopy findings</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Magna Graecia University of Catanzaro, approved in July 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN90497703</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>UMG0707</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, prospective, randomised, open-label, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bd31c314-ed01-4a91-aae1-e54fec08db13">
	  <name>Magna Graecia University of Catanzaro</name>
	  <address/>
	  <city>Catanzaro</city>
	  <state/>
	  <country>Italy</country>
	  <zip>88100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, age older than 18 
2. Intermediate or high risk superficial bladder cancer 
3. Indication for BCG intravesical adjuvant therapy after transurethral resection (TUR) 
4. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70</totalTarget>
      <exclusion>1. Patient age older than 85 years
2. World Health Organization (WHO) performance status 3 or 4
3. Previous treatment with BCG during the previous 3 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>BCG-induced toxicity in patients with superficial bladder cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Malignant neoplasm of bladder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three-day prophylactic administration of prulifoxacin (oral) 600 mg vs no prulifoxacin at each BCG intravesical instillation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prulifoxacin,  Bacillus Calmette-Guerin (BCG)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder18005-0</funderId>
      <contactId>Contact55988_18005</contactId>
      <sponsorId>Sponsor54554</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55988_18005">
    <title>Prof</title>
    <forename>Rocco</forename>
    <surname>Damiano</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Magna Graecia University of Catanzaro 
Campus Universitario di Germaneto </address>
      <city>Catanzaro</city>
      <country>Italy</country>
      <zip>88100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">damiano@unicz.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54554">
    <organisation>Magna Graecia University of Catanzaro (UMG) (Italy) </organisation>
    <website>http://www.unicz.it</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Campus Universitario di Germaneto</address>
      <city>Catanzaro</city>
      <country>Italy</country>
      <zip>88100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411489.1</gridId>
    <rorId>https://ror.org/0530bdk91</rorId>
  </sponsor>
  <funder id="Funder18005-0">
    <name>Magna Graecia University of Catanzaro (UMG) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-31T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-31T00:00:00.000Z">14802064</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>External Cephalic Version (ECV) Tocolysis Trial: Oral nifedipine vs subcutaneous terbutaline</title>
      <scientificTitle>Oral nifepidine versus subcutaneous terbutaline tocolysis for external cephalic version: A double blind randomised trial</scientificTitle>
      <acronym>STONE Trial</acronym>
      <studyHypothesis>Oral nifedipine is comparable to subcutaneous terbutaline as tocolysis for external cephalic version</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Successful version to cephalic presentation 
2. Caesarean delivery</primaryOutcome>
      <secondaryOutcome>1. Cephalic presentation at birth
2. Post-ECV cardiotocographic anomalies
3. Visual analogue scale satisfaction score with ECV procedure
4. Onset of labour
5. Neonatal outcome
6. Survey on patient preference of oral vs injection mode of medication
7. Maternal peri-delivery blood loss
8. Indication for operative delivery
9. Adverse drug events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Malaya Medical Centre, Medical Ethics Committee. Date of approval: 17/08/2005 (ref: 459.5)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14802064</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>459.5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Malaysia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d0282198-f65a-4226-ba74-fdaa3de847e0">
	  <name>Department of Obstetrics &amp; Gynaecology</name>
	  <address/>
	  <city>Kuala Lumpur</city>
	  <state/>
	  <country>Malaysia</country>
	  <zip>50603</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Breech presentation or transverse lie 
2. Viable, singleton pregnancy 
3. Gestation age 36 to 41 weeks 
4. Intact membranes 
5. Not in established labour</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Known gross foetal anomaly
2. Severe hypertension
3. Intrauterine growth restriction
4. Oligohydramnios
5. Antepartum haemorrhage within last 3 months
6. Uterine scar from any source
7. Known allergy to nifedipine or terbutaline
8. Other potential obstetric indication for Caesarean delivery
8.1. Placenta praevia
8.2. Suspected macrosomia &gt;4 kg
8.3. Uterine anomaly 
8.4. Obstructive pelvic tumour</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breech presentation at term gestation</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Maternal care for known or suspected malpresentation of fetus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants were randomised to treatment with 10 milligram oral nifedipine tablet and subcutaneous saline placebo injection or oral placebo tablet and subcutaneous 250 microgram terbutaline injection administered 20-30 minutes before commencing external cephalic version.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17969-0</funderId>
      <contactId>Contact55952_17969</contactId>
      <sponsorId>Sponsor54516</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55952_17969">
    <title>Prof</title>
    <forename>Peng Chiong</forename>
    <surname>Tan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Obstetrics &amp; Gynaecology
Faculty of Medicine
University of Malaya
Lembah Pantai</address>
      <city>Kuala Lumpur</city>
      <country>Malaysia</country>
      <zip>50603</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54516">
    <organisation>University of Malaya Medical Centre (Malaysia)</organisation>
    <website>http://www.ummc.edu.my</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Lembah Pantai</address>
      <city>Kuala Lumpur</city>
      <country>Malaysia</country>
      <zip>50603</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413018.f</gridId>
    <rorId>https://ror.org/00vkrxq08</rorId>
  </sponsor>
  <funder id="Funder17969-0">
    <name>University of Malaya, Department of Obstetrics and Gynaecology (Malaysia)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-31T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-31T00:00:00.000Z">18106465</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective, randomised, multicentre trial to assess short- and long-term results after laparoscopic and conventional resection of colorectal carcinoma</title>
      <scientificTitle/>
      <acronym>Lapkon II study</acronym>
      <studyHypothesis>Null hypothesis: The hypothesis of the randomised, controlled, multicentre study Lapkon II was that the rate of recurrence after five years is not higher after laparoscopic compared to conventional resection of colonic and upper rectal cancer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cancer-free survival 5 years after surgery</primaryOutcome>
      <secondaryOutcome>1. Short-term overall, general and local morbidity
2. Intraoperative complications
3. Duration of surgery
4. Length of the specimen
5. Number of lymphnodes removed
6. Status of resection margins
7. Postoperative hospital stay</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Central Ethical Committee of Charité - University Medicine Berlin. Date of approval: 24/07/1998 (ref: 565/96)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18106465</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>01091998</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, multicentre study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ca7fefbe-3080-47dd-b106-37dde7cf9161">
	  <name>General, Visceral, Vascular and Thoracic Surgery</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Tumour located in the upper rectum (above 12 cm from the anal verge) or the colon
3. Scheduled for right hemicolectomy, sigmoidectomy, or anterior rectal resection</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,200</totalTarget>
      <exclusion>1. Adenocarcinoma of the transverse colon or the colonic flexures necessitating extended left or right 2. Hemicolectomy or subtotal colectomy
3. Distant metastasis (i.e. liver or lung)
4. Contraindications to pneumoperitoneum
5. Acute intestinal obstruction
6. Perforation
7. Abscess
8. Malignant disease in the past 5 years (excluding skin basiloma or carcinoma in situ of the cervix)
9. Synchronous adenocarcinoma of the colorectum
10. Pregnancy
11. Age below 18 years
12. Unwilling to consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colonic and upper rectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Malignant neoplasm of colon</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Laparoscopic vs conventional resection of colorectal carcinoma 

After initial diagnostic laparoscopy, the result of the randomisation was intraoperatively revealed and the resection was carried out with either the laparoscopic or open technique.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17970-0</funderId>
      <contactId>Contact55953_17970</contactId>
      <sponsorId>Sponsor54517</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55953_17970">
    <title>Prof</title>
    <forename>Wolfgang</forename>
    <surname>Schwenk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>General, Visceral, Vascular and Thoracic Surgery 
Charité - University Medicine Berlin 
Campus Mitte
Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54517">
    <organisation>Charité - University Medicine Berlin (Germany)</organisation>
    <website>http://www.charite.de/en/charite/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder17970-0">
    <name>Participating hospitals will cover their costs for this trial. The lead hospital is Charité Campus Mitte - University Medicine Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-31T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-31T00:00:00.000Z">73608522</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled clinical trial on timing versus 3D-accuracy of fast-set impression materials</title>
      <scientificTitle>Clinical trial of the influence of time on the three-dimensional accuracy of fast-set polyether and fast-set polyvinyl siloxane impression materials</scientificTitle>
      <acronym>Poly Q</acronym>
      <studyHypothesis>Clinical studies have shown a correlation between the fitting precision of fixed dental restorations and the clinical success or survival rate. Since dental impressions mainly determine the fitting precision of fixed restorations, they play an important role. So far, the working times of impression materials have only been evaluated in-vitro. In the clinical routine, deviations from the exact timing occur very often and are either caused by an early filling of the impression tray by the dental assistance or by a delay during syringing of the light-body impression material. The clinical relevance of the exact timing gains even more importance when fast-setting impression materials with shorter working times and setting times are used. 

A non-optimal timing will have an influence on the three-dimensional precision of fast-set impressions materials. Due to the kinetics of their chemical reaction, polyethers may be of advantage compared to polyvinyl siloxane impression materials.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The precision of the three-dimensional (3D) tooth surface reproduction and the reproduction of the subgingival tooth surface, measured within 24 hours after impression taking.</primaryOutcome>
      <secondaryOutcome>1. Influence of environment temperature, measured in the impression session
2. Timing, measured in the impression session
3. Tray size, measured in the impression session
4. Accordance with subjective clinical impression rating, measured within four weeks after the impression session has taken place, throughout the study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Commission of the Medical Faculty Carl Gustav Carus of the Technical University Dresden on the 11th August 2004 (ref: EK 180092004)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73608522</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P-10199 CR 04/05</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pilot study and prospective, randomised clinical trial with triple-blind evaluation</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="81b3f30b-bcf6-4c5a-86ee-1f1f69f7f37d">
	  <name>Center of Dentistry</name>
	  <address/>
	  <city>Ulm</city>
	  <state/>
	  <country>Germany</country>
	  <zip>89081</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Suitable probands were aged between 18 and 80 years, either sex, and showed a complete set of either healthy or restored teeth in the lower right quadrant up to the second molar.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>104</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>8 for pilot study, 96 for main study</totalTarget>
      <exclusion>1. Alcohol or drug dependence
2. Persons with restricted legal capacity
3. Pregnant women
4. Probands who would face a conflict of interest due to the participation in another study
5. Patients with periodontal disease (periodontal screening index greater than 2)
6. Probands with missing teeth in the according quadrant (except for third molars and orthodontically closed spaces)
7. Probands excluded from the dental education course because of an infectious disease such as hepatitis or acquired immune deficiency syndrome (AIDS)</exclusion>
      <patientInfoSheet>Patient information material can be found at: http://www.uniklinik-ulm.de/fileadmin/Kliniken/Zahnmedizin/ZMK2/SIMTOM/20040726_Patienteninfo_PolyQ_SQ.pdf (in German)</patientInfoSheet>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fitting precision of fixed dental restorations</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Dental procedure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study gains information on the dependency between mixing timing of a one-stage putty-and-wash dental impression and three-dimensional precision of the resulting gypsum models under clinical conditions. Differences between two types of fast-set impression materials (polyether and polyvinyl siloxane) are to be analysed with a computer-aided procedure.

Three impressions were taken from the probands, after they had undergone a professional tooth cleaning, in randomised order. Either a polyether impression or a polyvinyl siloxane impression were taken under exact timing conditions and served as a reference. Two additional impressions were taken with non-optimal timing using the same impression material as for the respective reference impression. The two additional impressions were taken with two out of eight different non-optimal timings. The order in which the three impressions were taken as well as the material and the non-optimal timing were assigned to each proband according to a randomisation list. Standardised-made master-casts were digitised and the data resulting from the non-optimal timed impressions was compared to the reference. Probands were treated with fluoride gel afterwards in order to complete the benefit of the professional tooth cleaning.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Polyether, polyvinyl siloxane</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17705-0</funderId>
      <contactId>Contact55679_17705</contactId>
      <sponsorId>Sponsor54251</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55679_17705">
    <title>Prof</title>
    <forename>Ralph</forename>
    <surname>Luthardt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center of Dentistry
Department of Prosthetic Dentistry
Albert-Einstein-Allee 11</address>
      <city>Ulm</city>
      <country>Germany</country>
      <zip>89081</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54251">
    <organisation>3M ESPE AG (Germany) </organisation>
    <website>http://www.3mespe.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Dr Timo Kuretzky
Espe Platz</address>
      <city>Seefeld</city>
      <country>Germany</country>
      <zip>82229</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)8152 700 1376</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">timo.kuretzky@mmm.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.434574.5</gridId>
    <rorId>https://ror.org/047cnmy82</rorId>
  </sponsor>
  <funder id="Funder17705-0">
    <name>M ESPE AG (Germany) (ref: P 10 244 CR 04/01.04.04)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-07-30T00:00:00.000Z">58419709</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of an information leaflet about surgical wound infection (SWI) on recollection of information and satisfaction of patients operated on for scheduled surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Supplying patients who are scheduled to be operated on with a leaflet about surgical wound infection (SWI) could influence recollection of information, satisfaction regarding information and patient's opinion regarding SWI.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients' satisfaction concerning information about surgical wound infection, assessed by a telephone interview 5 +/- 1 week after surgery.</primaryOutcome>
      <secondaryOutcome>The following were assessed by a telephone interview 5 +/- 1 week after surgery:
1. Recollection of information
2. Attitude towards surgery and surgical wound infection</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval was not required as this study involved only usual processes of care;  neither invasive procedures nor medical interventions were involved.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58419709</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, randomised, single-blind trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b813aa2-eaab-4c46-9f34-e7c77b9f1e2a">
	  <name>Department of Epidemiology and Public Health</name>
	  <address/>
	  <city>Rouen</city>
	  <state/>
	  <country>France</country>
	  <zip>76031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 18 years, both males and females
2. Patients scheduled for surgery in the Digestive Surgery Department of the Rouen University Hospital</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Patients younger than 18 years
2. Patients requiring an emergency surgery
3. Patients with literacy difficulties or with cognitive impairment
4. Patients who do not speak French
5. Patients refusing to be interviewed 5 weeks after surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgical wound infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Complications of procedures, not elsewhere classified</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>According to the French regulation, no formal approval was required from the patient. To avoid memorisation bias, patients were told that the subject of the study was quality of care, and not information. They were asked if they agreed to be interviewed by phone 5 weeks after surgery about quality of their care. 

Intervention group: Patients received oral information about surgical wound infection from the surgeon plus an information leaflet. 
Control group: Patients received only oral information about surgical wound infection from the surgeon. 

Both oral information and the leaflet were given to the patients before surgery, during an outpatient visit with the surgeon.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17697-0</funderId>
      <contactId>Contact55669_17697</contactId>
      <sponsorId>Sponsor54243</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55669_17697">
    <title>Dr</title>
    <forename>Véronique</forename>
    <surname>Merle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Epidemiology and Public Health 
Rouen University Hospital</address>
      <city>Rouen </city>
      <country>France</country>
      <zip>76031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">veronique.merle@chu-rouen.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54243">
    <organisation>Rouen University Hospital (France)</organisation>
    <website>http://www.chu-rouen.fr</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1 Rue de Germont</address>
      <city>Rouen</city>
      <country>France</country>
      <zip>76031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">secretariat.DRC@chu-rouen.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.41724.34</gridId>
    <rorId>https://ror.org/04cdk4t75</rorId>
  </sponsor>
  <funder id="Funder17697-0">
    <name>Rouen University Hospital (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-30T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2008-07-25T00:00:00.000Z">06959967</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Investigation into the effectiveness of progesterone prevention of preterm labour in women who became pregnant by in vitro fertilisation (IVF)/ intra-cytoplasmic sperm injection (ICSI)</title>
      <scientificTitle>Effect of progesterone administration on the duration of pregnancy after in vitro fertilisation (IVF)/ intra-cytoplasmic sperm injection (ICSI): a prospective randomised study</scientificTitle>
      <acronym/>
      <studyHypothesis>Treatment with progesterone is emerging as the standard of care for prevention of preterm delivery in women at high risk for preterm birth. Randomised controlled trials (RCTs) have generally shown efficacy in reducing the rate of recurrent preterm delivery in women with singleton pregnancies who were at high risk for preterm labour and delivery. Most of the successful trials have employed 17-alpha-hydroxyprogesterone caproate, and one trial has reported positive results using progesterone vaginal suppositories. Very few trials of progestogens have been reported for women at risk for preterm delivery because of multiple gestations.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Delivery &lt;37 weeks' gestation.</primaryOutcome>
      <secondaryOutcome>1. Neonatal outcome
2. Incidence of prematurity
3. Admission to neonatal intensive care unit (ICU)
4. Complication of prematurity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Egyptian IVF-ET Center Ethics Committee. Date of approval: 17/06/2008 (ref: 4/2008)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06959967</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Egypt</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="98276db8-7e45-40b4-8335-db01686c48af">
	  <name>The Egyptian IVF-ET Center</name>
	  <address/>
	  <city>Cairo</city>
	  <state/>
	  <country>Egypt</country>
	  <zip>11431</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy women who became pregnant after IVF/ICSI (singleton or twin). Randomisation will be carried out, on average, during the 20th week of gestation.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>302</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>302</totalTarget>
      <exclusion>1. Rupture of membranes 
2. Smokers 
3. Major known foetal anomalies 
4. Uterine anomalies 
5. Cervical cerclage 
6. Treatment during this pregnancy with progesterone after 12 weeks' gestation (use up to 10 weeks' gestation is permitted) 
7. Contraindications to tocolysis, including foetal distress, chorioamnionitis, preeclampsia, hemodynamic instability 
8. Patients treated with oral beta adrenergics for asthma 
9. Age &lt;18 years</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prevention of preterm labour after IVF/ICSI</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Preterm labour</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Natural progesterone will be administered in the form of natural Prontogest® 400 mg daily through the vaginal route (pessaries). Progesterone administration will continue until delivery. 
Control group: Standard care only
 
Serum progesterone will be measured at start of trial (20 weeks gestation) and at 32 weeks gestation in all participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17915-0</funderId>
      <contactId>Contact55898_17915</contactId>
      <sponsorId>Sponsor54462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55898_17915">
    <title>Dr</title>
    <forename>Mona</forename>
    <surname>Aboulghar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Egyptian IVF-ET Center
3, St. 161 Hadaek Al Maadi
Maadi</address>
      <city>Cairo</city>
      <country>Egypt</country>
      <zip>11431</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54462">
    <organisation>Marcyrl (Egypt)</organisation>
    <website>http://www.marcyrl.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Habib Scientific Office
Buildings Sheraton Square No. 1227 
Building No. 8C</address>
      <city>Cairo</city>
      <country>Egypt</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17915-0">
    <name>This trial is funded mainly by the Egyptian IVF-ET Center (Egypt). The cost of medication is funded by Institut Biochimique SA (IBSA; Egypt).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-24T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2008-07-24T00:00:00.000Z">62313758</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>High Intensity Training in patients with rheumatoid arthritis</title>
      <scientificTitle>High Intensity Training in rheumatoid arthritis (RA)-molecular pathways related to inflammation, fatigue and pain</scientificTitle>
      <acronym>HIT-study</acronym>
      <studyHypothesis>The overall aim of the present study is to explore the underlying mechanisms of muscle weakness, inflammation, and pain with particular reference to the role of muscle strength in females with early rheumatoid arthritis (RA) by investigating the effects of high-intensity strength training on clinical variables, systemic and local molecular expression, and pathophysiological pain mechanisms. 

Specific research questions are:
1. What are the effects of a twelve-week high intensity muscle strength training program on muscle strength, pain, fatigue and general health perception? (Hypothesis I)
2. Can training reduce C-reactive protein (CRP) levels in serum? (Hypothesis II)
3. Can training reduce the number of swollen joints? (Hypothesis II) 
4. Can training decrease gene expression of inflammatory molecules in peripheral blood and in muscle tissue? (Hypothesis II)
5. Can training affect the phenotype of peripheral blood cells (of special interest the CD28 null T cells)? (Hypothesis II)
6. Can training have a positive effect on metabolic changes in muscle tissue? (Hypothesis III)
7. Can training affect concentration of reactive oxygen species (ROS) and reduced mitochondrial density in muscle tissue of RA patients? (Hypotheses II and III)
8. Is the expression of oestrogen receptors in muscle tissue different between patients with RA and healthy controls? (Hypothesis IV)
9. Can training alter the expression of oestrogen receptor? (Hypothesis V)
10. Is increased pain sensitivity at baseline related to the intensity of clinical pain? (Hypothesis VI)
11. Do increased pain sensitivity or a dysfunction of endogenous pain inhibitory controls at baseline predict poor treatment outcome following training? (Hypothesis VI)
12. Does training reduce pressure pain sensitivity and improve the function of endogenous pain inhibitory mechanisms? (Hypothesis VI)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Static and isokinetic muscle strength in knee extensors and knee flexors measured electronically with the Kin-Com.

Both the primary and the secondary outcomes will be measured at baseline and at three month follow up.</primaryOutcome>
      <secondaryOutcome>1. Clinical outcome (body functions, pain, fatigue and perceived health)
2. Inflammation
3. Pain mechanisms
4. Comorbidity
5. Muscle biopsies from vastus lateralis analysed for reactive oxygen species/reactive nitrogen species and expression of oestrogen receptors in muscles from patients with RA patients and controls before and after the intervention

Both the primary and the secondary outcomes will be measured at baseline and at three month follow up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Regional Research Ethics committee, Karolinska Institute, Stockholm on the 10th March 2008 (ref: 2008/243-32 2007/897-31).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN62313758</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-blind, randomised controlled trial (2 arms)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7f3eb43c-a955-43ae-9d13-7920c020b764">
	  <name>Department of Clinical Science and Education</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE 171 77</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Twenty female patients after menopause
2. RA according to American College of Rheumatology criteria
3. Less than 12 months since diagnosis
4. Stable medication since at least three months
5. Independent in daily living
6. Passed menopause
7. Speak and understand Swedish
8. No other major disease that prevent them from performing intensive strength training</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Twenty females</totalTarget>
      <exclusion>Does not comply with the above inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis (RA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Seropositive rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention group will participate in strength training three times a week in a 75-minute training program for 12 weeks. Eight major muscle groups will each be trained in three sets of eight repetitions at approximately 80% of maximum performance and a couple minutes of rest between each set. Each participant's maximum performance will be tested at baseline and every other week thereafter. Every training occasion starts with five minutes of warming up and ends with 10 minutes' cool down. Two weekly training sessions take place in training machines under the supervision of a physiotherapist. One weekly session is performed in the participants' home with the help of an instructive DVD and with their own body weight and rubber bands as resistance. 

The control group continues their normal contacts with the health care, which during the time of the intervention does not include strength training. At the end of the intervention they will be offered the same strength training program.

Patients will be followed up for three months for the intervention group and three months for the control group.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17817-0</funderId>
      <contactId>Contact55799_17817</contactId>
      <sponsorId>Sponsor54364</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55799_17817">
    <title>Dr</title>
    <forename>Birgitta</forename>
    <surname>Glenmark</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Science and Education
Södersjukhuset, KI</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE 171 77</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 601 5239</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">birgitta.glenmark@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54364">
    <organisation>ALF Foundation (Sweden) </organisation>
    <website>http://www.forskningsstod.sll.se</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>FoUU-kansliet
Stockholms läns landsting 
Box 22550</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>10422</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 737 4841</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">magnus.hammarberg@sll.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17817-0">
    <name>ALF Foundation (Sweden) (ref: 20070087 and 20080117)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-21T00:00:00.000Z">78326544</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective randomised clinical trial for closure of the pancreatic remnant following distal pancreatectomy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pancreatic fistula and intra-abdominal fluid collection are the most common complications of distal pancreatectomy. Our aim is to compare post-operative complication rates of  the techniques of the closure of the pancreatic stump such as the simple stapling or the combined method of covering the stapled stump with a seromuscular patch of the jejunum.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The rate of post-operative pancreatic fistula and intra-abdominal fluid collection. The 3-month post-operative period was analysed.</primaryOutcome>
      <secondaryOutcome>1. The rate of re-interventions, either surgical or radiological
2. Length of hospital stay

The 3-month post-operative period was analysed.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Regional Committee of Science and Research Ethics. Date of approval: 20/11/2001 (ref: 76-1-73/A/09)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78326544</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>7/2001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised single-centre clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hungary</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1b5e4df-d182-438c-a86f-5d439d822140">
	  <name>Petz Aladar Teaching Hospital</name>
	  <address/>
	  <city>Gyor</city>
	  <state/>
	  <country>Hungary</country>
	  <zip>9024</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 to 80 years, either sex
2. Distal pancreatectomy is indicated because of a benign or malignant tumour of the pancreas, chronic pancreatitis or malignant neoplasm of other organs infiltrating the pancreas, provided the parenchyma of the pancreas is suitable for stapling</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 patients</totalTarget>
      <exclusion>1. Aged under the age of 18 or over the age of 80 years
2. Too thick or wide parenchyma of the pancreas 
3. Death in the first 72 hours of the post-operative period</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pancreatic fistula and/or intra-abdominal fluid collection</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Other diseases of pancreas</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Distal pancreatectomy was performed in both groups. In the control group the pancreatic stump was closed by a stapler. In the intervention group the pancreatic remnant was first closed by a stapler then covered by a seromuscular patch of the jejunum.

The total duration of follow-up was 3 months in both groups.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17953-0</funderId>
      <contactId>Contact55936_17953</contactId>
      <sponsorId>Sponsor54500</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55936_17953">
    <title>Prof</title>
    <forename>Attila</forename>
    <surname>Olah</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Petz Aladar Teaching Hospital
Vasvari P. u. 2.</address>
      <city>Gyor</city>
      <country>Hungary</country>
      <zip>9024</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54500">
    <organisation>Petz Aladar Teaching Hospital (Hungary) </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>PO Box 92</address>
      <city>Gyor</city>
      <country>Hungary</country>
      <zip>9024</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417258.d</gridId>
    <rorId>https://ror.org/03vqk1b90</rorId>
  </sponsor>
  <funder id="Funder17953-0">
    <name>Petz Aladar Teaching Hospital (Hungary)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-21T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2008-07-21T00:00:00.000Z">18282428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A dynamic exercise programme to improve patients' disability in rheumatoid arthritis: a prospective randomised controlled trial</title>
      <scientificTitle/>
      <acronym>PREDYP</acronym>
      <studyHypothesis>The dynamic exercise programme improves quality of life in rheumatoid arthritis (RA) patients</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Functional status, evaluated by the Health Assessment Questionnaire (HAQ) at 1 and 6 months and 1 year. HAQ total score ranges from 0 (no functional limitation) to 3 (dramatic functional impairment).</primaryOutcome>
      <secondaryOutcome>The following were assessed at 1, 6 and 12 months:
1. Functional, clinical, radiological, therapeutic and biological modifications in both groups using the following tools: 
1.1. The French version of Arthritis Impact Score 2- short form (AIMS2-SF) is a specific questionnaire to assess quality of life in RA patients. AIMS2-SF was not converted to a score of 0 to 10 but was expressed on a scale from 0 to 50. 
1.2. Nottingham Health Profile (NHP) is a 38 item generic health-related quality of life measure (range 0 to 600, higher score for greater health problems)
2. Patient dexterity, evaluated by occupational therapists using Sequential Occupational Dexterity Assessment (SODA) or self reported by patients using Duruoz Hand Index (DHI) and a self report questionnaire. 
2.1. SODA consists of 12 standardized tasks evaluated by occupational therapists and ranges from 0 to 108. 
2.2. The purpose of DHI (range 0-90) was to measure hand ability while performing personal hygiene, office tasks and other general activities
3. Simple Erosions Narrowing Score (SENS, range 0-86) considers erosions in 32 joints in the hands and 12 in the feet, and joint space narrowing in 30 and 12 joints respectively. The total SENS score was assessed by a single radiologist unaware of the group assignment. 
4. Disease activity was determined using Disease Activity Score (DAS 28, range 0.14-9.3). A 28 joint count for swelling and tenderness was assessed by a rheumatologist unaware of the treatment allocation. Patients rated their general health on a 100 mm visual analogue scale. DAS 28 was calculated using the three previously mentioned parameters and Erythrocyte Sedimentation Rate (ESR). 
5. Aerobic capacity was measured on an exercise bike as the distance covered in 5 minutes. 
6. Use of oral and intra-articular drug, as well as other medical devices were recorded</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Protection of Human Subjects in Biomedical Research (Comités de Consultation pour la Protection des Personnes se prêtant à la Recherche Biomédicale [CCPPRB]), Grenoble II. Date of approval: 11/12/2002</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18282428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, single-blind, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="61745612-71a4-4e1e-b021-55aa8658a22f">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Echirolles</city>
	  <state/>
	  <country>France</country>
	  <zip>38434</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 1987 modified American College of Rheumatology (ACR) criteria for RA 
2. Treated with a disease-modifying anti-rheumatic drug</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. &gt;10 mg glucocorticoid per day
2. No or unstable Disease Modifying Anti-Rheumatic Drug (DMARD) regimen
3. DAS28 variation &gt;1.2 in the past 3 months
4. Age  &lt;18 or &gt;70 
5. Severe comorbidity causing a reduced life expectancy
6. Global functional status in RA class III or IV
7. Patients unable to follow the educational program or complete a questionnaire because of cognitive impairment, psychiatric disease, social frailty or language difficulty</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Roeder manipulative aptitude test, five-handle position grip test and grip and pinch strength test were carried out at baseline to avoid discrepancy in term of patients' skill between the two groups.

The dynamic exercise program was consistent with the 1990 recommendation of the American College of Sports Medicine. Three or four members of the medical staff (rheumatologist, physiotherapist or occupational therapist) took part in each session for 5 hours a day during a 4 week period. During the first week, patients benefited from hydrotherapy and occupational therapy input. Knowledge of the disease and physical capacity was evaluated for each participant in order to design, after multidisciplinary co-ordination, a patient-specific exercise program. The second week of the program focused on the influence of RA on daily activities. Muscle strengthening against resistance (of pain-free joints) replaced the hydrotherapy. The occupational therapy program in the third week included skill exercises and daily activities with increasing difficulty (endurance and exercises against resistance). During the forth week the exercises focused on office tasks. Pain and fatigue were prevented by regular breaks and relaxation in order to improve pain tolerance and self-esteem. 

Patients allocated to control group had usual care physical therapy according to French recommendations. Briefly, standard joint rehabilitation consisted of interactive lessons taught by rheumatologists, physiotherapists or occupational therapists and meetings for groups of 3 to 4 patients over the course of three days. Occupational therapy advices (verbal information, short movies, booklet) were given and splints were designed to prevent joint deformation and to help patients in daily living tasks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17390-0</funderId>
      <contactId>Contact55351_17390</contactId>
      <sponsorId>Sponsor53921</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55351_17390">
    <title>Prof</title>
    <forename>Philippe</forename>
    <surname>Gaudin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Hôpital Sud
Grenoble Teaching Hospital
Avenue de Kimberley
BP 338</address>
      <city>Echirolles</city>
      <country>France</country>
      <zip>38434 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53921">
    <organisation>Association for Research on Osteoarticular Disease  (ARPOA) (France)</organisation>
    <website>http://www.chu-grenoble.fr</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Department of Rheumatology
Hôpital Sud
Grenoble Teaching Hospital
Avenue de Kimberley
BP 338</address>
      <city>Echirolles</city>
      <country>France</country>
      <zip>38434 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pgaudin@chu-grenoble.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17390-0">
    <name>Association for Research on Osteoarticular Disease (Association de Recherche en Pathologie Ostéo-Articulaire; ARPOA) (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-07-17T00:00:00.000Z">48477221</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparative clinical trial of Krytantek Ofteno® versus Combigan D® in patients with primary open-angle glaucoma</title>
      <scientificTitle>Comparative clinical trial of the safety and efficacy of Krytantek Ofteno® formulated by Laboratorios Sophia S.A. de C.V. versus Combigan D® in the treatment of patients with primary open-angle glaucoma or ocular hypertension</scientificTitle>
      <acronym>KOEG</acronym>
      <studyHypothesis>There is no difference between the hypotensive effect of Krytantek Ofteno® versus Combigan D® in patients with a diagnosis of primary open-angle glaucoma (POAG) and/or ocular hypertension with or without pseudoexfoliation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intraocular pressure, measured at days 0, 7, 15, 30, 60 and 90. In all days the measurement will be at 8:00 am.</primaryOutcome>
      <secondaryOutcome>1. Visual fields, evaluation at at days 0 and 90
2. Ocular surface fluorescein staining, measured at at days 0 and 90</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Nuestra Señora de la Luz Hospital, Mexico City) on the 20th June 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48477221</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>KKVSCD0208FII</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, prospective, longitudinal, comparative, double-blind clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-04-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bolivia</country>
	<country>Chile</country>
	<country>Colombia</country>
	<country>Dominican Republic</country>
	<country>Ecuador</country>
	<country>El Salvador</country>
	<country>Guatemala</country>
	<country>Honduras</country>
	<country>Mexico</country>
	<country>Nicaragua</country>
	<country>Panama</country>
	<country>Peru</country>
	<country>Venezuela</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9710991e-456a-48a0-b922-e1cabb927b55">
	  <name>Hidalgo No. 861-A</name>
	  <address/>
	  <city>Guadalajara</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>44100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients must have a clinical diagnosis of mild to moderate primary open-angle glaucoma (POAG) with or without pseudoexfoliation and pigmentary dispersion or ocular hypertension
2. Patients may be of both masculine or feminine genders and must be 18 years old or older
3. Patients with intraocular pressure between 21 - 30 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>88</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>88 patients</totalTarget>
      <exclusion>1. Patients with one blind eye
2. Patients with visual acuity of 20/40 or worst in any of both eyes without a justifying cause
3. Patients with active stage history of any concomitant ocular disease besides the required one
4. Patients taking any medication, whether topically or by any route of administration, that decisively interferes in the study's results, until 48 hours previous to the day 1 of the trial or until a time period in which residual effects could be present
5. Sulfa allergy patients
6. Patients with history of hypersensibility or any medical situation that contraindicates or makes the using of risky for any of the study articles or their compounds under any route of administration as well as any drug or formulation derived from them or related to them
7. Contact lenses users
8. Fertile-age women who are not using an adequate contraceptive method as well as pregnant or breast-feeding women
9. Patients with history of cataract surgery with or without IOL implant (Pseudoaphakia or aphakia) three months or less prior to day 1 of the trial
10. Patients enrolled in any medical trial out of the Laboratorios Sophia S.A. de C.V. sponsorship under the last 90 days prior to this trial
11. Legally disqualified or mentally disabled patients who cannot sign the informed consent to participate in this clinical trial
12. Patients who cannot comply with the medical appointments or with all the protocol requirements
13. Patients who refuse to participate in this clinical trial
14. Patients with optic disc excavation equal to 0.8 or more
15. Normal-tension glaucoma patients</exclusion>
      <patientInfoSheet>Not available in web format, please contact drbvista@sophia.com.mx to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-04-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary open angle glaucoma</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>According to the random chart, 44 patients will receive over each eye one drop of a topical ophthalmic solution composed of timolol 0.5%, dorzolamide 2%, and brimonidine 0.2% in a fixed-combination formula (Krytantek Ofteno®) developed by Laboratorios Sophia S.A. de C.V. each 12 hours. The other 44 patients will be administered one drop of Combigan D® over each eye every 12 hours; both medications will be administered during a period of 90 days. All the study articles will be labeled with a non-consecutive "code number" that is randomly-generated by computer.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Krytantek Ofteno®, Combigan D®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17672-0</funderId>
      <contactId>Contact55643_17672</contactId>
      <sponsorId>Sponsor54218</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55643_17672">
    <title>Dr</title>
    <forename>Leopoldo</forename>
    <surname>Baiza-Duran</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hidalgo No. 861-A
Colonia Centro
Sector Hidalgo</address>
      <city>Guadalajara</city>
      <country>Mexico</country>
      <zip>44100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 (01)33 3826 4152</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drbvista@sophia.com.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54218">
    <organisation>Laboratorios Sophia S.A. de C.V. (Mexico) </organisation>
    <website>http://www.sophia.com.mx</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Hidalgo No. 737
Colonia Centro
Sector Hidalgo</address>
      <city>Guadalajara</city>
      <country>Mexico</country>
      <zip>44100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 (01)33 3826 4251</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drbvista@sophia.com.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487303.b</gridId>
    <rorId>https://ror.org/00zpf2822</rorId>
  </sponsor>
  <funder id="Funder17672-0">
    <name>Laboratorios Sophia S.A. de C.V. (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-16T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-17T00:00:00.000Z">17146141</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Enhancing dermatological diagnoses in patients with skin diseases at the National Institute for Infectious and Tropical Diseases in Hanoi</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The rationale of this protocol is to begin the first steps of skin research at National Institute for Infectious and Tropical Diseases in Hanoi.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Clinical diagnosis</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Oxford Tropical Medicine Research Ethics Committee (OXTREC) (UK) on the 20th June 2008 (ref: 12/08). Ethics approval pending as of 16/07/2008 from the ethics committee of the National Institute of Infectious and Tropical Diseases (NIITD).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17146141</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ctu01dtfec08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>This is a pilot study without a formal sample size calculation.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-07-31T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Viet Nam</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5319f8c7-b018-47ec-a9e8-4a5ab7debd83">
	  <name>The Oxford University Clinical Research Unit (OUCRU)</name>
	  <address/>
	  <city>Hanoi</city>
	  <state/>
	  <country>Viet Nam</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients admitted to the NIITD of any age, either sex
2. Obtaining informed consent
3. Any patient with an undiagnosed rash
4. Any patient with suspected Streptococcus suis, Penicillium marneffei, typhus or dengue</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 patients</totalTarget>
      <exclusion>An active bleeding tendency</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-07-31T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dermatology/skin rashes</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disorder of skin and subcutaneous tissue, unspecified</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This pilot study is not randomised or controlled. Potential study participants will be patients with a rash of unknown cause of with a suspected rash of one of the diseases of interest. For the patients in whom a skin biopsy is thought to be clinically important, a discussion will first take place between the research team and the treating physicians. If it is decided that a skin biopsy is indicated, the patient will be told about the study and, if interested, a member of the research team will go through the informed consent process. 

Skin biopsies will be divided and placed in suitable media for further investigation. This will include:
1. 10% buffered formalin for routine histology and polymerase chain reaction (PCR)
2. Michel's solution for immunoflourescence
3. Viral transport medium for viral culture
4. Sterile container for bacterial or fungal culture
5. Glutaldehyde for electron microscopy

If a skin scraping is done, it will be sent for microscopy (KOH stain) and/or fungal culture. Fluid from vesicles may be sent to the laboratory for herpes PCR. Basic clinical history history, past medical history, drug history, previous skin diseases, physical examination, including the skin rash distribution, and the results of routine investigations will also be performed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17974-0</funderId>
      <contactId>Contact55957_17974</contactId>
      <sponsorId>Sponsor54521</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55957_17974">
    <title>Dr</title>
    <forename>Walter Bob</forename>
    <surname>Taylor</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Oxford University Clinical Research Unit (OUCRU)
National Institute of Infectious and Tropical Diseases (NIITD)
78 Giai Phong Street</address>
      <city>Hanoi</city>
      <country>Viet Nam</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+84 4 576 4320</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">btaylor@oucru.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54521">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Clinical Trials and Research Governance
Manor House
John Radcliffe Hospital
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 9DZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder17974-0">
    <name>The Wellcome Trust (UK) (grant ref: 077078)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-17T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-17T00:00:00.000Z">81497217</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Investigation of the carriage of invasive Salmonellae in gall bladders in Kathmandu, Nepal</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To understand why some people become chronic carriers of Salmonella we need to investigate the variation within the infecting pathogen and the host.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. The titre of Vi antibodies in patients from whom Salmonella is isolated
2. Specific histological characteristics favouring carriage of Salmonella 
3. Traits of the bacterium favouring their chronic carriage</primaryOutcome>
      <secondaryOutcome>1. Investigation of the host genetic variation 
2. The human expression profile involved with Salmonella carriage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Oxford Tropical Medicine Research Ethics Committee (OXTREC) (UK) on the 25th June 2008 (ref: 21/08). The Nepal Health Research Committee (NHRC) has given verbal approval and the written approval will follow.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81497217</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CTU02AVJUN08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective descriptive study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Nepal</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9d35fce1-75c5-42ca-b7b0-bdd5d0d56147">
	  <name>Patan Hospital</name>
	  <address/>
	  <city>Kathmandu</city>
	  <state/>
	  <country>Nepal</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients referred for Cholecystectomy at Patan Hospital (no age limit, either sex) that complete the consent form and agree to be admitted to the study will be included in the study.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>Does not comply with the above inclusion criteria.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Enteric fever/tropical diseases</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Other salmonella infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Prior to admission to the study:
Full history and clinical examination. In particular the following data will be documented: clinical manifestations according to a standard case record form (CRF).

2. On admission to the study:
2.1. Name and address of the patient will be recorded on a detachable cover sheet of the CRF
2.2. Blood for on-going host genetic studies of enteric fever from the patient 
2.3. Storage of serum for antibody analysis  
2.4. Storage of blood for expression microarray profiling to identify biomarkers of carriage
2.5. Storage of bile and gallbladder
2.6. Culture of bile and gall stones (if present)
2.7. Stool culture 

3. Follow up visit from health-workers after 3 months:
3.1. Stool culture
3.2. GPS mapping of patients house
3.3. The gallbladders and bile will be stored in appropriate media and temperatures for: 
3.3.1. Polymerase chain reaction (PCR) of Salmonella deoxyribonucleic acid (DNA) in all samples that are culture negative
3.3.2. Bacterial ribonucleic acid (RNA) extraction for expression profiling of the organism
3.3.3. Routine histology of the organ
3.3.4. Immunohistochemistry of the tissue
3.3.5. Electron microscopy of the tissue
3.4. Blood and serum will be stored in appropriate media and temperatures for:
3.4.1. Storage of blood for expression microarray profiling to identify biomarkers of carriage
3.4.2. Blood for on-going host genetic studies of enteric fever from the patient
3.4.3. Storage of serum for antibody analysis
3.5. Storage of bacterial isolates; all strains isolated from the bile will be stored at -700°C for bacteriological assessment 
3.6. Spatial clustering of typhoid fever cases

Patients will be visited twice daily at home by a member of the study team. At the first visit the staff member will record the patient's house in a global positioning system (GPS).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17975-0</funderId>
      <contactId>Contact55958_17975</contactId>
      <sponsorId>Sponsor54522</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55958_17975">
    <title>Dr</title>
    <forename>Maskey</forename>
    <surname>Pukar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Patan Hospital
GPO Box 252</address>
      <city>Kathmandu</city>
      <country>Nepal</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+977 (0)1 985 107 9779</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">docpukarmaskey@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54522">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Clinical Trials and Research Governance
Manor House
John Radcliffe Hospital
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 9DZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder17975-0">
    <name>The Wellcome Trust (UK) (grant ref: 077078)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-16T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-16T00:00:00.000Z">74130527</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Riyadh benign prostatic hyperplasia (BPH) protocol</title>
      <scientificTitle>Prospective randomised placebo-controlled double-blind crossover trial in using anti-cholinergics with alpha blockers for the treatment of benign prostatic hyperplasia (BPH) in newly diagnosed patients</scientificTitle>
      <acronym/>
      <studyHypothesis>Anti-cholinergics might improve symptomatic benign prostatic hyperplasia (BPH).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Symptoms measured by:
1. The International Prostatic Symptoms Score (IPSS) 
2. Peak urinary flow rate (Q max) 

All outcomes will be assessed at visit one (zero time), visit two (eight weeks), visit three (one week from the last visit for wash out) and visit four (final visit at sixteen weeks).</primaryOutcome>
      <secondaryOutcome>1. Post voiding urine volume (PVR) 
2. Ultrasound (optional) 

All outcomes will be assessed at visit one (zero time), visit two (eight weeks), visit three (one week from the last visit for wash out) and visit four (final visit at sixteen weeks).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the Ethical Committee of the Continuous Medical Research Centre at King Khaled University Hospital in late 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74130527</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised placebo-controlled double-blinded crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Saudi Arabia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a807c968-833b-4313-bca9-48d43deeedd4">
	  <name>P.O.Box 5439</name>
	  <address/>
	  <city>Riyadh</city>
	  <state/>
	  <country>Saudi Arabia</country>
	  <zip>11422</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male patients; no specific age group but for the condition most patients will be aged 50 years and older
2. Naive patients with BPH
3. Have an International Prostate Symptom Score (IPSS) more than seven
4. Must be living in Riyadh city; patients from the peripheries will be excluded
5. Patients who are already on alpha blockers can be included after a washout period of two weeks</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>260</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>260 patients</totalTarget>
      <exclusion>1. Patients with renal failure
2. Acute angle glaucoma
3. Arrythmias (will be excluded by the past medical history and the current cardiac medication)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Benign prostatic hyperplasia</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Prostatic hyperplasia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients will have the following investigations at the recruitment visit: prostate specific antigen (PSA), peak urinary flow rate, post-voiding urine volume, ultrasound for the prostate, kidneys and the bladder with the ditrusal wall thickness, urine analysis, digital rectal exam, the symptoms are more voiding or imitative in nature creatinine level and International Prostatic Symptoms Score (IPSS).

1. Anti-cholinergic group: the patients in this group should receive alpha-blockers (tamsulosin) 0.4 mg orally (PO) once daily (OD) and anti-cholinergic (tolterodine) 2 mg PO twice daily (BID) for eight weeks
2. Control group: the patients in this group should receive alpha-blockers (tamsulosin) 0.4 mg PO OD and placebo tablet PO BID for eight weeks.

The patients will then be crossed over for another four weeks. All of them will be followed up throughout the study.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Alpha blocker (tamsulosin), anti-cholinergic (tolterodine)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17627-0</funderId>
      <contactId>Contact55598_17627</contactId>
      <sponsorId>Sponsor54173</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55598_17627">
    <title>Dr</title>
    <forename>Abdulaziz</forename>
    <surname>Al Thunayan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O.Box 5439</address>
      <city>Riyadh</city>
      <country>Saudi Arabia</country>
      <zip>11422</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54173">
    <organisation>The Continuous Medical Research Centre at King Khaled University Hospital (Saudi Arabia) </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>College of Medicine 
University Hospital
P.O. Box 245</address>
      <city>Riyadh</city>
      <country>Saudi Arabia</country>
      <zip>11411</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.459455.c</gridId>
    <rorId>https://ror.org/046gga527</rorId>
  </sponsor>
  <funder id="Funder17627-0">
    <name>The Continuous Medical Research Centre at King Khaled University Hospital (Saudi Arabia)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-11T00:00:00.000Z">42997954</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Immediate versus delayed restoration of immediate single-tooth implants in the anterior maxilla</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The influence of immediate versus delayed restoration of immediate single-tooth implants in the aesthetic region is evaluated. The study documents the treatment outcome of both strategies as well as the hard and soft tissue response. All parameters are carefully recorded to identify the treatment strategy with the best aesthetic results.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mucosa levels were recorded by means of an acrylic stent provided with three direction grooves: mesial, midfacial and distal. All measurements were assessed with a periodontal probe.
1. Papilla levels: a papilla level (mesial papilla level - distal papilla level) is defined as the distance between the top of the corresponding groove and the top of the papilla
2. Midfacial mucosa level: the midfacial level is defined as the distance between the top of the groove and the first contact with the peri-implant mucosa</primaryOutcome>
      <secondaryOutcome>At each re-assessment, namely 3, 6 and 12 months after baseline (i.e. provisional crown connection), mesial and distal marginal bone changes over time were calculated using standardised peri-apical radiographs.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Commissie Medische Ethiek (O.G.016) on the 18th October 2007 (ref: B.U.N. B14320072578).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42997954</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, randomised single-blind controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="48722719-bb25-4807-bb70-d3b504e053be">
	  <name>Laarbeeklaan 1O3</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients were selected and consecutively treated in the Dental Clinic of the Free University in Brussels (VUB):
1. 18 years or older, either sex (the mean age was 53 with a range of 24 to 76 years)
2. Good oral hygiene
3. Existence of one failing tooth in the anterior maxilla (15 - 25) with both neighbouring teeth present
4. Healthy soft tissues surrounding the facial aspect of the hopeless tooth in perfect harmony with the adjacent teeth
5. Normal to thick-flat gingival biotype
6. Adequate bone height apical to the alveolus of the failing tooth (greater than or equal to 5 mm) to ensure primary implant stability of at least 35 Ncm</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Two groups of 24 participants</totalTarget>
      <exclusion>1. Systemic diseases
2. Smoking (greater than or equal to 10 cigarettes a day)
3. Bruxism, lack of posterior occlusion
4. Non-treated periodontal diseases
5. Presence of active infection (pus, fistula) around the hopeless tooth
6. Loss of the labial crest after extraction of the failing tooth</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2005-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dental implants</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Dental implants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two separate treatment groups were randomly created: 

Immediate restoration group:
The total treatment is be done in one surgical appointment. After extraction of the failing tooth, the implant is immediately inserted into the extraction cavity. Within 3 hours the implant is loaded with a provisional restoration. At the 6 month recall visit the final restoration (crown) is connected. 

Delayed restoration group: 
This treatment involves two surgical interventions. First the tooth is extracted and an implant is immediately inserted into the extraction cavity. The surgical site is closed and a 3-month healing period started. Following this healing period implants were uncovered at second-stage surgery and a provisional restoration was connected to the implant. Again at the 6-month recall visit the final restoration (crown) is connected. 

For both groups the moment of provisional crown connection is selected as baseline. Restorations were followed-up for at least one year following provisional crown connection.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17779-0</funderId>
      <contactId>Contact55755_17779</contactId>
      <sponsorId>Sponsor54325</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55755_17779">
    <title>Mr</title>
    <forename>Tim</forename>
    <surname>De Rouck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Laarbeeklaan 1O3
School of Dental Medicine (Gebouw K)</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+32 (0)2 4774960</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tim.de.rouck@vub.ac.be</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54325">
    <organisation>Free University of Brussels (VUB) (Belgium) - School of Dental Medicine </organisation>
    <website>http://www.vub.ac.be</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Laarbeeklaan 103</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+32 (0)2 4774960</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tim.de.rouck@vub.ac.be</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8767.e</gridId>
    <rorId>https://ror.org/006e5kg04</rorId>
  </sponsor>
  <funder id="Funder17779-0">
    <name>Free University of Brussels (VUB) (Belgium) - School of Dental Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-11T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-10T00:00:00.000Z">78922760</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early Clinical outcome of Modified retropubic Versus Transvesical prostatectomy in Management of Benign prostatic hyperplasia: a Randomised Clinical Trial</title>
      <scientificTitle/>
      <acronym>ECMVTMB: RCT</acronym>
      <studyHypothesis>There is no clinical advantage of modified retropubic prostatectomy over transvesical prostatectomy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Blood loss determined by haemoglobin and haematocrit levels on the third post operative day</primaryOutcome>
      <secondaryOutcome>1. Wound sepsis following surgery
2. Rate of return to operating theatre for clot retention</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Research and Ethics Committee of the Faculty of Medicine, Makerere University. Date of approval: 30/07/2007 
2. The Mulago National Referral Hospital Research and Ethics Committee. Date of approval: 30/07/2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78922760</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b0bf14c6-d093-47cf-8557-a732e6dba609">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Kampala</city>
	  <state/>
	  <country>Uganda</country>
	  <zip>256</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients admitted between August 2007 and March 2008 with diagnosis of Benign Prostatic Hyperplasia (BPH)
2. Haemoglobin level of 10 g/dL or more
3. Haematocrit of more than 30%</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Suspected prostatic carcinoma
2. Renal failure
3. Cardiac disease
4. Abnormal bleeding tendencies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Benign prostatic hyperplasia</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Hyperplasia of prostate</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Modified retropubic prostatectomy 
2. Transvesical prostatectomy</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16834-0</funderId>
      <funderId>Funder16834-1</funderId>
      <contactId>Contact54792_16834</contactId>
      <sponsorId>Sponsor53348</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54792_16834">
    <title>Dr</title>
    <forename>Masaba</forename>
    <surname>Joseph Benon</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Mulago Hospital 
Po Box 7051</address>
      <city>Kampala</city>
      <country>Uganda</country>
      <zip>256</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+256 77536089</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jmasaba@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53348">
    <organisation>Mulago Hospital (Uganda)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Po Box 7051 </address>
      <city>Kampala</city>
      <country>Uganda</country>
      <zip>256</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416252.6</gridId>
    <rorId>https://ror.org/02rhp5f96</rorId>
  </sponsor>
  <funder id="Funder16834-0">
    <name>Mulago Hospital (Uganda)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16834-1">
    <name>Resources of Investigator as part of Masters' thesis in surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-10-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-10T00:00:00.000Z">49216096</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ultrasound study of echocardiographic artifacts in mechanically ventilated patients</title>
      <scientificTitle>The "cardiac-lung mass" artifact: an echocardiographic sign of lung atelectasis and/or pleural effusion</scientificTitle>
      <acronym/>
      <studyHypothesis>We performed an ultrasound study to investigate echocardiographic artifacts in mechanically ventilated patients with lung pathology, based upon the incidental discovery of such findings in five critically ill patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Occurence of possible echocardiographic artifacts generated by adjacent lung pathology.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of the General Hospital of Athens Intensive Care Unit in August 2005 (ref: 006/08).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49216096</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Artifact2008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational progressive ultrasound study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="056b7c8c-4bf9-4185-8741-5ff3cb370d94">
	  <name>Intensive Care Unit</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>11527</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Critically ill patients (adults, either sex) 
2. Body mass index less than 30 kg/m^2
3. Acute Physiology And Chronic Health Evaluation (APACHE II) score less than 25
4. Exhibited the same initial findings on lung echography, lung atelectasis and/or pleural effusion</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Mechanically ventilated patients without any signs of lung pathology</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lung atelectasis or consolidation, and/or pleural effusion</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Other respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects underwent lung echography and transthoracic echocardiography (TTE) with a Philips XD11 XE ultrasound device (Philips, Bothell, USA) equipped with a convex 5 to 7 MHz and with a 1.5 to 3.6-MHz wide-angle, phased-array transducer, respectively. Patients were examined by two experienced observers blinded to each others' interpretation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18826590 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="92a01ad9-4316-4a5f-8c75-617986677413" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18826590"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17936-0</funderId>
      <contactId>Contact55919_17936</contactId>
      <sponsorId>Sponsor54483</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55919_17936">
    <title>Dr</title>
    <forename>Andreas</forename>
    <surname>Karabinis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Intensive Care Unit
General Hospital of Athens
154 Mesogeion Ave</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 21 0748 0188</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">echolabicu@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54483">
    <organisation>General Hospital of Athens (Greece)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Andreas Karabinis
Intensive Care Unit
154 Mesogeion Ave</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>11527</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 21 0748 0188</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">echolabicu@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17936-0">
    <name>General State Hospital of Athens (Greece) - Intensive Care Unit</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-07-04T00:00:00.000Z">33347454</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Study drug 017 will be superior to placebo in the treatment of chronic neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain intensity measured during the last week of treatment in each phase.</primaryOutcome>
      <secondaryOutcome>All assessments measured during the last week of treatment in each phase:
1. Neuropathic Pain Scale
2. Pain and sleep
3. Pain and disability
4. Quality of life
5. Depression inventory</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval for the lead centre was received from Institutional Review Board (IRB) Services, Aurora, ON (Canada) on 11 January 2008. All other participating centres obtained ethics approval before recruiting study participants.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33347454</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>017-010</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centred, randomised, double-blind, placebo-controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="12adf95b-a09b-4978-9246-577d7c1ea47e">
	  <name>Purdue Pharma</name>
	  <address/>
	  <city>Pickerin, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>L1W 3W8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For diabetic neuropathy patients:
1. Stable glycaemic control
2. Patients with pain in the lower extremities on a daily basis and one or more signs or symptoms of peripheral neuropathy not attributable to any other cause
3. Patients with absent or decreased ankle reflexes and loss of perception of 128 Hz vibration of the great toe

For post-herpetic neuralgia patients:
1. Primary diagnosis of PHN defined by pain for at least three months after healing of a herpes zoster skin rash

For all patients:
1. Male or non-pregnant females at least 18 years of age
2. Patients who answer yes to at least four items on the the neuropathic pain diagnostic questionnaire (DN4)
3. Patients whose pain has been of moderate intensity on most days for at least three months
4. Patients who have required the use of analgesic medication for at least three months</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70</totalTarget>
      <exclusion>1. Patients who do not have stable glycaemic control (HbA1c greater than 2 x normal) or whose anti-diabetic therapy is likely to require adjustment during the study
2. Patients with peripheral neuropathy attributable to other causes
3. Significant pain of other origin that may obscure the assessment of efficacy
4. Patients whose opioid requirement may exceed eight tablets of acetaminophen plus codeine (300/30 mg) or analgesic equivalent per day
5. Patients with true allergy to acetaminophen or any opioid, sufficient that therapy is contraindicated
6. Patients with any of the following medical conditions:
6.1. Active, severe psychiatric disorder, including severe depression
6.2. Postural hypotension
6.3. Clinically significant hepatic dysfunction (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [Alk Phos] greater than 2 x normal)
6.4. Symptomatic coronary artery peripheral vascular disease
6.5. Intermittent claudication
6.6. Brittle diabetes
6.7. Low serum cobalamin (vitamin B12)
6.8. Abnormal serum folic acid levels
6.9. Colostomy, ileostomy or shortened gastrointestinal (GI) transit time
6.10. Active or recent peptic ulcer or gastrointestinal (GI) inflammatory disease
6.11. Epilepsy, history of seizures or recognised risk for seizure
6.12. Any condition that may adversely affect patient safety or obscure assessment of efficacy
7. Patients receiving any of the following medications:
7.1. Monoamine oxidase inhibitors 
7.2. Carbamazepine
7.3. Quinidine
7.4. Selective serotonin reuptake inhibitors
7.5. Serotonin norepinephrine reuptake inhibitors
7.6. Neuroleptics
7.7. Warfarin
7.8. Digoxin
8. Patients who have received an investigational drug within the previous month
9. Patients with a known or suspected history of drug or alcohol abuse</exclusion>
      <patientInfoSheet>Not available in web format. Please have your family physician use the contact details below to request information on the study.</patientInfoSheet>
      <recruitmentStart>2008-01-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neuropathic pain</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Polyneuropathy in diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Centrally-acting oral opioid anlagesic (017) titrated to effect over a 4-week phase with matched placebo arm.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Study drug 017 (a centrally acting opioid analgesic)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17633-0</funderId>
      <contactId>Contact55604_17633</contactId>
      <sponsorId>Sponsor54179</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55604_17633">
    <title>Dr</title>
    <forename>John</forename>
    <surname>Eisenhoffer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Purdue Pharma
575 Granite Court</address>
      <city>Pickerin, Ontario</city>
      <country>Canada</country>
      <zip>L1W 3W8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 420 6400</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">medinfo@purdue.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54179">
    <organisation>Purdue Pharma Canada </organisation>
    <website>http://www.purdue.ca/main/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>575 Granite Court</address>
      <city>Pickering, Ontario</city>
      <country>Canada</country>
      <zip>L1W 3W8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487460.9</gridId>
    <rorId>https://ror.org/023sxys58</rorId>
  </sponsor>
  <funder id="Funder17633-0">
    <name>Purdue Pharma Canada</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-03T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-03T00:00:00.000Z">81864187</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Double-blind (practitioner-patient masking) trial of acupuncture needles: does patient reaction reveal needle authenticity?</title>
      <scientificTitle>Research for effects of acupuncture stimulation on somatosensory function and somatic nerve reflex</scientificTitle>
      <acronym/>
      <studyHypothesis>In our previous study (http://www.ncbi.nlm.nih.gov/pubmed/17925042) we demonstrated that the penetrating and non-penetrating needles that we have developed can successfully be used to conduct a practitioner-blinded acupuncture trial. However, it is possible that the penetrating needle occasionally elicits pain in the patient, and the reaction of the patient can reveal the authenticity of the needle to the practitioner. In the current study, we aimed to determine the frequency in which the pain elicited by the penetrating needle and the reaction of the patient reveal authenticity of the needle to the practitioner.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The practitoner recorded the following after each needle application:
1. Clues that led to acupuncturist's identification of authenticity of the needle, these included facial expression, body movement, verbal expression, bleeding, and no bleeding, in addition to the feeling of needle insertion and feeling of needle removal. 
2. Acupuncturist's confidence in identification of needle authenticity (i.e., the degree of certainty about his judgment) on a numerical rating scale (0 for no confidence and 100 for complete confidence)</primaryOutcome>
      <secondaryOutcome>Subjects' identification of the authenticity of the needles.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Showa University, School of Medicine on the 24th December 1999 (ref: 65).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81864187</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, placebo-controlled, single-centre study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dbdc102d-cc52-4238-87b9-f0fcac240549">
	  <name>20-1 Sakuragaoka-Machi</name>
	  <address/>
	  <city>Tokyo</city>
	  <state/>
	  <country>Japan</country>
	  <zip>150-0031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Healthy volunteers 
3. Age range: 18 - 55 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Unhealthy volunteers</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Healthy subjects</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>24 men and 6 women were recruited, mean (SD) age = 31.0 (9.8) years. 

This study was conducted to determine the frequency in which the penetrating needle elicits pain in the participant, and whether the participant reaction to the pain serves as a significant clue in revealing the authenticity of the needle in a practitioner-blinded acupuncture trial. 

In this trial, although only penetrating needles were actually provided, the acupuncturist was told that he was provided with a mixture of penetrating and non-penetrating needles. The acupuncturist then applied a pair of needles at the bilateral TE-5 points, one needle on each side, in the 30 subjects using the alternating twirling technique. Following each needle application, the acupuncturist recorded whether he thought the needle was a penetrating or non-penetrating needle, and the clues that led him to his decision (e.g., the participant's facial expression, body movement, verbal expression) and the level of confidence in his decision.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17803-0</funderId>
      <contactId>Contact55781_17803</contactId>
      <sponsorId>Sponsor54350</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55781_17803">
    <title>Dr</title>
    <forename>Nobuari</forename>
    <surname>Takakura</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20-1 Sakuragaoka-Machi
Shibuya-ku</address>
      <city>Tokyo</city>
      <country>Japan</country>
      <zip>150-0031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54350">
    <organisation>Hanada College (Japan)</organisation>
    <website>http://www.hanada.ac.jp</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>20-1 Sakuragaoka-Machi
Shibuya-ku</address>
      <city>Tokyo</city>
      <country>Japan</country>
      <zip>150-0031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+81 (0)3 3461 4787</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m-hanada@hanada.ac.jp</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.472136.5</gridId>
    <rorId>https://ror.org/0373a6k33</rorId>
  </sponsor>
  <funder id="Funder17803-0">
    <name>Hanada College (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-02T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-07-02T00:00:00.000Z">93858860</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of a nutrition care and support intervention to prevent wasting in people living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) not yet on antiretroviral treatment</title>
      <scientificTitle>Nutrition care and support for the prevention of weight loss in people living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) (PLWHA)</scientificTitle>
      <acronym>PREWAS</acronym>
      <studyHypothesis>The human immunodeficiency virus (HIV) infection is a sexually transmitted disease that causes a severe immunodeficiency and the acquired immune deficiency syndrome (AIDS). There are more than 40.3 million people living with HIV/AIDS worldwide and Malawi is heavily affected by this pandemic with an estimated prevalence rate of 12% in 15 - 49 year olds, resulting in a rise in morbidity and mortality. While the scale-up of the life saving treatment with antiretroviral drugs (ART) is underway worldwide and in Malawi, the role of malnutrition in increasing risk of death for patients on ART has been widely demonstrated. Unfortunately, up to 50% of patients suffering from HIV become wasted and wasting is frequently the first AIDS-defining condition. Thus, identifying an intervention to help prevent malnutrition in people living with HIV and AIDS (PLWHA) to eventually delay ART initiation or improve outcomes of those on ART is of utmost importance. 

Hypothesis: 
An aggressive two weeks course of nutrition support with ready-to-use therapeutic food (RUTF) after each episode of weight loss will prevent wasting, delay the progression of HIV into AIDS and reduce the prevalence of wasting at initiation of ART.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be assessed at 12 and 24 months after admission in the programme:
1. Mean monthly CD4 count decrease 
2. Mean monthly viral load change 
3. Incidence of CD4 count less than 350 cells/ml 
4. Incidence of WHO HIV stage 3 or 4 defining event 
5. Time to commencing ART 
6. Three-monthly MUAC change</primaryOutcome>
      <secondaryOutcome>The following will be assessed at 12 and 24 months after admission in the programme:
1. Incidence of short period and long period of weight loss 
2. Incidence of wasting defined as a MUAC less than 22 cm for women and less than 23 cm for men 
3. Three-monthly weight change 
4. Incidence of opportunistic infection 
5. Probability of dying within the two years 
6. Incidence of WHO clinical stage defining illnesses 

Outcomes of interest after discharged from the study for secondary end-point of interest: 
7. Probability of dying within the two years 
8. Mortality during the first trimester of ART treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Health Sciences Research Committee based at the Ministry of Health in Malawi on the 11th April 2008 (ref: 528).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN93858860</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster-randomised unblinded controlled study. Only the statistician performing the analysis will be blinded.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Malawi</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5d5bfa98-b847-4587-a3e4-8214b5b5c293">
	  <name>Valid International</name>
	  <address/>
	  <city>Lilongwe</city>
	  <state/>
	  <country>Malawi</country>
	  <zip>265</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The study targets both female and male adults aged between 18 years and 59 years of age, already registered by one HIV positive living group. Participants will be recruited among the positive living group members who fulfill the following criteria: 
1. Confirmed HIV status (HIV positive) 
2. World Health Organization (WHO) stage: no clinical event compatible with stage 3 or 4 
3. CD4 count greater than or equal to 350 cells/µL 
4. Good nutritional status: absence of oedema, mid-upper arm circumference [MUAC] greater than 220 mm for women and greater than 230 mm for men, body mass index (BMI) greater than 18.5 kg/m^2 and no history of weight loss above 5% of usual weight 
5. Physically active (Karnofsky score above 80%) 
6. Permanent resident of the catchment area of the positive living group 
7. Willingness to participate (signed consent form)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,100 patients (550 per group), to be recruited in 32 clusters (Positive Living groups)</totalTarget>
      <exclusion>1. CD4 less than 350 cells/µL 
2. Malnutrition (MUAC less than 220 mm for female and less than 230 mm for male, BMI less than or equal to 18.5 kg/m^2, presence of bilateral oedema)
3. On ART 
4. Hypertension 
5. Diabetes 
6. Kidney disease 
7. HIV clinical stage 3 or 4 
8. Karnofsky score less than 80%</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus [HIV] disease resulting in other specified diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: 
Participants of the intervention group will receive nutrition counselling once per month and a disease oriented nutrition counselling plus 1,500 Kcal/day of chickpea sesame ready-to-use therapeutic food (CS-RUTF) for a period of two weeks each time the participants present a significant weight loss. 

To ensure that individuals in the intervention group receive their CS-RUTF when needed, each patient will be linked to community volunteers to whom he will report any occurrence of disease. Weight and MUAC will be measured each time the patient reports an occurrence of disease and RUTF prescribed if the weight loss is above 2.5% (table to be created to ease the calculation of 2.5% weight loss). 

Control group: 
Individuals of the control group will receive nutrition counselling once per month and a disease oriented nutrition counselling after any episode of common or opportunistic infection or significant weight loss. 

Both groups: 
The programme will ensure that all the episodes of disease are treated by ensuring timely referral to the nearest health facility. The research manager will visit the health facilities prior to commencing the study and seek their permission or collaboration and participation. 

Individuals of both groups who develop wasting will be treated using the interim national guidelines for the management of moderate and severe malnutrition for adolescents and adults. 

Community volunteers from all participating Positive Living Groups will receive refresher training on nutrition counselling at baseline and every 6 months during follow up. Community volunteers will be carrying out fortnightly visits to collect information on morbidity. Additional visits will be carried out by volunteers at participants' request in case of any disease between volunteer visits. During the visit, volunteers will measure weight and MUAC, collect information on symptoms and signs of diseases using standardised forms translated into the local language. 

Total duration of intervention: 24 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17833-0</funderId>
      <funderId>Funder17833-1</funderId>
      <contactId>Contact55816_17833</contactId>
      <sponsorId>Sponsor54380</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55816_17833">
    <title>Mrs</title>
    <forename>Theresa</forename>
    <surname>Banda</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Valid International
PO Box X339
Crossroads</address>
      <city>Lilongwe</city>
      <country>Malawi</country>
      <zip>265</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54380">
    <organisation>Valid International (UK)</organisation>
    <website>http://www.validinternational.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Unit 9
Standing Ford House
26 Cave Street</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX4 1BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487390.1</gridId>
    <rorId>https://ror.org/00sb6vz77</rorId>
  </sponsor>
  <funder id="Funder17833-0">
    <name>Valid International (UK) (ref: S-30)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17833-1">
    <name>Concern Worldwide (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-02T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-07-02T00:00:00.000Z">62376241</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Acceptability, effectiveness and cost-effectiveness of soya maize sorghum-based ready-to-use therapeutic food in treating severe acute malnutrition in children under five in Lusaka, Zambia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. The acceptability of soya maize sorghum ready-to-use therapeutic food (RUTF) among children is equivalent to that of peanut RUTF
2. The effectiveness of soya maize sorghum RUTF is equivalent to peanut RUTF in the treatment of severe acute malnutrition
3. Soya maize sorghum RUTF is less costly and therefore more cost-effective than peanut RUTF in the treatment of severe acute malnutrition</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Acceptability study: RUTF acceptability, measured at end of five weeks. Data will be analysed to compare the acceptability of the RUTFs compared.
2. Randomised trial: recovery rate. Data for recovery rate will be measured routinely and analysed on monthly basis, however final analysis will be done at the end of the study period.
3. Cost effectiveness evaluation:
3.1. Incremental cost per death prevented, and per recovered child, measured at the end of the study period
3.2. Probability that the intervention is cost effective for different levels of willingness to pay per outcome (e.g. US$150/DALY gained), measured at the end of the study period</primaryOutcome>
      <secondaryOutcome>1. Acceptability study:
1.1. Dietary intake, measured daily during the five week period
1.2. Morbidity, measured daily for the whole duration
1.3. Weight gain, measured at entry, at the end of week 2, the beginning of week 4 and the end of week 5. In week three will be a wash out period.
2. Randomised trial:
2.1. Defaulter rate. Data for default rate will be collected and analysed routinely. However final comparison will be made at the end of the study.
2.2. Average weight gain from baseline (or, in oedematous children, from time of loss of oedema) until exit from the programme. Weight gain will be measured for each individual child and an average taken at the end. This will be done for children who successfully complete the treatment.
2.3. Morbidity (diarrhoea, vomiting, fever, cough). Incidence of morbidity will be compared between the two groups on regular basis (weekly) and at the end of the study.
2.4. Hospital referral. The number of children referred and outcome for referral will be measured and compared at the end of the study.
2.5. Mortality. Mortality data will be collected and analysed routinely. However final analysis will be made at the end of the study and comparison between the two arms will be made.
2.6. Length gain. Data on height will be captured at admission, week four, week eight and at discharge.
3. Cost effectiveness evaluation: cost of Community-based Therapeutic Care, including RUTF, measured at the end of study period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University of Zambia, Biomedical Research Ethics Committee on the 6th May 2008 (Assurance no: FWA00000338 IRB00001131 of IORG0000774; ref: 10-04-08).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN62376241</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Irish Aid 07/01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Crossover design for acceptability, followed by a cluster randomised non-blind trial for the effectiveness study finished with a cost-effectiveness analysis</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-08-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Zambia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="10073ba5-db60-4d5c-b980-1fc653f909f5">
	  <name>Valid Nutrition</name>
	  <address/>
	  <city>Lusaka</city>
	  <state/>
	  <country>Zambia</country>
	  <zip>N/A</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both male and female severely acutely malnourished children in the age range of 6 - 59 months
2. Mid-upper arm circumference less than 110 mm or oedema of + or ++ 
3. Admitted into the Outpatient Therapeutic Programme at the health centre 
4. Good appetite 
5. No serious medical complication</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>1654</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Acceptability study: 50 children; effectiveness study: 1,604 children (total = 1654)</totalTarget>
      <exclusion>There are no exclusion criteria to be used as all severely malnourished children with no complications need to be treated at the health centre level until recovery. However, severely malnourished children who do not have an appetite or have severe medical complications or marasmic-kwashiorkor will be first referred to the stabilisation centre (University Teaching Hospital) straight away. These children will be taken into the study once stabilised at the inpatient unit of University Teaching Hospital. They will receive the respective RUTF being used in the health centre then return to follow up treatment.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-08-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe acute malnutrition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Unspecified protein-energy malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Total duration of treatment for the acceptability study is five weeks.

Soya, maize and sorghum based RUTF will be compared to the control of peanut based RUTF. All admitted children in both arms will receive standard dose of medication as per Community-based Therapeutic Care protocol in use in Lusaka. In addition children in the intervention arm will be provided soya, maize and sorghum based RUTF tailored to weight (200 KCal/kg/Day) and children in the control arm will receive peanut based RUTF tailored to weight (200 KCal/kg/day). Both groups will receive the food until exit from the programme. 

From experience the average length of stay is 8 weeks and the maximum stay in the programme is 17 weeks, i.e. from time of recruitment until exit from the programme (either cured from severe acute malnutrition, or default, or death, or transfer, or non-cured).

Those children who are discharged cured will be followed up at week 4, 6 months and 12 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Soya maize sorghum ready-to-use therapeutic food (RUTF), peanut RUTF</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17846-0</funderId>
      <contactId>Contact55829_17846</contactId>
      <sponsorId>Sponsor54393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55829_17846">
    <title>Dr</title>
    <forename>Abel Hailu</forename>
    <surname>Irena</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Valid Nutrition
9026 Buluwe Road
Woodlands</address>
      <city>Lusaka</city>
      <country>Zambia</country>
      <zip>N/A</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+260 1 261 375</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">abel@validinternational.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54393">
    <organisation>Irish Aid (Ireland) </organisation>
    <website>http://www.dci.gov.ie</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Department of Foreign Affairs
Bishops Square
Redmond Hill</address>
      <city>Dublin</city>
      <country>Ireland</country>
      <zip>2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">irishaid@dfa.ie</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.467653.5</gridId>
    <rorId>https://ror.org/03kyawa63</rorId>
  </sponsor>
  <funder id="Funder17846-0">
    <name>Valid Nutrition (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-06-30T00:00:00.000Z">95974322</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brazilian pentavalent vaccine</title>
      <scientificTitle>Immunogenicity and safety of Brazilian combined vaccine against diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib)</scientificTitle>
      <acronym/>
      <studyHypothesis>The Brazilian combined diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib) vaccine is as immunogenic and safe as the current DTPw/Hib and HB vaccines administered separately.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Antibody titres to diphtheria, tetanus, pertussis, haemophilus influenzae (PRP) and hepatitis B, and seroprotection rate, measured after third dose, shoud be non-inferior to that from the reference vaccines (DTP/Hib and HB vaccines given separately).</primaryOutcome>
      <secondaryOutcome>1. Adverse event after each dose shoud be equivalent to reference vaccines
2. Consistency of production evaluated by equivalence in immunogenicity and safety of three lots of the experimental vaccine DTPw/HB/Hib</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Fiocruz Ethics Committee on the 14th January 2007 (ref: 400/07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95974322</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ASCLIN/001/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, non-inferiority randomised controlled trial, partially blinded.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="705a0939-fcc5-4d99-aabe-974459d56b68">
	  <name>Rua Leoplodo Bulhões 1480/820</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21041-210</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy newborns (newborns and infants up to 7 months of age, of both sexes) whose parents/tutors understand the risk and benefits of the trial and agree to participate with written and informed consent.</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Months" value="7.0"/>
      <gender>Both</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200 volunteers</totalTarget>
      <exclusion>Newborns or mothers:
1. Hepatitis B surface antigen (HBsAg) positive
2. Human immunodeficiency virus (HIV) seropositive 
3. With positive serology for syphilis</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type B diseases</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Bacterial infection of unspecified site</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Experimental group: vaccine (DTPw/HB/Hib) at 2, 4 and 6 months of age
2. Control group: DTPw/Hib and HB vaccines in concomitant injections at different sites

Both groups will receive HB vaccine at birth.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Combined diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib) vaccine, DTPw/Hib vaccine, HB vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17918-0</funderId>
      <funderId>Funder17918-1</funderId>
      <contactId>Contact55901_17918</contactId>
      <sponsorId>Sponsor54465</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55901_17918">
    <title>Dr</title>
    <forename>Luiz Antônio Bastos</forename>
    <surname>Camacho</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Leoplodo Bulhões 1480/820 
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21041-210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 2598 2630</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">luiz.camacho@ensp.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54465">
    <organisation>Bio-Manguinhos/Fiocruz (Brazil)</organisation>
    <website>http://www.bio.fiocruz.br</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Akira Homma 
Director
Avenida Brasil 4365 
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424703.6</gridId>
    <rorId>https://ror.org/05gj5j117</rorId>
  </sponsor>
  <funder id="Funder17918-0">
    <name>Brazilian Ministry of Health (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17918-1">
    <name>Brazilian Ministry of Science and Technology (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-07-11T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-06-24T00:00:00.000Z">64846643</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Social intervention for depressed women: Pilot randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>There will be a reduction in depressive symptoms in a group of chronically depressed Pakistani women by attending a social group intervention at a local community centre.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be carried out before and after attendance at the social activities group for 10 sessions or taking antidepressants for 10 weeks:
1. Self Rating Questionnaire (SRQ)
2. Hamilton depression scale</primaryOutcome>
      <secondaryOutcome>Quality of life, assessed by EuroQol (EQ-5D) at 12 weeks.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethical Research Committee of Pakistan Institute of Learning and Living (PILL). Date of approval: 19/03/2008 (ref: PILL-080311)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64846643</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, rater-blind trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="abea2743-4036-42ff-bd69-bd580caea761">
	  <name>11-C</name>
	  <address/>
	  <city>Karachi</city>
	  <state/>
	  <country>Pakistan</country>
	  <zip>74500</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Depressed women aged 16-55</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>66</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>66</totalTarget>
      <exclusion>Anyone leaving community within the next six months</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depressive episode</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The 66 participants will be divided into 3 groups (22 participants each), and then they will be randomly allocated to the intervention and control sub-groups (therefore, each sub-group consists of 11 participants). The control group will be provided with antidepressants and another will be provided with a psychosocial intervention. 

Phychosocial intervention: The group structure will be informal, active participation by the women will be encouraged at all times. The facilitators will motivate and encourage these women. The overall aim would be to provide social support, stimulation, education on mental and physical health needs, problem solving training and possibly giving these women a break from their distressing environment. This will provide an opportunity for them to initiate a process of getting acquainted with other women, even making friends. We hope that some of these relationships would be long lasting and would continue even when the group ends. Total number of sessions: 10. Duration of each session is 1 hour. 

Total duration of interventions: 12 weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17859-0</funderId>
      <contactId>Contact55842_17859</contactId>
      <sponsorId>Sponsor54406</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55842_17859">
    <title>Dr</title>
    <forename>Nusrat</forename>
    <surname>Hussain</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>11-C
6 Commercial Zamzama Lane
DHA
Phase 5</address>
      <city>Karachi</city>
      <country>Pakistan</country>
      <zip>74500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54406">
    <organisation>Remedial Centre (Pakistan)</organisation>
    <website>http://remedialcentre.com</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>D-9, Block I
North Nazimabad</address>
      <city>Karachi</city>
      <country>Pakistan</country>
      <zip>74500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487340.c</gridId>
    <rorId>https://ror.org/03wdref81</rorId>
  </sponsor>
  <funder id="Funder17859-0">
    <name>Remedial Centre (Pakistan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-20T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-06-20T00:00:00.000Z">34433965</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre study of the reduction of steps (measured by an electronic pedometer) after 4 different types of repair for inguinal hernia</title>
      <scientificTitle>Multicentre cohort study evaluating ambulatory activity reduction after LIchtenstein, laparoscopic Totally ExtraPeritoneal, KUgel patch or Polysoft repair of primary inguinal hernia (LITEKUP trial)</scientificTitle>
      <acronym>LITEKUP trial</acronym>
      <studyHypothesis>To compare the short-term functional outcome after four different techniques of inguinal hernia repair in an ambulatory setting, namely, the Lichtenstein repair, the laparoscopic totally extraperitoneal repair, the open retroperitoneal Kugel patch repair and the Polysoft® patch repair.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Count of steps 1 week before and 2 weeks after scheduled inguinal hernia repair, measured with an electronic pedometer.</primaryOutcome>
      <secondaryOutcome>1. Recurrence rate after 12-24 months. This will be assessed by clinical examination during clinical follow-up after 2 weeks, 6, 12 and 24 months. Independent examination will be performed at 12 and 24 months to assess recurrence and chronic pain. 
2. Acute pain at the affected groin side measured daily the week before, the day of and the first 2 weeks after surgery, using a visual analogue scale (VAS) indicating no pain at 0 mm and worst pain ever experienced at 100 mm. 
3. Chronic groin pain syndrome at the operated side after 12-24 months. Classified as follows:
No pain: no discomfort experienced
Mild pain: defined to the patient as discomfort that did not limit activity, with a return to pre-hernia lifestyle
Moderate pain: defined as pain preventing return to normal preoperative activities (i.e. inability to continue with prehernia activities such as golf, tennis and other sports, and inability to lift objects, without pain, that patient had been lifting before the hernia occurrence)
Severe pain: pain that incapacitated the patient at frequent intervals or interfered with activities of daily living (i.e. pain constantly present or intermittently present but so severe as to impair normal activities, such as walking)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Leading Ethical Committee of the University Hospital Brussels (Universitair Ziekenhuis Brussel). Date of approval: 11/10/2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34433965</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>B.U.N. B14320072331</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, multicentre, cohort, observational study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5a1278bf-bfaf-4f90-b8eb-487ecfc01ac9">
	  <name>Laarbeeklaan 101</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consecutive patients (both males and females, &gt;18 years of age) with a diagnosis of primary unilateral inguinal hernia presenting in the participating centres for the surgical repair of their hernia in an ambulatory setting.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>976</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>976</totalTarget>
      <exclusion>1. Incarcerated inguinal hernia
2. Life expectancy less than two years
3. Pregnancy
4. American Society of Anaesthesiology (ASA) class IV or V
5. Extensive lower abdominal surgery or severe local inflammation
6. Inability to sign the informed consent. 
7. Indication for other type of surgery for various reasons
8. Patients unable to walk (paralysed or bedridden patients)
9. Bilateral hernia repair
10. Large scrotal hernias
11. Concomitant abdominal surgery
12. Body mass index (BMI) &gt;= 35 kg/m2
13. Liver cirrhosis (Child C)
14. Known abuse of alcohol or drugs
15. Ongoing long term analgesic or steroid treatment
16. Patients under clopidogrel or warfarin must be switched to subcutaneous (sc) low-molecular-weight (lmw) heparin
17. Severely compromised physical or psychological health, that in the investigator&#146;s opinion will affect patient&#146;s compliance
18. Concurrently participating in another clinical trial</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Inguinal hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Inguinal hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an observational cohort study comparing the reduction in ambulatory activity (RAA) after four common techniques of inguinal hernia repair of patients with primary inguinal hernia. The four techniques are:
1. Lichtenstein repair
2. Laparoscopic totally extraperitoneal repair
3. Open retroperitoneal Kugel patch repair
4. Polysoft® patch repair

Count of steps will be carried out 1 week before and 2 weeks after scheduled inguinal hernia repair, measured with an electronic pedometer.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17840-0</funderId>
      <contactId>Contact55823_17840</contactId>
      <sponsorId>Sponsor54387</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55823_17840">
    <title>Prof</title>
    <forename>Yves</forename>
    <surname>Van Nieuwenhove</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Laarbeeklaan 101</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54387">
    <organisation>Royal Belgian Society of Surgery, Section of Abdominal Wall Surgery (BSAWS) (Belgium)</organisation>
    <website>http://www.belsurg.org</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Koninklijk Belgisch Genootschap voor Heelkunde
W. Churchill-laan 11/30</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1180</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">amb@skynet.be</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487362.c</gridId>
    <rorId>https://ror.org/04yy1mz94</rorId>
  </sponsor>
  <funder id="Funder17840-0">
    <name>Royal Belgian Society of Surgery, Section of Abdominal Wall Surgery (BSAWS) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-06-18T00:00:00.000Z">74420611</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of pharmacists ACCESs to clinical information on the quality and the continuity of care in poly-medicamented community patients: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>ACCES</acronym>
      <studyHypothesis>Drug-related problems (DRP) are associated with an increased morbidity and mortality. In the primary care setting, the number of poly-medicamented patients is constantly increasing, resulting in an increased risk of DRP. 

Access to clinical information, such as laboratory results and health problems, should help the community pharmacist detect more DRPs. The detection of these DRPs, and better documented pharmacist's suggestions, can result in an increase of the acceptance rate by general practitioners. To our knowledge, there are few studies on the impact of access to clinical information on the detection of DRPs by community pharmacists.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be assessed after two months of follow-up: 
1. Compare the mean number of DRP per patient identified by community pharmacists in both groups (intervention group and control group)
2. Compare the mean number of pharmacotherapy changes per patient between both groups (intervention group and control group)</primaryOutcome>
      <secondaryOutcome>The following will be assessed after two months of follow-up:
1. Compare the proportion of patients in each group for whom at least one intervention was made by the community pharmacists  
2. For each type of intervention, compare the proportion of interventions made by the community pharmacists in both groups
3. Compare the proportion of pharmaceutical opinions that resulted in a pharmacotherapy change in both groups
4. Describe and compare the type of contact made between community pharmacists and Family Medicine Clinic&#146;s pharmacists in both groups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Centre de santé et de services sociaux [CSSS] de Laval Ethics Committee) on the 24th September 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74420611</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-24T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="51e07670-96b0-4bd9-bc9e-b236611634e1">
	  <name>Resaerch Team in Primary Care</name>
	  <address/>
	  <city>Laval</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H7M 3L9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Family doctors or residents: 
1. Practicing at the Family Medicine Clinic of CSSS de Laval
2. Agree to participate and sign the consent form

Community pharmacists:
1. Practicing in one of the pharmacies in the area of Laval or surrounding areas 
2. Have one or more patients eligible for the study 
3. Agree to participate and sign the consent form 

Patients: 
1. 18 years old or older, either sex 
2. Have an appointment at the Family Medicine Clinic of CSSS de Laval between October 2007 and March 2008 
3. Takes at least five chronic medications 
4. Reports being a patient of one of the participating pharmacies
5. Agrees to participate and sign the consent form 
6. Is considered eligible by his family doctor</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>170</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>170</totalTarget>
      <exclusion>1. Is not able to speak or read French 
2. Is a patient of more than one community pharmacy 
3. Is not able to give a informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-24T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Drug-related problems from multiple prescription drugs</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Drug-related problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All pharmacists in the area of Laval were invited to a three-hour workshop on the interpretation of laboratory results. They also have access to a consultation service with pharmacists currently working at the Family Medicine Clinic of CSSS de Laval. For all patients, the family doctor asked the community pharmacist to perform an analysis of the pharmacotherapy.

To help the pharmacist analyse the drug profile, the intervention group received the following clinical information: 
1. Most recent laboratory results: 
1.1. Creatinine clearance
1.2. Potassium
1.3. Sodium
1.4. Lipid profile
1.5. Alanine aminotransferase (ALT)
1.6. Creatine kinase (CK)
1.7. Glycosylated haemoglobin (HbA1c)
1.8. Thyroid stimulating hormone (TSH) and free thyroxine (FT4)
1.9. Complete blood count
1.10. Blood levels of certain drugs (phenytoin, digoxin, lithium)
2. Health problems 
3. Drug profile as figured in the medical record 

The control group received usual care. 

The duration of follow-up was 8 weeks in both groups.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17713-0</funderId>
      <contactId>Contact55687_17713</contactId>
      <sponsorId>Sponsor54259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55687_17713">
    <title>Dr</title>
    <forename>Lyne</forename>
    <surname>Lalonde</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Resaerch Team in Primary Care
CSSS de Laval, Hôpital de la Cité-de-la-Santé 
1755 René-Laennec, room D-S145</address>
      <city>Laval</city>
      <country>Canada</country>
      <zip>H7M 3L9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 450 668 1010 ext. 2743</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lyne.lalonde@umontreal.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54259">
    <organisation>Pfizer (Canada) </organisation>
    <website>http://www.pfizer.ca</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Chideh Motallebi, PhD, MBA
Spécialiste régional médical et de la recherche Cardiovasculaire - QC 
Pfizer Canada Inc. Division Médicale
17300, autoroute Transcanadienne</address>
      <city>Kirkland</city>
      <country>Canada</country>
      <zip>H9J 2M5 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 450 466 3952</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Chideh.Motallebi@Pfizer.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.421137.2</gridId>
    <rorId>https://ror.org/059g90c15</rorId>
  </sponsor>
  <funder id="Funder17713-0">
    <name>Pfizer (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/100004319</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-13T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-06-13T00:00:00.000Z">08911796</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neuragen® for the relief of neuropathic pain part 2: a randomised, double-blind, placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Neuragen® with a different amount of effective ingredients will reduce neuropathic pain more than the placebo whilst having different levels of effectiveness.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Foot sole pain on 11-point numerical pain scale. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.</primaryOutcome>
      <secondaryOutcome>Duration of pain reduction. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Louisiana State University as an extension of IRB#2754, approved on 28th September 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08911796</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-27T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e12a35df-bca0-4f42-b6d8-ccf76ca5d734">
	  <name>Department of Kinesiology</name>
	  <address/>
	  <city>Baton Rouge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>70803</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female, over 21 years
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3 - 8 on a 0 - 10 visual pain scale
4. Does not have mental and communication impairments</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-05-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-27T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Peripheral neuropathy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Other polyneuropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Topical application of Neuragen® with different amounts of effective ingredients versus a placebo. The medicine was sprayed onto the subjects feet at the sole and on top of the feet. One time application with an 8-hour follow-up.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Neuragen®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17864-0</funderId>
      <contactId>Contact55847_17864</contactId>
      <sponsorId>Sponsor54411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55847_17864">
    <title>Dr</title>
    <forename>Li</forename>
    <surname>Li</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address> Department of Kinesiology
Louisiana State University </address>
      <city>Baton Rouge</city>
      <country>United States of America</country>
      <zip>70803</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54411">
    <organisation>Origin BioMed, Inc. (Canada)</organisation>
    <website>http://www.originbiomed.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>5162 Duke St, Suite 300 </address>
      <city>Halifax</city>
      <country>Canada</country>
      <zip>B3J 1N7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487321.b</gridId>
    <rorId>https://ror.org/008mcnd42</rorId>
  </sponsor>
  <funder id="Funder17864-0">
    <name>Origin BioMed, Inc. (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-12T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-06-12T00:00:00.000Z">36604462</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of a restraint minimisation education programme on physical restraints use, staff knowledge, attitudes and perceived job strain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It is hypothesised that an educational intervention in group dwellings for persons with dementia will increase staff knowledge about and change their attitudes towards the use of physical restraints. This will lead to a reduction in physical restraints use which in turn will have an positive effect on staffs' perceived job strain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Residents: 
1. Physical restraints were recorded daily for each patient, for three weeks before interventions, and then until the end of interventions (6 months). The information recorded include type of physical restraints used, hours restrained and reasons for restraining. 

Outcomes concerning staff, measured before interventions and at 6 months: 
1. Staff knowledge about current legislation, measured by a seven-item index score ranging between 0-7 (higher values indicate higher knowledge) 
2. Staff subjective knowledge relating to care of people with dementia, measured by a visual analogue scale (VAS) 
3. Staff attitudes, measured by the 17-item Perceptions of Restraint Use Questionnaire (PRUQ) 
4. Job strain, measured by three instruments: 
4.1. The Job-Demand and Social Support Questionnaire
4.2. Stress of Conscience Questionnaire 
4.3. Caring climate, measured by a VAS</primaryOutcome>
      <secondaryOutcome>Outcomes concerning residents:
1. Fall accidents, recorded during the whole study period (8 months [1 month prior to interventions, 6 months during interventions and 1 month after interventions)
2. Psychoactive drug use, assessed before interventions and at 6 months
3. Motor function, vision, hearing and speech, assessed by the Multi-Dimensional Dementia Assessment Scale (MDDAS) before interventions and at 6 months. MDDAS included the Activity of Daily Living (ADL) functions and behavioural and psychiatric symptoms questionnaire. Gottfries cognitive level questionnaire (subscale to the MDDAS) was used for the measurement of cognitive level.
 
Staff characteristics:
4. Demography
5. Education level
6. Years worked
7. Evaluation of the intervention, carried out within one week after the end of intervention</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Medical Faculty of Umeå University. Date of approval: 12/03/2002 (ref: Section 92/02, dnr 02-105)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36604462</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="27d9e973-21de-4321-b88d-b08ee3f6ecfc">
	  <name>Umeå University</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-90187</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Residents (both men and women) living in group dwellings for persons with dementia, which have at least 20% of the residents restrained.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>320</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>320 residents</totalTarget>
      <exclusion>Units with less than 20% of the residents restrained.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Use of physical restraints in group dwellings.</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Unspecified dementia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consisted of an education programme for the nursing staff (registered nurses, licensed practical nurses and nurse aid). The content of the programme included dementia diseases, symptoms, treatment and related complications, fall prevention, prevention and treatment of delirium, interaction and communication in dementia care and negative effects of, alternatives to and legislation directing the use of physical restraints. 

First, the head-nurse at each intervention unit selected one person who underwent the whole education programme compressed during two seminar days. Remaining staff received their education via 30-minute videotaped lectures. Three of the lectures also included a clinical written vignettes forming the basis for group discussions. At each unit it was up to the staff to make arrangements for watching the films and if desired to arrange group discussions. Each unit was responsible for making arrangements for taking part of the lectures and if desired to arrange group discussions. The education programme ran alongside ordinary work at the units without further involvement of the researchers besides distribution of the video taped lectures and data collection. In the education programme the emphasis was on the importance of investigating the underlying causes instead of working in a symptom-oriented manner e.g. a resident that have sustained a fall accident should be investigated for the cause of the fall instead of just using physical restraints. The staff was encouraged to use physical restraints only as the last resort. The intervention/education programme was carried out over six months. 

The control units did not receive any interventions during the study period; they did receive interventions after the study was completed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17720-0</funderId>
      <funderId>Funder17720-1</funderId>
      <funderId>Funder17720-2</funderId>
      <funderId>Funder17720-3</funderId>
      <contactId>Contact55694_17720</contactId>
      <sponsorId>Sponsor54266</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55694_17720">
    <title>Dr</title>
    <forename>Stig</forename>
    <surname>Karlsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Umeå University</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>SE-90187</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 90 7869259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stig.karlsson@nurs.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54266">
    <organisation>Umeå University (Sweden)</organisation>
    <website>http://www.umu.se/umu/index_eng.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Umeå</address>
      <city>-</city>
      <country>Sweden</country>
      <zip>SE-90187</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 90 7869259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stig.karlsson@nurs.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.12650.30</gridId>
    <rorId>https://ror.org/05kb8h459</rorId>
  </sponsor>
  <funder id="Funder17720-0">
    <name>Lions Research Foundation for Age Related Diseases (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-1">
    <name>King Gustaf V's and Queen Victoria's Freemason Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-2">
    <name>The Field Research Centre for the Elderly in Västerbotten (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-3">
    <name>The Swedisch Research Council (Grant ref: K2005-27-VX-15357-01A)(Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>